

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
20 January 2005 (20.01.2005)

PCT

(10) International Publication Number  
**WO 2005/004791 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K** 513 Crestview, OK, Edmond, OK 73003 (US). **MOUREZ, Michael** [FR/—]; -.
- (21) International Application Number: PCT/US2003/035733 (74) Agent: **BIEKER-BRADY, Kristina**; Clark & Elbing LLP, 101 Federal Street, Boston, MA 02110 (US).
- (22) International Filing Date: 10 November 2003 (10.11.2003) (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/424,987 8 November 2002 (08.11.2002) US (84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicants (*for all designated States except US*): **PRESIDENT AND FELLOWS OF HARVARD COLLEGE** [US/US]; 17 Quincy Street, Cambridge, MA 02138 (US). **THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA** [US/US]; 660 Parrington Oval, Evans Hall, Norman, OK 73019 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **COLLIER, R., John** [US/US]; 43 Garden Road, Wellesley, MA 02181 (US). **BALLARD, Jimmy, D.** [US/US]; 1904 Danfield, Norman, OK 73072 (US). **TWETEN, Rodney** [US/US];
- Published:**  
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: COMPOUNDS AND METHODS FOR THE TREATMENT AND PREVENTION OF BACTERIAL INFECTION

(57) Abstract: The invention provides mutant forms of pore-forming toxins. These mutant toxins may be used in vaccines for the prevention of bacterial infection. Additionally, dominant negative mutants may be administered as therapeutics for the treatment of bacterial infection.

WO 2005/004791 A2

5                   **COMPOUNDS AND METHODS FOR THE TREATMENT AND  
                    PREVENTION OF BACTERIAL INFECTION**

**Statement as to Federally Sponsored Research**

                    This invention was funded by grants R37-AI22021 and 2T32-AI07410 from the National Institute of Health. The government may have  
10     certain rights in the invention.

**Background of the Invention**

                    In general, the invention features compounds and methods for the treatment of bacterial infections, such as anthrax infection.

15                   The etiologic agent of anthrax (*Bacillus anthracis*) is a potential threat as an agent of biowarfare or bioterrorism because exposure to aerosolized *B. anthracis* spores can be lethal to mammals, such as humans. The major virulence factors produced by this organism are the poly-D-glutamic acid capsule and anthrax toxin (ATx). Both the capsule and the toxin assist in  
20     colonization and immune evasion by the bacterium. ATx alone can cause death of the host. Vaccination against the toxin protects the host against infection.

                    Anthrax toxin is a member of the class of bacterial toxins termed A-B toxins. A-B toxins are composed of two moieties; the A moiety is the  
25     enzymic portion of the toxin that catalyzes the toxic effect upon a cytoplasmic target within a target cell. The B moiety binds to a cellular receptor and facilitates the translocation of the A moiety across the cell membrane into the cytoplasm of the cell.

                    The B moieties of A-B toxins from tetanus, botulinum, diphtheria  
30     and anthrax all form channels in membranes. It has been hypothesized that these channels might act as the conduit for the membrane translocation of the A moiety. The A and B moieties of anthrax toxin are secreted from the bacterial

cell as distinct polypeptides. The A and B subunits of other A-B toxins are produced as single chain polypeptides or as separate chains that are assembled into oligomeric toxins before release from the bacteria. There are two alternative A subunits of anthrax toxin called edema factor (EF) and lethal factor (LF). Noncovalent complexes of EF or LF and the B subunit, protective antigen (PA), are called edema toxin and lethal toxin, respectively. PA facilitates the translocation of both EF and LF across membranes.

PA is secreted as an 83 kDa monomeric polypeptide. Monomeric PA binds to a mammalian cell surface receptor and is proteolytically cleaved. The C-terminal 63 kDa fragment (PA63) remains bound to the cell and the N-terminal 20 kDa (PA20) dissociates from PA63. This proteolytic cleavage and subsequent dissociation of PA20 confer two new properties on PA63: (1) the ability to oligomerize into a ring-shaped heptameric SDS-dissociable structure termed prepore and (2) the ability to bind EF and LF. Oligomers containing PA63-EF, PA63-LF, or a combination of PA63-EF and PA63-LF are endocytosed and trafficked to an acidic compartment, where the PA63 prepore inserts into the membrane and forms a pore. During or after pore formation, EF and LF are translocated across the endosomal membrane into the cytoplasm. EF is a calmodulin-dependent adenylate cyclase which may protect the bacteria from destruction by phagocytes. LF is a metalloprotease that can kill macrophages or, at lower concentrations, induce macrophages to overproduce cytokines, possibly resulting in death of the host.

A crucial step in this intoxication pathway is pore formation by PA. Low pH serves as the trigger for conversion of the PA63 prepore to the pore. This conversion is accompanied by a transformation of the oligomer from an SDS-dissociable to an SDS-resistant state and formation of a transmembrane 14-strand  $\beta$ -barrel. These steps are believed to be necessary for translocation of EF and LF across the endosomal membrane and, thus, toxin action.

### Summary of the Invention

By screening a library of mutated forms of PA where residues have been changed one after the other to a cysteine residue, we identified new mutated forms of PA having dominant negative inhibitory (DNI) activity.

5 These PA mutants have been purified and tested for DNI activity in a cell culture assay.

Accordingly, the invention features a B moiety of a pore-forming binary A-B toxin. The B moiety has a mutation that results in inhibition of its pore-forming ability and is selected from the group of mutations of PA  
10 consisting of S382, N399, and N422. In a desirable embodiment, the amino acid mutation is to cysteine.

In yet another desirable embodiment, the PA mutant has an amino acid sequence that is at least 80%, 90%, 95% or 98% identical to a naturally-occurring PA protein (such as SEQ ID No.: 21; Fig. 13) and that has one of the  
15 following alterations: S382, N399, and N422.

In yet another desirable embodiment, mutant B moieties include *Clostridium difficile*, *C. perfringens*, *C. spiroforme*, *C. botulinum*, *Bacillus cereus*, and *B. thuringiensis* toxins that have an alteration in an amino acid that corresponds to S382, N399, and N422. Corresponding amino acids are shown  
20 in the alignments shown in Figures 15 and 16 and are also provided in Table 6.

In a second aspect, the invention features a vaccine composition having a mutant B moiety of the first aspect, or a fragment thereof, in a pharmaceutically acceptable carrier. In a desirable embodiment, the vaccine can be inactivated by chemical or physical means.

25 In a third aspect, the invention features a method of preventing or treating bacterial infection in a mammal, such as a human. This method includes administering the vaccine of the second aspect to the mammal. In one desirable embodiment, the vaccine is administered with a pharmaceutically suitable carrier or an adjuvant. The vaccine can be administered orally,  
30 intramuscularly, intravenously, subcutaneously, by inhalation, or by any other



route sufficient to provide a dose adequate to prevent or treat a bacterial infection. In another desirable embodiment, a vaccine that includes a mutant anthrax protective antigen is administered for the prevention or treatment of anthrax infection.

5           In a fourth aspect, the invention features a mutant B moiety of a pore-forming binary A-B toxin. The mutant B moiety has a mutation at amino acid residues S382, N399, and N422, resulting in inhibition of its pore-forming ability. The mutant B moiety also inhibits the pore-forming ability of a naturally occurring B moiety of the corresponding toxin *in vitro* and/or *in vivo*.

10       In one desirable embodiment, this mutation results in inhibition of the pore-forming ability of the protein *in vivo*. In another desirable embodiment, the mutant B moiety lacks pore-forming ability *in vitro* and/or *in vivo*. In yet another desirable embodiment, the B moiety is anthrax protective antigen (PA). The mutant B moiety may bind the A moiety of the corresponding toxin. For

15       example, a PA mutant may bind lethal factor (LF) or edema factor (EF) A moieties. The mutant B moiety may compete with a naturally occurring B moiety for binding to a receptor on the surface of a mammalian cell. The mutant B moiety may also bind a naturally occurring B moiety of the corresponding toxin. Such a mutant may oligomerize with a naturally

20       occurring B moiety to form a complex that has reduced ability to form a pore. In one desirable embodiment, the complex lacks the ability to form a pore and to translocate an A moiety (e.g., EF or LF) across the membrane into the host cell cytoplasm.

          In a fifth aspect, the invention features a method of preventing or

25       treating bacterial infection in a mammal, such as a human. This method includes administering a mutant B moiety of the fourth aspect, or a fragment thereof, that inhibits the pore-forming ability of a naturally-occurring B moiety to the mammal. In one embodiment, a PA mutant of the fourth aspect or a fragment thereof is administered to prevent or treat anthrax infection in

30       mammals that have been exposed to *B. anthracis* spores. In another

embodiment, the protein is administered prophylactically. In one desirable embodiment, the mutant B moiety is administered with a pharmaceutically suitable carrier. The mutant may be administered orally, intramuscularly, intravenously, subcutaneously, by inhalation, or by any other route sufficient to  
5 provide a dose adequate to prevent or treat an anthrax infection. In one embodiment, the method also includes administering an anti-B moiety antibody, such as an antibody that binds a naturally-occurring B moiety, but not the dominant negative mutant B moiety, to the mammal. In one particular embodiment, the antibody binds a naturally-occurring PA but not the dominant  
10 negative PA mutant.

In a sixth aspect, the invention features a nucleic acid encoding a mutant B moiety (e.g., a PA mutant) of the first or fourth aspects.

In a seventh aspect, the invention features a vector having the nucleic acid of the sixth aspect.

15 In an eighth aspect, the invention features a purified antibody that specifically binds a PA mutant protein of the foregoing aspects. The antibody may be a monoclonal or polyclonal antibody.

It should be understood that other pore-forming toxins, in addition to anthrax toxin, may be used in the compounds and methods of the invention.  
20 For example, pore-forming toxins, such as other A-B toxins, having mutations (e.g., point mutations or deletion mutations) that inhibit the pore-forming ability of the toxin or that inhibit the pore-forming ability of the naturally occurring toxin are included in the invention. The pore-forming toxins with these mutants can be used in the vaccine compositions or methods of the  
25 invention to prevent or treat infection by the etiologic agent of the toxin. While not meant to limit the invention in any way, other A-B binary toxins; hetero-oligomeric toxins (AB<sub>5</sub> toxins), such as cholera toxin; or single polypeptide A-B toxins, such as tetanus, botulinum, or diphtheria toxin can be used. Other toxins that can be used include  $\alpha$ -hemolysin from *Staphylococcus aureus*,  
30 aerolysin from *Aeromonas hydrophila*,  $\alpha$ -toxin from *Clostridium septicum*, and

cytotoxin from *Pseudomonas aeruginosa*. The invention is also relevant to any other pore-forming toxin such as cholesterol dependent cytolysins, hexameric toxins, or heptameric toxins. Examples of hexameric and heptameric toxins include toxins that are related to the Staphylococcal  $\alpha$ -toxin. In one  
5 embodiment, a deletion mutant of the VacA toxin from *Helicobacter pylori* is specifically excluded.

“Mutation” means an alteration in the nucleic acid sequence such that the amino acid sequence encoded by the nucleic acid sequence has at least one amino acid alteration from a naturally occurring sequence. The mutation  
10 may, without limitation, be an insertion, deletion, frameshift mutation, or missense mutation.

“Pore-forming toxin” means a toxin which forms a transmembrane aqueous pore.

“Pore-forming A-B toxin” means a pore-forming toxin with two  
15 functional moieties; one moiety (B) which forms a pore in a host cell barrier membrane, and the other (A) traverses the membrane barrier and enzymatically modifies specific intracellular substrates of a host cell.

“Pore-forming binary A-B toxin” means a pore-forming A-B toxin in which the A and B moieties of the pore-forming toxin inhabit separate proteins,  
20 and interact during the intoxication of host cells. An example of a binary toxin is anthrax toxin.

“B moiety” means the component of a pore-forming A-B toxin which binds a specific host cell-surface receptor, interacts with the A moiety of the toxin, and aids in internalization of the A moiety into the cell. Many B  
25 moieties, such as PA, also form transmembrane pores.

“Protective antigen (PA)” means a polypeptide having at least 60%, 70%, 80%, or 90%, of at least one of the biological activities of the anthrax PA polypeptide described herein. The polypeptide may be encoded by the PA gene that was reported by Vodkin *et al.* (Cell 34:693-697, 1983). The  
30 polypeptide can be identical to wild-type PA characterized by Miller *et al.*

(Biochemistry 38(32):10432-10441, 1999) (SEQ ID No.: 21) or any naturally occurring PA polypeptide from a strain of *Bacillus anthracis*. The PA polypeptide may be cloned and expressed in a heterologous host, such as *Escherichia coli* or *Bacillus subtilis*. It is understood that homologs and  
5 analogs have the characteristics of the anthrax PA described herein and may be used in the methods of the invention.

"PA63" means the carboxy-terminal portion that results from proteolytic cleavage of a 20 kDa N-terminal segment from the PA polypeptide. PA63 forms a heptameric prepore and binds the two alternative A moieties,  
10 edema factor (EF) and lethal factor (LF). The entire complex is trafficked to the endosome, where PA63 inserts into the membrane, forms a transmembrane pore, and translocates EF and LF into the host cell cytoplasm.

"Transmembrane pore" means a transmembrane aqueous channel. For example, the transmembrane pore can be a  $\beta$ -barrel channel formed by  
15 alternating hydrophilic and hydrophobic residues of PA63 such that the hydrophobic residues form an exterior membrane-contiguous surface of the barrel, and the hydrophilic residues face an aqueous lumen of a pore that spans across the host cell membrane.

"Hydrophilic face of a transmembrane pore" means the amino acids  
20 of PA that face the aqueous lumen of a pore that spans across the host cell membrane.

"An amino acid that forms the transmembrane pore" means an amino acid of PA that is located in a  $\beta$ -barrel channel of a transmembrane pore.

"D2L2 loop" means the amphipathic loop which connects strands  
25  $2\beta 2$  and  $2\beta 3$  of PA polypeptide and PA63 polypeptide as described herein.

"Inhibits the pore-forming ability" means reduces the amount of pores formed in membranes or reduces the rate or amount of an A moiety (e.g., EF or LF) that is translocated into the host cell cytoplasm. This decrease in pore formation or toxin translocation is positively correlated with, and could be  
30 predicted by, a decrease in activity in the cell surface translocation, LFnDTA

toxicity, or rubidium release assays described herein. This decreased activity can be correlated with a decrease in the amount of a radiolabeled ligand that is translocated into cells in the cell surface translocation assay, a decrease in the inhibition of protein synthesis due to the translocation of a ligand into cells in the LFnDTA toxicity assay, or a decrease in the release of radiolabeled ions from cells in the rubidium release assay. Additionally, this decreased activity can be correlated with a decrease in toxicity due to the translocation of a toxic ligand into cells. In one desirable embodiment, the decrease in pore formation or translocation of an A moiety is at least 20%, more desirably at least 40%, and most desirably at least 80% relative to a naturally-occurring B moiety of the corresponding toxin. In another desirable embodiment, the decrease in pore formation or translocation of EF or LF by a PA mutant is at least 20%, more desirably at least 40%, and most desirably at least 80% relative to naturally occurring PA63

“Lacks pore-forming ability” means does not form a significant amount of pores in membranes or does not transfer a significant amount of EF or LF into the host cell cytoplasm. This lack of significant pore-forming or toxin translocating activity is positively correlated with, and could be predicted by, a lack of significant activity in the cell surface translocation, LFnDTA toxicity, or rubidium release assays described herein. In one desirable embodiment, the amount of pores formed or the amount of toxin translocated is less than 5 times the amount detected in a control assay without PA. More desirably, the amount is less than 2 times the amount in a control assay without PA.

“Fragment” means polypeptide having a region of consecutive amino acids that is identical to the corresponding region in a PA mutant. The fragment has either a reduced ability to form pores or translocate toxins compared to naturally-occurring PA. The fragment may also inhibit the pore-forming ability of naturally-occurring PA. This decrease in pore formation or toxin translocation is positively correlated with, and could be predicted by, a

decrease in activity in the cell surface translocation, LFnDTA toxicity, or rubidium release assays described herein. This decreased activity can be correlated with a decrease in the amount of a radiolabeled ligand that is translocated into cells in the cell surface translocation assay, a decrease in the inhibition of protein synthesis due to the translocation of a ligand into cells in the LFnDTA toxicity assay, or a decrease in the release of radiolabeled ions from cells in the rubidium release assay. In one desirable embodiment, the decrease in pore formation or translocation of EF or LF is at least 20% relative to naturally-occurring PA63. More desirably, the decrease is at least 40%, and most desirably, the decrease is at least 80%. The inhibition of the pore-forming ability of naturally-occurring PA is positively correlated with, and could be predicted by, a decrease in activity in an assay described above using an equimolar mixture of naturally-occurring PA and a PA fragment compared to using naturally-occurring PA alone. In one desirable embodiment, the decrease is at least 20, 40, 60, 80, or 99% compared to the activity using only naturally-occurring PA. Desirably, the fragment is immunogenic and induces the production of protective antibodies against naturally-occurring PA. In another desirable embodiment, the administration of the fragment to a mammal, as described in Example 9, prevents or diminishes an anthrax infection for a period of at least 1 month, more desirably 3 months, or most desirably 6 months. Examples of possible fragments include the C-terminal 63 kDA tryptic fragment of a PA mutant or a PA mutant having a deletion of amino acids that form the transmembrane pore

By "purified antibody" is meant an antibody which is at least 60%, by weight, free from proteins and naturally-occurring organic molecules with which it is naturally associated. Desirably, the preparation is at least 75%, more desirably 90%, and most desirably at least 99%, by weight, antibody. A purified antibody may be obtained, for example, by affinity chromatography using recombinantly-produced protein or conserved motif peptides and standard techniques.

By “competes with a naturally occurring B moiety” is meant binds to a cellular receptor and displaces a naturally-occurring B moiety. In one embodiment, an alteration that inhibits the pore-forming ability of a mutant B moiety does not alter, relative to wild-type, the B moiety’s ability to bind a cellular receptor.

By “specifically binds” is meant an antibody that recognizes and binds to, for example, wild-type PA or a PA mutant but does not substantially recognize and bind to other non-PA molecules in a sample, e.g., a biological sample, that naturally includes protein. A desirable antibody specifically binds any of the PA mutants of the invention (i.e., S382C, N399C, and N422C). Other desirable antibodies bind wild-type PA with at least 2, 5, 10, or 20 fold greater affinity than they bind one or more of the PA mutants of the invention.

Sequence identity is typically measured using sequence analysis software with the default parameters specified therein (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705). This software program matches similar sequences by assigning degrees of homology to various substitutions, deletions, and other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine, valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.

Other features and advantages of the invention will be apparent from the following detailed description.

25

### **Brief Description of the Drawings**

Fig. 1 is a schematic illustration of the intoxication pathway for ATx toxin. The PA component of ATx binds to a receptor on the surface of mammalian cells and delivers the enzymic A moieties of the toxin, edema factor (EF) and lethal factor (LF), to the cytosol, as described above.

30

Fig. 2A is a picture of SDS-PAGE gels showing the formation of nicked PA mutant proteins and the formation of SDS-resistant oligomers by wild-type, K397Q, and  $\Delta$ D2L2 PA. Fig. 2B is a picture of a native gel showing the formation of prepores by wild-type, K397A, and D425A PA.

5 Fig. 3 is a bar graph showing the amount of  $^{86}\text{Rb}$  released from  $^{86}\text{Rb}$  loaded cells after incubation with wild-type, K397A, or D425A PA compared to the no PA control.

Fig. 4A is a bar graph showing the similar level of  $^{35}\text{S}$ -LFn (N-terminal 1-255 amino acid PA binding domain of LF) binding by cells that  
10 have been incubated with wild-type, K397A, or D425A PA. Fig. 4B is a graph showing the reduction in translocation of  $^{35}\text{S}$ -LFn into cells that is mediated by K397A or D425A PA compared to wild-type PA.

Fig. 5 is a graph showing the percent of  $^3\text{H}$ -Leu in the TCA insoluble fraction (protein fraction) after incubation of cells with wild-type, K397A, or  
15 D425A PA in the LFnDTA toxicity assay. Translocation of LFnDTA, which contains LFn fused to the A-chain of diphtheria toxin, into the cell leads to ribosylation of EF-2, resulting in the inhibition of protein synthesis and a decrease in the amount of  $^3\text{H}$ -Leu in the protein fraction.

Fig. 6A is a bar graph showing the similar binding of  $^{35}\text{S}$ -LFn to  
20 cells incubated with wild-type,  $\Delta$ D2L2, the double mutant K397D + D425K, or a mixture of wild-type and  $\Delta$ D2L2 or K397D + D425K PA. Fig. 6B is a bar graph showing the reduction of wild-type PA-mediated translocation of  $^{35}\text{S}$ -LFn by  $\Delta$ D2L2 or K397D + D425K PA.

Fig. 7 is a graph showing the higher percent of  $^3\text{H}$ -Leu in the TCA  
25 insoluble fraction after incubation of  $\Delta$ D2L2 or K397D + D425K PA and wild-type PA compared to wild-type PA alone. This result corresponds to a decrease in wild-type PA-mediated inhibition of protein synthesis in the LFnDTA toxicity assay.



Fig. 8A is a graph showing the decrease in wild-type PA-mediated inhibition of protein synthesis in the LFnDTA toxicity assay. Increasing concentrations of mutant PA proteins relieve the wild-type PA-mediated inhibition of  $^3\text{H}$ -Leu uptake into the TCA insoluble fraction. Fig. 8B is a graph showing that much higher amounts of PA-SSR relative to wild-type PA are required to relieve the wild-type PA-mediated inhibition of  $^3\text{H}$ -Leu uptake compared to the amounts required for the mutants listed in Fig. 8A.

Fig. 9 is a graph showing the decrease in wild-type PA-mediated inhibition of protein synthesis in the LFnDTA toxicity assay due to the presence of increasing concentrations of a dominant negative PA mutant. The effect of the dominant negative mutants K397D + D425K ( $\square$ ),  $\Delta$ D2L2 ( $\blacksquare$ ), F427A ( $\circ$ ), D425K ( $\Delta$ ), and K397D ( $\diamond$ ) and the control mutant SSSR ( $\blacklozenge$ ) are shown in this figure.

Fig. 10 is a graph showing the decrease in wild-type PA-mediated inhibition of protein synthesis in the LFnDTA toxicity assay due to the presence of increasing concentrations of one of the following dominant negative PA mutants: K397D + D425K ( $\blacksquare$ ), F427A +  $\Delta$ D2L2 ( $\square$ ), K397D + D425K + F427A ( $\circ$ ), and K397D + F427A +  $\Delta$ D2L2 ( $\blacktriangle$ ).

Fig. 11 is a bar graph showing the inhibition of protein synthesis by a hetero-heptamer formed by mixing wild-type PA with a mutant PA (K397D + D425K,  $\Delta$ D2L2, F427A, or D425K) and then cleaving the PA molecules with trypsin. Inhibition of protein synthesis by an equivalent amount of a 1:1 mixture of the corresponding mutant and wild-type homo-heptamers was also measured.

Fig. 12 is a bar graph showing the effect of the dominant negative mutants K397D + D425K,  $\Delta$ D2L2, F427A, and D425K on the low-pH triggered translocation of  $^{35}\text{S}$  LFN across the plasma membrane. The results presented are the mean of three experiments  $\pm$  SEM.

Fig. 13 is the amino acid sequence of wild-type PA protein used for the assays described herein (SEQ ID No.: 21). The PA mutant proteins described herein are based on this wild-type sequence.

Fig. 14 is the polynucleotide sequence encoding the wild-type PA protein used for the assays described herein (SEQ ID No.: 22).

Fig. 15 is an alignment of the amino acid sequence of PA (SEQ ID No.: 24) with other binary A-B toxins that have ADP ribosyltransferase activity. The amino acid sequences of toxins from *Clostridium difficile* ("AcdADPRT"; SEQ ID No.: 25), *C. perfringens* ("Acpiota"; SEQ ID No.: 26), *C. spiroforme* ("Acsiota"; SEQ ID No.: 27), and *C. botulinum* ("Acbc2"; SEQ ID No.: 28) are listed. The *C. perfringens* and *C. spiroforme* toxins are frequently referred to as iota toxins while the botulinum toxin is referred to as C2. Additionally, the alignment includes the sequence of the toxin produced by *Bacillus cereus* ("AVIP1"; SEQ ID No.: 29), which is frequently referred to as VIP for vegetative insecticidal protein. Corresponding amino acids are aligned between PA and the other toxins shown.

Fig. 16 is an alignment of the amino acid sequence of PA (SEQ ID No.: 30) with the amino acid sequences of toxins from *Clostridium difficile* ("AcdADPRT"; SEQ ID No.: 31), *C. perfringens* ("Acpiota"; SEQ ID No.: 32), *C. spiroforme* ("Acsiota"; SEQ ID No.: 33), *C. botulinum* ("Acbc2"; SEQ ID No.: 34), and *Bacillus cereus* ("AVIP1"; SEQ ID No.: 35). Corresponding amino acids are aligned between PA and the other toxins shown. This alignment shows the complete sequences of the toxins.

25

### Detailed Description

We have found a means by which infection by A-B toxin producing bacteria can be halted. Thus, the invention provides a composition for use as an antidote to particular bacterial infections, including anthrax and gangrene. Because the composition is safe and immunogenic, it may also be used as a vaccine.

30

The multiple mutants of anthrax PA were constructed, expressed, purified, and assayed to determine whether they have reduced activity compared to wild-type PA. In particular, these mutants were assayed for the ability to bind PA ligands and receptors; to form prepores, SDS-resistant  
5 oligomers, and pores; and to translocate ligands across membranes as wild-type PA does (Figure 1). Based on the x-ray structure of PA, the mutated residues are predicted to project into the lumen of the PA prepore. PA mutants, or fragments thereof, with reduced or no detectable ability to form pores in membranes can be used as vaccines for the induction of protective antibodies to  
10 prevent anthrax infection. In addition, these mutants might be more effective than wild-type PA in treating anthrax infection because of their reduced ability to translocate EF and LF secreted by *Bacillus anthracis* in the infected mammal.

These point mutants and the previously reported deletion mutant  
15 lacking residues 302-325 of putative membrane spanning loop 2 of domain 2 ( $\Delta$ D2L2) (Miller *et al.*, Biochemistry 38:10432-10441, 1999) were further characterized to determine whether they could act as dominant negative inhibitors by reducing the pore formation of wild-type PA. This inhibition could result from the binding of ligands or receptors by the mutants so that  
20 fewer molecules were available for wild-type PA to bind. The mutants could also form oligomers with wild-type PA that have reduced or no detectable ability to form pores and translocate ligands. Dominant negative PA mutants, and fragments thereof, could be used as vaccines to elicit protective antibodies for the prevention or treatment of anthrax infection, as described above.  
25 Additionally, mutants or fragments with dominant negative activity could be used as therapeutics to treat anthrax infection by inhibiting the activity of PA secreted by *Bacillus anthracis* in the infected mammal. Because dominant negative mutants can induce the production of protective antibodies and inhibit the activity of PA produced by the infecting bacteria, they can be used as a  
30 combination vaccine/therapeutic that is particularly effective in treating

individuals suffering from, or at risk of developing, anthrax infection. Besides the need to abrogate toxin action as quickly as possible, it is also important to vaccinate individuals who have been exposed to aerosolized *B. anthracis* spores. This vaccination is essential to guard against delayed contraction of anthrax by germination of spores that can remain in the body for prolonged periods (at least a month).

Several mutants of PA were identified that lack the ability to form pores in membranes and translocate ligands and, thus, are potential vaccines for the prevention or treatment of anthrax infection (Table 1). Mutants # 1-12 were able to be proteolytically activated, to form the SDS-dissociable PA63 prepore state, and to bind a cellular receptor, EF, and LF. Some of the mutations prevented the conversion of the prepore to an SDS-resistant state (Table 1). These mutants (K397A, K397C, K397D, D425A, D425N, D425K D425E, D425K, K397D + D425K, and K395D + K397D + D425K + D426K) are also defective in pore formation and membrane translocation. The other class of mutants ( $\Delta$ D2L2 PA, K397Q, and F427A) forms SDS-resistant oligomers but does not undergo membrane insertion and pore formation. These results were unexpected.

In this study, several mutants of PA were identified (S382C, N399C, and N422C) that lack the ability to form pores in membranes and translocate ligands and, thus, are potential vaccines for the prevention or treatment of anthrax infection. These mutants were able to be proteolytically activated, to form the SDS-dissociable PA63 prepore state, and to bind a cellular receptor, EF, and LF.

**Table 1: PA Mutants and Phenotypes**

Mutant #	Mutation	Forms SDS-resistant oligomer?	Forms channels?	Dominant negative?
1	K397A	No	No	No
2	K397D	No	No	No
3	K397C	No	No	No
4	K397Q	Yes	No	No
5	D425A	No	No	No
6	D425N	No	No	Not determined
7	D425E	No	No	Not determined
8	D425K	No	No	No
9	F427A	Yes	No	Not determined
10	K397D + D425K	No	No	Yes
11	K395D + K397D + D425K + D426K	No	No	Yes
12	$\Delta$ D2L2	Yes	No	Yes
13	S382C			Yes
14	N399C			Yes
15	N422C			Yes

Several of the mutants (for example,  $\Delta$ D2L2, K397D + D425K double mutant, K395D+ K397D + D425K + D426K quadruple mutant, D425K, F427A, K397D +D425K + F427A triple mutant, F427A +  $\Delta$ D2L2 double mutant, K397D + F427A +  $\Delta$ D2L2 triple mutant, K397D + D425K + F427A +  $\Delta$ D2L2 quadruple mutant, F427D, and F427K) inhibit the wild-type PA-mediated translocation of ligands across membranes. The  $\Delta$ D2L2 and K397D + D425K PA mutants were shown to form oligomers with wild-type PA that are unable to translocate ligands. These results were unexpected. The presence of a single molecule of these mutants within a heptameric prepore may be sufficient to block conversion to the pore. This ability to block the pore formation by wild-type PA, coupled with the ability to compete with wild-type

PA for the binding of cellular receptors and to remove EF and LF from circulation, makes these mutants particularly attractive for use in the treatment and prevention of anthrax infection.

5 Mutation of other residues in PA could also inhibit pore formation or produce dominant negative activity. For example, residues that electrostatically interact with the charged side-chains of Lys397 or Asp425 may also be required for pore formation by PA, and the mutation of one or a combination of these residues may inhibit pore formation and result in dominant negative activity. Additionally, the deletion of smaller portions of  
10 the 302-325 D2L2 loop or the deletion of amino acids flanking the loop and part or all of the 302-325 region could produce these results.

The ability to obtain mutants of PA with no detectable ability to form pores or translocate ligands and mutants that serve as dominant negative inhibitors of wild-type PA suggests that similar mutants could be obtained in  
15 other toxins, such as  $\alpha$ -hemolysin from *Staphylococcus aureus*, aerolysin from *Aeromonas hydrophila*,  $\alpha$ -toxin from *Clostridium septicum*, cytotoxin from *Pseudomonas aeruginosa*, hetero-oligomeric toxins (AB5 toxins), or in the B moieties of tetanus, botulinum, or diphtheria toxins. Additionally, these results underscore the possibility of identifying dominant negative forms of a  
20 number of other oligomeric virulence factors, ranging from toxins to adhesins.

In anthrax toxin and other oligomeric systems in which the assembly process occurs in contact with the extracellular milieu, exogenously added mutant subunits can in principle be incorporated into the final structure, raising the possibility that such subunits could be used therapeutically. Systemic  
25 anthrax, although rare as a natural disease, is feared as an agent of biological warfare and terrorism, and dominant negative PA would seem to be a worthy candidate for a therapeutic. Assuming that administered dominant negative PA intermixes freely with wild-type PA produced in the body by *B. anthracis*, the proteins should co-assemble on cells to form inactive, dead-end complexes,  
30 thereby blocking the actions of both LF and EF. Besides preventing overt

symptoms, dominant negative mutants may also protect professional phagocytes from destruction, thereby aiding the host in eradicating the infection. No significant side effects have been observed following injection of wild-type PA into humans, and thus a mutant inactive form of the protein should pose no hazard.

Dominant negative PA may also be useful as a basis for a new vaccine against anthrax. As its name connotes, PA induces protective antibodies against anthrax, and indeed is the major immunogen of the vaccine currently licensed in the United States. The S382C, N399C, and N422C mutants described herein exhibit little or no diminution in immunogenicity relative to wild-type PA in Fisher rats. We have also found mutants that are unexpectedly dominant negative, such that administration of a 0.25:1 ratio of mutant to wild-type PA did not result in any detectable symptoms of anthrax infection in a rat model. Purified wild-type PA is under consideration as a replacement for the currently licensed vaccine, and if a dominant negative form of PA proves efficacious therapeutically, it might fulfill this role as well, eliminating the need to develop two almost identical pharmaceuticals.

The following examples are to illustrate the invention. They are not meant to limit the invention in any way. Unless otherwise noted, the data for the K397A and D425A PA mutants is representative of the data obtained for the PA mutants listed in Table 1 or other mutants described herein (e.g., S382, N399, and N422).

#### **Example 1: General methods**

##### *25 Cell culture, media and chemicals*

Chinese hamster ovary-K1 (CHO-K1) cells were obtained from the American Type Culture Collection (ATCC). The cells were grown in HAM's F-12 supplemented with 10% calf serum, 500 units/mL penicillin G, 2 mM L-glutamine and 500 units/mL streptomycin sulfate and maintained at 5% CO<sub>2</sub> in a humidified atmosphere. Cells were seeded into 24- or 96-well microtiter

plates (Costar, Cambridge, MA) 16-18 hours prior to the experiment. All media for cell culture was obtained from Gibco BRL unless noted otherwise. All chemicals were obtained from Sigma Chemical Co. unless specified.

## 5 *Construction and purification of PA proteins*

The  $\Delta$ D2L2 PA mutant, which does not contain amino acids 302-325 of PA (SEQ ID NO:21, Figure 13), was expressed and purified as described previously (Miller *et al.*, Biochemistry 38:10432-10441, 1999). The nucleic acid sequence encoding SEQ ID NO:21 is shown in Figure 14 (SEQ ID  
10 NO:22). The point mutations from Table 1 were constructed using the QuickChange method of site directed mutagenesis, following the manufacturer's protocol (Stratagene, La Jolla, CA). The plasmid of Miller *et al.* (*supra*) encoding wild-type PA was used as the template. The point mutants were cloned into a pET22-b(+) (Novagen) expression vector and transformed  
15 into BL21(DE3) (Novagen) for expression. The point mutants were expressed and purified as previously described (Miller, 1999). Briefly, cultures were grown in LB at 37 °C to an A<sub>600</sub> of 1.0. Expression of the recombinant protein was induced by the addition of  $\beta$ -D-isopropylthiogalactopyranoside to 1 mM. Following induction, the cells were grown for an additional 3 hours at 30 °C  
20 and harvested by centrifugation for 10 minutes at 8000 x g.

The proteins were released from the periplasm by osmotic shock. The cells were resuspended in 20 mM Tris-HCl, pH 8.0, 30% glucose and 1 mM EDTA and incubated at room temperature for 10 minutes with continuous stirring. The cells were harvested again by centrifugation, resuspended in 5  
25 mM MgSO<sub>4</sub> containing 20 mM Benzamidine, and incubated at 4 °C for 10 minutes with constant stirring. After the cells were again pelleted by centrifugation at 8000 x g, the periplasmic extract was decanted. Tris-HCL pH 8.0 was added to a final concentration of 20 mM, and the entire sample was loaded onto a Q-sepharose HP column. The unbound protein was washed off  
30 the column with buffer A (20 mM Tris, pH 8.0). The bound protein was eluted



with a 0% - 25% buffer B linear gradient (20 mM Tris, pH 8.0, 1 M NaCl). The PA containing fractions were concentrated, and the buffer was exchanged using a pd-10 column (Amersham-Pharmacia) containing buffer A. The PA-containing eluate was loaded onto a Mono-Q column and eluted with a 0 - 25%  
5 buffer B gradient. PA containing fractions were analyzed by SDS-PAGE and stored at -80 °C. Proteins concentrations were determined using the Bio-Rad protein assay kit based on the manufacturer's protocol. All liquid chromatography was performed using an AKTA-purifier liquid chromatography system (Amersham-Pharmacia).

10

#### *Proteolytic activation of PA*

Trypsin was used to proteolytically cleave PA83 to nicked PA (nPA). PA was diluted to a concentration of 0.5 mg/ml for the prepore-forming assay or 0.2 mg/ml for the other assays. Trypsin was added to a final trypsin to  
15 PA ratio of 1:1000 (w/w), and the mixture was incubated at room temperature for 20 minutes, followed by inhibition of the trypsin with a 10 molar excess of soybean trypsin inhibitor.

#### *Cell surface translocation assay*

20 A cell surface translocation assay to measure the PA-mediated translocation of radiolabeled LFn (N-terminal 1-255 amino acid PA binding domain of LF) was performed as previously described (Wesche *et al.*, Biochemistry 37:15737, 1998). Briefly, nPA ( $2 \times 10^{-8}$  M) was first bound to CHO cells, followed by  $^{35}\text{S}$  LFn which binds to the PA63 on the cell surface.  
25 Excess LFn was removed, and the cells were washed and subjected to a pH 5.0 pulse at 37°C. The low pH pulse mimics the acidification of the endosome and results in the PA-mediated translocation of LFn across the plasma membrane and into the cell. The samples were treated with pronase which proteolytically degrades extracellular  $^{35}\text{S}$ -LFn, but not  $^{35}\text{S}$ -LFn that has been translocated into  
30 the cell. The cells were then washed and lysed. To determine the total amount

of  $^{35}\text{S}$ -LFn that bound to the cells, some of the cells were not treated with pronase. Following lysis, the amount of  $^{35}\text{S}$ -LFn in the supernatant was determined using a scintillation counter. The percent translocation was calculated as follows:

5 
$$(\text{DPM protected from pronase})/(\text{DPM bound to cells}) \times 100 = \% \text{ translocated.}$$

To determine if mutant PA proteins inhibit the translocation of LFn by wild-type PA, this assay was also performed using equimolar amounts of mutant and wild-type PA that were combined prior to trypsinization and diluted to  $2 \times 10^{-8}$  M PA ( $1 \times 10^{-8}$  M of each protein) before being added to cells. When  
10 PA at a concentration of  $1 \times 10^{-8}$  M was used as a control, the translocation efficiency was only slightly affected by the drop in PA compared to the assay above with  $2 \times 10^{-8}$  M wild-type PA, suggesting that any decrease in translocation and binding was not the result of the drop in the concentration of wild-type PA (Figure 12).

15

#### *Inhibition of protein synthesis*

LFnDTA inhibition of protein synthesis was used as another method to measure PA-mediated translocation of ligands into cells (Milne *et al.*, Mol. Microbiol. 15:66, 1995). For assaying PA mutants in Table 1, CHO-K1 cells  
20 were plated at  $2.5 \times 10^4$  cells/well in a 96 well plate 16 hours prior to the addition of PA protein. PA83 ( $1 \times 10^{-12}$  M to  $1 \times 10^{-7}$  M) was incubated with cells in the presence of  $1 \times 10^{-8}$  M LFnDTA for 4 hours. The media was then removed and replaced with leucine free HAM's F-12 media supplemented with  $^3\text{H}$ -Leu at 1 mCi/ml. After a one hour incubation, the cells were washed with  
25 ice cold PBS followed by ice-cold trichloro acetic acid (10%) to precipitate proteins. The quantity of  $^3\text{H}$ -leu incorporated into the TCA insoluble material was determined using a scintillation counter and was used as a measure of the amount of newly synthesized protein.

Mutant PA proteins were also tested in this assay to see if they relieved the wild-type PA-mediated inhibition of  $^3\text{H}$ -Leu uptake. Wild-type PA was added to CHO cells at a concentration of  $1 \times 10^{-9}$  M with  $1 \times 10^{-8}$  M LFnDTA. Increasing amounts of one of the mutants were also added. The  
5 cells were incubated with the toxin for 4 hours and the samples were processed as described above.

The PA mutants listed in Fig. 9 were tested similarly. CHO-K1 cells ( $2.5 \times 10^4$  cells/well) in a 96-well plate were incubated for 18 hours at  $37^\circ\text{C}$  with wild-type PA (100 pM) in the presence of LFN-DTA (100 pM) and  
10 various amounts of individual PA mutants (K397D + D425K,  $\Delta\text{D2L2}$ , F427A, D425K, K397D, or SSSR). The medium was then removed and replaced with leucine-free HAM F-12 supplemented  $^3\text{H}$ -Leu at 1  $\mu\text{Ci/ml}$ . After incubation for one hour at  $37^\circ\text{C}$ , the cells were washed with ice-cold PBS followed by ice-cold 10% trichloroacetic acid (TCA). The quantity of  $^3\text{H}$ -Leu incorporated  
15 into the TCA-precipitable material was measured and is expressed as percent of that incorporated in the absence of PA. At the concentrations of wild-type PA and LFnDTA chosen, protein synthesis was inhibited by about 90% in the absence of mutant PA (dotted line). The mean of three experiments  $\pm$  SEM is reported. Similar results were seen when the initial incubation was four hours,  
20 instead of 18 hours. The K397D + D425K + F427A, F427A +  $\Delta\text{D2L2}$ , and K397D + F427A +  $\Delta\text{D2L2}$  PA mutants listed in Fig. 10 were tested similarly.

The PA-mediated inhibition of protein synthesis by hetero-heptamers of wild-type and mutant PA was compared to that of mixtures of the corresponding homo-heptamers. Homo-heptamers of wild-type PA<sub>63</sub> and  
25 K397D + D425K,  $\Delta\text{D2L2}$ , F427A, K397D, and D425K mutants, were prepared as described above. Putative hetero-heptamers were prepared by mixing each mutant PA with wild-type PA in a 1:1 ratio before trypsinization and column chromatography (Fig. 11). Wild-type PA (1 nM), hetero-heptamer (H) (final concentration 2 nM), or an equimolar mixture (M) (1 nM each) of the  
30 corresponding mutant homo-heptamer and wild-type-heptamer, was incubated

with CHO-K1 cells in the presence of LFnDTA (100 pM) for 18 hours, and inhibition of protein synthesis was measured as described above for Fig. 9. Heptamer concentrations are expressed in terms of monomeric PA63 subunits. Protein synthesis is expressed as the percent of a control without PA. The mean of three experiments  $\pm$  SEM is reported. Similar results were seen after a four hour incubation.

#### *Prepore and SDS-resistant oligomer formation*

The formation of prepores and SDS-resistant oligomers was measured by incubating nPA with an equimolar amount of LFn for 30 minutes at room temperature. To determine whether prepores had formed, the samples were subjected to electrophoresis in a 4-12% native gradient gel (FMC) using 50 mM CHES, pH 9.0, 2 mg/ml CHAPS as the running buffer. To determine whether low pH induced the formation of SDS-resistant heptamers, 100 mM sodium acetate, pH 4.5 was added until the pH of the solution reached 5.0, and then the sample was incubated at room temperature for 30 minutes. The sample was then dissolved in SDS-PAGE sample buffer and run on a 4-12% SDS-PAGE gradient gel. Proteins in the gels were visualized with Coomassie brilliant blue.

20

#### *Rubidium release*

CHO-K1 cells were plated at a density of  $2 \times 10^5$  cells/well and incubated at 37 °C for 24 hours. The media was then aspirated and replaced with media containing 1  $\mu$ Ci/ml  $^{86}$ RbCl and incubated for 16 hours. The cells were chilled on ice for 20 minutes, and the media was removed. The cells were washed, and nPA ( $2 \times 10^{-8}$ M) in HEPES buffered media was added. The cells were incubated with nPA for 2 hours on ice, followed by the addition of ice cold pH 5.0 buffer. After 30 minutes, samples from the supernatant were collected and counted in a scintillation counter to determine the amount of released  $^{86}$ Rb.

30

This standard assay may also be used to determine the effect of other pore-forming toxins on the amount of released  $^{86}\text{Rb}$ . Thus, other mutant toxins of the present invention may be tested in this assay to determine whether they have a reduced ability to form transmembrane pores.

5

**Example 2: Failure of most mutants to form SDS-resistant oligomers**

All PA mutants in Table 1 and wild type PA proteins were proteolytically nicked with trypsin as described above, forming nicked PA (nPA) proteins that migrated as lower molecular species when analyzed by SDS-PAGE (Figure 2A). Formation of SDS-dissociable prepores by PA mutants in Table 1 was detected by the decreased mobility in native gels of heptameric PA63 complexed with LFn compared to monomeric nPA (Figure 2B). The formation of prepores by the K397A and D425A PA mutants was further supported by the elution of the prepores from a MonoQ column at a higher salt concentration than that which elutes monomeric PA. The nPA mutants were also analyzed for the formation of SDS-resistant oligomers. As a positive control, wild-type PA was treated with LFn. The low pH pulse converted wild-type PA into SDS-resistant oligomers, which migrated as high molecular weight complexes when analyzed by SDS-PAGE.  $\Delta\text{D2L2}$  (PA lacking residues 302-325) and K397Q (Figure 2B). Wild-type, K397Q, F427A, and  $\Delta\text{D2L2}$  PA formed SDS-resistant oligomers when treated with low pH (Figure 2A and Table 1).

15

20

**Example 3: Failure of PA mutants to form pores in membranes**

25

The failure of most of the PA mutants to form SDS-resistant oligomers suggested that pore formation in cell membranes would also be inhibited. Pore formation was assayed by binding nPA proteins to cells loaded with the radioactive potassium analogue,  $^{86}\text{Rb}$ , pulsing with low pH, and measuring the release of  $^{86}\text{Rb}$  into the surrounding media, as described in Example 1. Wild-type nPA induced the release of  $^{86}\text{Rb}$  due to the insertion of

30

nPA into the membrane forming ion permeable pores. In contrast, none of the mutants in Table 1 induced  $^{86}\text{Rb}$  release (Figure 3 and Table 1). Thus, the inability of most PA mutants to form SDS-resistant oligomers (Example 2) correlates with an inability of these mutants to form pores in cell membranes.

5

#### **Example 4: Failure of PA mutants to translocate LFn across membranes**

Pore formation is a requisite step in the PA dependent translocation of ligands (i.e., LF, EF or LFn) across membranes. A cell surface translocation assay was used to directly measure the translocation of PA ligands into the cytoplasm of the cell (Example 1). None of the PA mutants in Table 1 had a significantly decreased ability to bind LFn (Fig. 4A); however, all of the assayed mutants had a significantly reduced ability to translocate LFn in this assay (Figs. 4B and 12). The SSSR control mutant caused little inhibition under these conditions. These data suggest that the mutants retain structural integrity and the ability to bind to the cellular receptor and LFn but are not able to form pores or translocate ligands across membranes.

10

15

#### **Example 5: Failure of PA mutants to translocate LFnDTA across membranes**

Another method used to measure translocation of PA ligands across membranes is the LFnDTA toxicity assay (Example 1). In this assay, CHO cells are treated with PA and a ligand containing LFn fused to the A-chain of diphtheria toxin DTA (LFnDTA). The translocated A-chain of diphtheria toxin ADP ribosylates the cytoplasmic protein EF-2, resulting in the inhibition of protein synthesis and the induction of cell death. This assay is a measure of translocation of a ligand from an endosomal compartment as opposed to a cell surface, as measured in Example 4. After incubation with LFnDTA and wild-type or mutant PA, cells were washed and incubated in leucine-free media supplemented with  $^3\text{H}$ -leucine. If protein synthesis is not inhibited,  $^3\text{H}$ -leucine will be incorporated into newly synthesized proteins. If protein synthesis is

20

25

30

inhibited by LFnDTA, little  $^3\text{H}$  will be incorporated. All of the mutants tested did not significantly inhibit protein synthesis in this assay (Figure 5). This result further supports the hypothesis that the lack of significant pore formation by PA mutants results in decreased membrane translocation of PA ligands by these mutants.

#### **Example 6: Inhibition of wild-type PA pore formation by PA mutants**

Since the PA mutants in Table 1 were defective in pore formation, they were tested to determine whether they could form inactive hetero-oligomers with wild-type PA thus inhibiting PA-mediated translocation of ligands across membranes.  $\Delta\text{D2L2}$ , K397D + D425K, and K395D + K397D + D425K + D426K PA inhibited wild-type PA in this manner. When mixed with an equimolar amount of wild-type PA, each of these three mutants markedly inhibited translocation of  $^{35}\text{S}$ -LFn into the cells in the cell surface translocation assay (Figure 6).  $^{35}\text{S}$ -LFn binding to cells was not inhibited (Figure. 6).

#### **Example 7: Inhibition of wild-type PA pore formation by PA mutants**

The effect of these mutant proteins on PA mediated LFnDTA toxicity was also measured. When the  $\Delta\text{D2L2}$ , K397D + D425K double mutant, or K395D + K397D + D425K + D426K quadruple mutant PA was mixed with an equimolar amount of wild-type PA in the LFnDTA assay, there was an approximately 2-log decrease in the wild-type PA-mediated inhibition of  $^3\text{H}$ -Leu (Fig. 7). Thus, the mutants inhibited PA-mediated translocation by 99%. The activity retained in the presence of the mutant proteins is probably the result of heptamers containing 7 wild-type PA molecules and 0 mutant PA molecules ( $\text{WT}_7\text{Mut}_0$ ). Using Pascal's triangle, 1% of the heptamers formed from the equimolar mixture of wild-type and mutant PA are expected to be 100% wild-type ( $\text{WT}_7\text{Mut}_0$ ) (Table 2). This calculated result agrees with the 1% experimentally measured residual activity present in the mixture.

Inhibition studies in which various ratios of wild-type to  $\Delta$ D2L2 or K397D + D425K mutant PA were tested in the LFnDTA assay indicate that the only active species in the mix is probably WT<sub>7</sub>Mut<sub>0</sub>. Thus, the majority of heptamers containing one molecule of  $\Delta$ D2L2 or K397D + D425K PA are inactive (Table 2), further supporting the dominant negative nature of these inhibitors.

**Table 2. Predicted and Measured Compositions of PA Oligomers Formed from Various Ratios of Mutant to Wild-type PA**

Mutant:WT (mole:mole)	Predicted % of the total heptamer population			Activity Retained	
	WT <sub>7</sub> Mut <sub>0</sub>	WT <sub>6</sub> Mut <sub>1</sub>	WT <sub>5</sub> Mut <sub>2</sub>	$\Delta$ D2L2 Mix	K397D + D425A Mix
1:1	0.78%	6%	22%	0.7% $\pm$ .2	0.9% $\pm$ .06
0.75:1	2	10.4	23.5%	3.8% $\pm$ 2	1.2% $\pm$ .2
0.5:1	5.8	25.8	56.8	13.5% $\pm$ .5	5.8% $\pm$ 3.6
0.25:1	21	57	85	14.3% $\pm$ 2	10% $\pm$ 2

N.B. The predicted values represent the percent of the total heptamers that are expected to have at least the indicated number of wild-type molecules in the mixtures containing varying ratios of mutant and wild-type PA. The WT<sub>7</sub>Mut<sub>0</sub> column represents the percent of the total heptamers that are expected to contain seven wild-type PA molecules. The WT<sub>6</sub>Mut<sub>1</sub> column represents the percent of the total heptamers that are expected to contain at least six wild-type PA molecules (*i.e.*, the heptamers that either contain six wild-type PA molecules and one mutant PA molecule or contain seven wild-type PA molecules and zero mutant PA molecules. Similarly, the WT<sub>5</sub>Mut<sub>2</sub> column represents the percent of the total heptamers that are expected to contain at least five wild-type PA molecules. These values were calculated using Pascal's triangle. The values listed under "Activity Retained" are the actual experimental values seen in these mixtures.

A titration of mutant with wild-type PA in the LFnDTA assay was performed to further characterize the inhibition of wild-type PA. Increasing amounts of one of the mutants was added to incubations of cells with wild-type PA and LFnDTA (Fig. 8A). The mutant PA-SSSR, which has the furin recognition site mutated from <sup>164</sup>RKKR<sup>167</sup> to <sup>164</sup>SSSR<sup>167</sup>, was included as a control. Since this mutant cannot be nicked by furin or other furin-like proteases and thus can not form pores, the mutant can only inhibit PA by



competing for the receptor. Both  $\Delta$ D2L2 and K397D + D425K greatly inhibited PA mediated translocation. Most importantly these mutants do not inhibit solely by competing for the receptor since far less protein is required by these mutants to see 50% inhibition than is required by PA-SSSR (Fig. 7B).

- 5 The single mutant constituents of K397D + D425K do not inhibit as well as the double mutant but inhibit better than PA-SSSR. Taken together these data suggest that  $\Delta$ D2L2, K397D + D425K, and K395D + K397D + D425K + D426K PA are dominant negative inhibitors of wild-type PA.

- The dominant negative inhibitory activity of the F427A, D425K, K397D + D425K + F427A, F427A +  $\Delta$ D2L2, K397D + F427A +  $\Delta$ D2L2 PA mutants was also measured. For this assay, increasing amounts of the mutant forms of PA were mixed with a constant amount of wild-type PA as described above. The most potent member of this group, the K397D + D425K + F427A triple mutant, almost completely blocked toxin action at a 1:1 ratio of mutant:wild-type PA. The D2L2, K397D + D425K, F427A, F427A +  $\Delta$ D2L2, and K397D + F427A +  $\Delta$ D2L2 PA mutants also had inhibitory activity. The K397D + D425K + F427A +  $\Delta$ D2L2, F427D, and F427K PA mutants also exhibited dominant negative activity in the LFnDTA toxicity assay. In contrast, another translocation-deficient mutant, K397D, caused virtually no inhibition at a 1:1 ratio, showing that not all mutants of this type are strongly inhibitory (Fig. 9). The SSSR control mutant caused no detectable inhibition of toxin action, even in 10-fold excess over wild-type PA, implying that competition for receptors did not contribute significantly to the inhibitory activities of the other mutants.

- 25 The hypothesis that inhibition by the dominant negative mutants depends upon the ability of their PA63 moieties to form hybrid complexes with wild-type PA63 was tested using purified homo- and hetero-heptamers. PA in solution can be cleaved at the furin site by mild trypsinization, and the resulting fragments can be separated by chromatography of the trypsin-nicked molecule on an anion-exchange column (Miller *et al.*, Biochemistry 38, 10432, 1999).
- 30

Purified PA63 isolated by this method is heptameric, indicating that the oligomerization equilibrium is greatly in favor of this form, and may be structurally similar or identical to the prepore. Purified homo-heptamers were prepared from wild-type PA and each of the K397D + D425K,  $\Delta$ D2L2, F427A, D425K, and K397D translocation-deficient PA mutants. Putative hetero-heptamers were prepared by mixing each mutant PA 1:1 with wild-type PA, followed by trypsinization of the mixture and chromatography of the products on an anion-exchange column.

The LFnDTA-dependent inhibition of protein synthesis by each hetero-heptamer and by an equivalent amount of a 1:1 mixture of the corresponding mutant and wild-type homo-heptamers was measured. Hetero-heptamers containing the K397D + D425K,  $\Delta$ D2L2, F427A and D425K mutants did not mediate the action of LFnDTA, whereas the corresponding mixtures of homo-heptamers were highly active (Fig. 11). In contrast, the putative hetero-heptamer formed by mixing K397D with wild-type PA was as active as the mixture of homo-K397D PA and homo-wild-type PA. These results are consistent with the properties of these mutants in the experiment of Fig. 9 and support the notion that PA63 from the dominant negative mutants inactivates the wild-type protein by co-oligomerizing with it. The absence of inhibitory activity of K397D in the hetero-heptamer preparation may reflect a defect either in ability to co-oligomerize with the wild-type protein or in ability to inhibit its activity within a heptamer. The finding that mutant homo-heptamers did not inhibit the activity of the wild-type indicates that little competition for receptors and little or no subunit exchange among heptamers occurred under the conditions of the experiment.

As described above, the fact that the K397D + D425K double mutant almost completely blocked activity in these LFnDTA toxicity assays suggests both that a single molecule of the mutant inactivates a heptamer and that oligomerization is stochastic. The  $\Delta$ D2L2, D425K, and F427A mutants appear to be slightly less inhibitory, implying that more than one molecule of these

mutants per heptamer may be required for inactivation and/or that their co-oligomerization with wild-type PA may not be purely stochastic. Other factors, such as the order of addition of B moieties to a growing heptamer complex (e.g., the B moiety that is added first or last) may also effect inactivation. It is not intended that the invention be limited by any proposed mechanism for inhibition set forth in the specification.

#### **Example 8: Formation of SDS-resistant oligomers containing mutant and wild-type PA**

To examine the interaction of  $\Delta$ D2L2 and K397D + D425K mutants with wild-type PA, an equimolar ratio of mutant to wild-type PA was mixed, nicked with trypsin, and analyzed by SDS-PAGE for SDS-resistant oligomer formation. When either mutant was mixed with wild-type PA, a new species of SDS-resistant PA was formed. In contrast to wild-type PA alone which produces a diffuse high molecular weight smear in the gel, the mixture of mutant and wild-type PA results in the formation of a sharp high molecular weight band. This sharp band also differs from what is seen for either of the mutants alone: K397D + D425K alone does not form an SDS-resistant oligomer, and  $\Delta$ D2L2 PA alone forms an oligomer which migrates farther in the gel than the band formed when wild-type PA is also present. Although the exact composition or nature of this band has not been determined, this band further suggests that the mutants interact with wild-type PA in SDS-resistant oligomers resulting in a change in the mobility of the oligomer in the gel.

#### **Example 9: Toxin inhibition *in vivo***

The properties displayed by the dominant negative mutants *in vitro* imply that they should inhibit toxin action *in vivo*. To test this hypothesis, activities of three of these mutants (K397D + D425K,  $\Delta$ D2L2, and F427A) were measured in a classical *in vivo* model for anthrax toxin action, the Fisher 344 rat (Ivins *et al.*, Appl. Environ. Microbiol. 55:2098, 1989). Male rats

(250-300 g) injected intravenously with a mixture of 8 µg LF and 40 µg PA (approximately 10 times the minimal lethal dose) become moribund after about 90 minutes (Table 3). When wild-type PA was replaced with any of the dominant negatives mutants, the animals showed no symptoms of intoxication during the two week time period before the animals were sacrificed. When a dominant negative PA was added to the wild-type PA/LF mixture before injection, either at a 1:1 ratio relative to wild-type PA (40 µg dominant negative PA) or at a 0.25:1 ratio (10 µg dominant negative PA), the injected animals also survived without symptoms. The SSSR mutant had little effect on the activity of the toxin. These results are consistent with our *in vitro* results and demonstrate that the dominant negative mutants can ablate anthrax toxin action *in vivo*, even at a sub-stoichiometric (0.25:1) ratio to wild-type PA.

15

**Table 3: Inhibition of wild-type PA by PA mutants *in vivo***

Quantity of protein (μg)					
WT	ΔD2L2	K397D + D425K	F427A	SSR	TTM
40	-	-	-	-	90 ± 11 min
-	40	-	-	-	Survived
-	-	40	-	-	Survived
-	-	-	40	-	Survived
40	40	-	-	-	Survived
40	-	40	-	-	Survived
40	-	-	40	-	Survived
40	-	-	-	40	100 ± 3 min
40	10	-	-	-	Survived
40	-	10	-	-	Survived
40	-	-	10	-	Survived

The ability of the K397D + D425K + F427A triple mutant ("Triple") to inhibit the activity of wild-type PA *in vivo* was compared to that of the K397D + D425K double mutant ("Double") (Table 4). This experiment was performed as described above using rats injected with a mixture of 40 μg wild-type PA, 10 μg LF, and either PBS or a dominant negative PA mutant.

**Table 4: Inhibition of wild-type PA by PA mutants *in vivo***

	Animals	amount of mutant PA	TTM
PBS	2	-	~100 minutes
Double	2	40 µg	Survived
Triple	2	40 µg	Survived
Double	4	4 µg	Survived
Triple	4	4 µg	Survived

The anti-PA and the neutralizing antibody titer generated by vaccination of rats with K397D + D425K, ΔD2L2, or F427A PA was also measured. For this determination, groups of six animals were vaccinated three times each at 0, 3, and 6 weeks with 50 µg of protein in 200 µl of Ribi Tri-Mix adjuvant (Sigma) by intramuscular injection into the hind-quarters. Two days prior to the first injection and 14 days following each injection, blood was drawn from each animal and the serum was collected. Sixteen days following the final injection the rats were challenged with a lethal dose of LF (30 µg PA + 6 µg LF) by IV injection as described in Table 5. The mean anti-PA antibody titers in the serum were determined in a standard ELISA assay against PA. The titers are reported as the reciprocal of the geometric mean of the dilution at which the reactivity of the serum ends. Neutralizing antibodies were titrated in an LFnDTA assay at  $1 \times 10^{-10}$  M PA and  $1 \times 10^{-10}$  M LFnDTA. Antibody dilutions were incubated with PA at 37°C for one hour prior to starting the assay. Protein synthesis inhibition was measured using the LFnDTA toxicity assay as described above. The neutralizing titers are represented as the reciprocal of the geometric mean dilution required to inhibit PA activity by 50%. As illustrated in Table 5, the K397D + D425K, ΔD2L2, and F427A PA mutants exhibited little or no diminution in immunogenicity relative to wild-

type PA in Fisher rats. The neutralizing and anti-PA antibody titers after three injections were similar, regardless of immunogen employed, and all vaccinated animals survived challenge with a lethal dose of wild-type PA plus LF administered 16 days after the last injection.

5

**Table 5: Anti-PA and the neutralizing antibody titer generated by vaccination of rats with PA mutants**

	Animals	Anti-PA Titer	Neutralizing Titer	TTM
PBS	6	< 10	< 10	74.2 ± 1.5
WT	5	43,300	2,490	Survived
ΔD2L2	6	47,500	3,350	Survived
K397D + D425K	6	65,500	2,260	Survived
F427A	6	132,000	6,090	Survived

**Example 10: Antibodies to PA**

Antibodies to a PA protein may be used as therapeutics and/or diagnostics. Antibodies may be produced using standard methods by immunologically challenging a B-cell-containing biological system, e.g., an animal such as a mouse or rabbit, with a PA protein or a fragment thereof to stimulate production of an anti-PA antibody by the B-cells, followed by isolation of the antibody from the biological system. For the generation of monoclonal antibodies, the spleen may be harvested from the animal with the highest ELISA-determined immune response to the PA protein, and the B-cells fused to NS-1 myeloma cells to generate hybridomas. Hybridomas that secrete antibodies which bind PA may be selected using a standard ELISA assay or by western blotting. Monoclonal cell lines producing a high antibody titer and specifically recognizing a PA protein are saved.

The cell lines may also be screened to identify lines that produce antibodies which bind naturally-occurring PA with greater affinity than a mutant PA protein. These antibodies may be generated by administering to animals fragments of naturally-occurring PA that contain residues such as K397, D425, D426, or F427. The resulting antibodies may then be screened to determine which antibodies bind naturally-occurring PA but do not bind a mutant PA protein in which one or more of residues K397, D425, D426, or F427 is mutated or deleted. For example, the antibodies may be applied to a column containing an immobilized mutant PA protein, and the antibodies that do not bind the mutant PA protein may be selected. Antibodies may also be generated that are reactive with residues in the D2L2 loop; these antibodies may be produced by administering a fragment of PA containing the D2L2 loop to an animal, as described above. Antibodies that are reactive with residues in the D2L2 loop of naturally-occurring PA may also be screened to select the antibodies that do not bind a mutant PA protein in which one or more residues in the D2L2 loop are deleted. Alternatively, antibodies may be generated that bind a mutant PA with greater affinity than a naturally-occurring PA molecule



by administering a fragment of a mutant PA to an animal as described above and selecting the antibodies with greater affinity for the mutant PA form. These antibodies may bind a residue in a mutant PA that is not present in a naturally-occurring PA.

5           Anti-PA antibodies may be used to measure PA protein in a biological sample such as serum, by contacting the sample with the antibody and then measuring immune complexes as a measure of the PA protein in the sample. Thus, these antibodies may be used in kits to determine whether a subject has been exposed to anthrax toxin.

10           Antibodies to PA can also be used as therapeutics for the treatment or prevention of anthrax infection. If a anti-PA antibody that binds wild-type PA but does not bind a dominant negative PA mutant is administered to a subject for passive immunization against anthrax infection, a dominant negative PA mutant may also be administered to the same subject as a  
15           therapeutic to inhibit the activity of wild-type PA. Because the administered anti-PA antibody does not react with the therapeutic dominant negative PA mutant, the anti-PA antibody should not reduce the ability of the dominant negative PA mutant to inhibit wild-type PA. Additionally, an anti-PA antibody that does not react with a therapeutic dominant negative PA mutant may be  
20           used to determine the amount of wild-type PA present in a sample from a subject who has been treated with the dominant negative PA mutant.

Similar antibodies may be generated for other mutant B moieties of the present invention.

#### 25   **Example 11: Administration of PA proteins and fragments**

It is not intended that the administration of the PA proteins or fragments of the invention be limited to a particular mode of administration, dosage, or frequency of dosing; the present mode contemplates all modes of administration, including oral, intramuscular, intravenous, subcutaneous, by  
30           inhalation, or any other route sufficient to provide a dose adequate to prevent or

treat an anthrax infection. One or more of the mutant PA proteins or fragments may be administered to a mammal in a single dose or multiple doses. When multiple doses are administered, the doses can be separated from one another by, for example, one week to one month. It is to be understood that for any particular subject, specific dosage regimes should be adjusted over time according to the individual need and the professional judgement of the person administering or supervising the administration of the compositions.

The pharmaceutical compositions containing one or more PA proteins or fragments of the invention can be prepared as described previously in Remington's Pharmaceutical Sciences by E. W. Martin. Pharmaceutical stabilizing compounds, delivery vehicles, carrier vehicles, or adjuvants may be used. For example, human serum albumin or other human or animal proteins can be used. Phospholipid vesicles or liposomal suspensions are possible pharmaceutically acceptable carriers or delivery vehicles. Adjuvants that can be used in the invention include aluminum compounds, such as aluminum hydroxide, aluminum phosphate, and aluminum hydroxy phosphate. These compositions can be prepared according to methods known to those skilled in the art.

Other mutant B moieties or fragments of the invention may be administered similarly.

#### **Example 12: Other pore-forming mutants**

The crystal structure of PA identified four domains of PA (Petosa *et al.*, Nature 385(6619): 833-838, 1997). Domain 2 (residues 259-487) contains a large flexible loop that may undergo a major conformational change during conversion from the prepore to the pore. Mutation, deletion, or insertion of one or more amino acids in this region may result in inhibition of the pore-forming ability of the protein *in vivo* and/or result in the ability of the PA mutant to inhibit the pore-forming ability of naturally-occurring PA. For example, residues in domain 2 of PA that are identical to the corresponding residues in

one or more other pore-forming toxins (such as toxins from *Clostridium difficile*, *C. perfringens*, *C. spiroforme*, *C. botulinum*, *Bacillus cereus*, or *B. thuringiensis*; Figs. 15 and 16) may be mutated. These residues may be mutated or deleted in PA to generate dominant negative PA mutants. The following residues of domain 2 in PA are invariant among the binary A-B toxins listed in Figs. 15 and 16: A259, P260, V262, V264, M266, E267, S272, E275, T298, N353, N361, N363, R365, Y366, N368, G370, T371, Y375, V377, P389, T380, T381, V384, T393, I394, P407, Y411, P412, A420, D425, F427, I432, N435, Q438, L450, T452, Q454, G457, G474, W477, and I484.

These residues may be mutated to any other amino acid. For example, the residues may be changed to an amino acid with a smaller side chain such as glycine or alanine, or the residues may be changed to an amino acid with a larger or branched side chain such as tryptophan, leucine, or methionine. Additionally, charged residues may be changed to residues with a neutral side chain or residues with a side chain of the opposite charge. Other examples of residues that may be used to replace a naturally-occurring residue are listed in Table 1.

In addition to anthrax toxin, the present invention is relevant to other pore-forming toxins. These toxins may also be mutated to generate toxins with reduced or negligible ability to oligomerize, to form transmembrane channels, or to translocate a ligand. Additionally, dominant negative mutants of other pore-forming mutants may be generated. For example, mutations that correspond to the PA mutations described herein may be made in other toxins that are homologous to PA (such as toxins from *Clostridium difficile*, *C. perfringens*, *C. spiroforme*, *C. botulinum*, *Bacillus cereus*, or *B. thuringiensis*) (Figs. 15 and 16 and Table 6). Residues in other toxins that correspond to residues in domain 2 of PA may be mutated as described above. Additionally, at least 1, 3, 5, 8, 10, 15, 20, or 24 of the amino acids in the region that corresponds to the D2L2 loop of PA may be deleted in other pore-forming toxins. Also, one or more point mutations may be made at residues that

correspond to the mutated PA residues described herein. Exemplary corresponding residues are shown in Table 6, below.

- 5 **Table 6:** Mutations in other pore-forming toxins that correspond to the mutations in anthrax PA are described herein. The residues in the other pore-forming toxins that correspond to the residues that were mutated in PA may also be mutated to any other amino acid.

anthrax PA	<i>C. difficile</i> toxin	<i>C.</i> <i>perfringens</i> toxin	<i>C.</i> <i>spiroforme</i> toxin	<i>C.</i> <i>botulinum</i> toxin	<i>B. cereus</i> toxin
K397A	Q425A	Q424A	Q428A	Q398A	K879A
K397D	Q425D	Q424D	Q428D	Q398D	K879D
K397C	Q425C	Q424C	Q428C	Q398C	K879C
K397Q	Q425Q	Q424Q	Q428Q	Q398Q	K879Q
D425A	D453A	D452A	D456A	D426A	D907A
D425N	D453N	D452N	D456N	D426N	D907N
D425E	D453E	D452E	D456E	D426E	D907E
D425K	D453K	D452K	D456K	D426K	D907K
F427A	F455A	F454A	F458A	F428A	F909A
K397D + D425K	Q425D + D453K	Q424D + D452K	Q428D + D456K	Q398D + D426K	K879D + D907K
K395D + K397D + D425K + D426K	K423D + Q425D + D453K + Q454K	K422D + Q424D + D452K + Q453K	K426D + Q428D + D456K + Q457K	K396D + Q398D + D426K + Q427K	T877D K879D + D907K + D908K
$\Delta$ D2L2	$\Delta$ 340–358	$\Delta$ 339–357	$\Delta$ 343–361	$\Delta$ 307–331	$\Delta$ 797–816
K397D + D425K + F427A	Q425D + D453K + F455A	Q424D + D452K + F454A	Q428D + D456K + F458A	Q398D + D426K + F428A	K879D + D907K + F909A
F427A + $\Delta$ D2L2	F455A + $\Delta$ 340–358	F454A + $\Delta$ 339–357	F458A + $\Delta$ 343–361	F428A + $\Delta$ 307–331	F909A + $\Delta$ 797–816
K397D + F427A + $\Delta$ D2L2	Q425D + F455A + $\Delta$ 340–358	Q424D + F454A + $\Delta$ 339–357	Q428D + F458A + $\Delta$ 343–361	Q398D + F428A + $\Delta$ 307–331	K879D + F909A + $\Delta$ 797–816
K397D + D425K + F427A + $\Delta$ D2L2	Q425D + D453K + F455A + $\Delta$ 340–358	Q424D + D452K + F454A + $\Delta$ 339–357	Q428D + D456K + F458A + $\Delta$ 343–361	Q398D + D426K + F428A + $\Delta$ 307–331	K879D + D907K + F909A + $\Delta$ 797–816
F427D	F455D	F454D	F458D	F428D	F909D
F427K	F455K	F454K	F458K	F428K	F909K
N399C	N427C	N426C	N430C	S400C	N881C
N422C	N450C	N449C	N453C	N423C	T904C
S382C	N411C	N410C	N414C	T384C	S865C

Any of these mutant forms of pore-forming toxins may be administered to a mammal for the treatment or prevention of infection by the pathogens (e.g., bacteria) that produce the corresponding toxin.

Alternatively, random mutagenesis may be performed on nucleic acids encoding pore-forming mutants (such as cholesterol dependent cytolysins or hexameric or heptameric toxins related to the Staphylococcal  $\alpha$ -toxin) using standard molecular biology methods. The encoded mutant toxins may be expressed and optionally purified using standard methods. The rubidium release assay described herein may be used to identify mutant toxins with a reduced ability to form a transmembrane channel. Additionally, animal models may be used to identify dominant negative toxin mutants that reduce the toxicity of the corresponding wild-type toxin when both the mutant and wild-type toxins are administered to the animal.

#### Other Embodiments

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by reference. U.S. utility application 09/848,909 and U.S. provisional application 60/424,987 is incorporated in its entirety.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure that come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth, and follows in the scope of the appended claims.

## Claims

1. A B moiety of a pore-forming binary A-B toxin, or a fragment thereof, wherein said B moiety has a mutation that inhibits said B moiety's pore-forming ability and is selected from the group consisting of S382, N399, and N422 of SEQ ID NO:21, or a corresponding amino acid of a bacterial toxin.
2. The B moiety of claim 1, wherein any one of said amino acids is mutated to cysteine.
3. The B moiety of claim 1, wherein said B moiety has an amino acid sequence that is at least 80% identical to SEQ ID NO:21 and that has an alteration selected from the group consisting of S382, N399, and N422.
4. The B moiety of claim 1, wherein said B moiety is selected from the group consisting of *Clostridium difficile*, *C. perfringens*, *C. spiroforme*, *C. botulinum*, and *Bacillus cereus*, wherein said B moiety has an alteration in an amino acid that corresponds to S382, N399, or N422.
5. A vaccine composition comprising a mutant B moiety of claim 1, or a fragment thereof, in a pharmaceutically acceptable carrier.
6. The vaccine composition of claim 5, wherein said vaccine is inactivated by chemical or physical means.
7. The vaccine composition of claim 5, wherein said vaccine is administered with a pharmaceutically suitable carrier or an adjuvant.

8. A method of preventing or treating a bacterial infection in a mammal by administering to said mammal the vaccine of claim 5.

9. The method of claim 8, wherein said mammal is a human.

10. A B moiety of a pore-forming binary A-B toxin, wherein said B moiety comprises an alteration in an amino acid selected from the group consisting of S382, N399, and N422 of SEQ ID NO:21, or a corresponding amino acid of a bacterial toxin, wherein said alteration inhibits the pore-forming ability of said B moiety and inhibits the pore-forming ability of a naturally-occurring B moiety.

11. The B moiety of claim 10, wherein said mutation inhibits the pore-forming ability of said toxin *in vivo*.

12. The B moiety of claim 10, wherein said B moiety lacks pore-forming ability *in vitro* or *in vivo*.

13. The B moiety of claim 10, wherein said B moiety is anthrax protective antigen (PA).

14. The B moiety of claim 10, wherein said B moiety binds the A moiety of anthrax protective antigen.

15. The B moiety of claim 10, wherein said B moiety binds lethal factor (LF) or edema factor (EF) A moieties.

16. The B moiety of claim 10, wherein said B moiety competes with a naturally-occurring B moiety for binding to a receptor on the surface of a mammalian cell.

17. The B moiety of claim 10, wherein said B moiety binds a naturally occurring B moiety of anthrax protective antigen.

18. The B moiety of claim 10, wherein said B moiety oligomerizes with a naturally-occurring B moiety to form a complex that has reduced ability to form a pore.

19. The B moiety of claim 10, wherein said B moiety fails to form a pore and fails to translocate an A moiety across the membrane into the host cell cytoplasm.

20. A method of preventing or treating bacterial infection in a mammal, said method comprising administering a B moiety of claim 1 or 10, or a fragment thereof, that inhibits the pore-forming ability of a naturally-occurring B moiety to said mammal.

21. The method of claim 20, wherein said mammal is a human.

22. The method of claim 20, wherein said method comprises administering the B moiety of claim 1 or 10, or a fragment thereof to a mammal that has been exposed to *B. anthracis* spores.

23. The method of claim 20, wherein said method comprises administering said B moiety prophylactically.

24. The method of claim 20, wherein said mutant B moiety is administered in a pharmaceutically suitable carrier.



25. The method of claim 20, wherein said method further comprises administering to said mammal an anti-B moiety antibody, wherein said antibody binds a naturally-occurring B moiety, but fails to bind a B moiety having an alteration.

26. A nucleic acid encoding the mutant B moiety of claim 1 or 10.

27. A vector comprising the nucleic acid of claim 26.

28. A purified antibody that specifically binds a B moiety of claim 1 or 10, but fails to bind a naturally-occurring B moiety.

29. The antibody of claim 28, wherein said antibody is a monoclonal antibody.

30. The antibody of claim 28, wherein said antibody is a polyclonal antibody.

FIG. 1




FIG. 2A




FIG. 2B




FIG. 3





FIG. 4

B



A




FIG. 5





FIG. 6

A



B






FIG. 7




FIG. 8A




FIG. 8B




FIG. 9





FIG. 10






FIG. 11




FIG. 12

## FIG. 13

Figure 13: SEQ ID No.: 21

EVKQENRLLNESESSQGLLGYFSDLNQAPMVVTSSTGDLSPSSELENIPSEN  
 QYFQSAIWSGFIKVKKSDEYTF  
 TSADNHVTMWVDDQEVINKASNSNKIRLEKGRLYQIKIQYQRENPTTEKGLDFKL  
 YWTDSONKKEVISSDNLQLPELKQS  
 SNRKKRSTAGPTVPDRDNDGIPDSLEVEGYTVDVKNKRTFLSPWISNIHEKKG  
 LTKYKSSPEKWSSTASDPYSDFEKVT  
 GRIDKNVSPEARHPLVAAYPVHVDMENILSKNEDQSTQNTDSETRTISKNTSTS  
 RTHTSEVHGNAEVHASFFDIGGSV  
 SAGFSNSNSTVAIDHSLSLAGERTWAETMGLNTADTARLNANIRYVNTGTAPIY  
 NVLPTTSLVLGKNQTLATIKAKENQ  
 LSQILAPNNYYPKSNLAPIALNAQDDFSSTPITMNYNQFLELEKTKQLRLDTDQV  
 YGNIAITYNFENGVRVDTGSNWSEV  
 LPQIQETTARIIFNGKDLNLVERRIAAVNPSDPLETTKPDMTLKEALKIAFGFNEPN  
 GNLQYQGKDITEFDNFQDQTSQ  
 NIKNQLAELNATNIYTVLDKIKLNAKMNILRDKRFHYDRNNIAVGADSVVKEA  
 HREVINSSTEGLLLNIDKIRKILS  
 GYTVEIEDTEGLKEVINDRYDMLNISSLRQDGKTFIDFKKYNDKLLPLYISNPNYKV  
 NVYAVTKENTINPSENGDTSTNG  
 IKKILFSKKGYEIGZ



## FIG. 14

Figure 14: SEQ ID No.: 22

GAAGTTAAACAGGAGAACCGGTTATTAATGAATCAGAATCAAGTTCCCAGG  
GGTTACTAGGATACTATTTTAGTGATT  
GAATTTTCAAGCACCCATGGTGGTTACCTCTTCTACTACAGGGGATTTATCTA  
TTCCTAGTTCTGAGTTAGAAAATATTC  
CATCGGAAAACCAATATTTTCAATCTGCTATTTGGTCAGGATTTATCAAAGTT  
AAGAAGAGTGATGAATATACATTTGCT  
ACTTCGCTGATAATCATGTAACAATGTGGGTAGATGACCAAGAAGTGATTA  
ATAAAGCTTCTAATTCTAACAAAATCAG  
ATTAGAAAAAGGAAGATTATATCAAATAAAAAATTCAATATCAACGAGAAAAT  
CCTACTGAAAAAGGATTGGATTTCAAGT  
TGTACTGGACCGATTCTCAAAATAAAAAAGAAGTGATTTCTAGTGATAACTT  
ACAATTGCCAGAATTAACAAAATCT  
TCGAACTCAAGAAAAAAGCGAAGTACAAGTGCTGGACCTACGGTTCCAGACC  
GTGACAATGATGGAATCCCTGATTCATT  
AGAGGTAGAAGGATATACGGTTGATGTCAAAAATAAAAGAACTTTTCTTTCA  
CCATGGATTTCTAATATTCATGAAAAGA  
AAGGATTAACCAAATATAAATCATCTCCTGAAAAATGGAGCACGGCTTCTGA  
TCCGTACAGTGATTTTCGAAAAGGTTACA  
GGACGGATTGATAAGAATGTATCACCAGAGGCAAGACACCCCCTTGTGGCAG  
CTTATCCGATTGTACATGTAGATATGGA  
GAATATTATTCTCTCAAAAAATGAGGATCAATCCACACAGAATACTGATAGT  
GAAACGAGAACAATAAGTAAAAATACTT  
CTACAAGTAGGACACATACTAGTGAAGTACATGGAAATGCAGAAGTGTCATGC  
GTCGTTCTTTGATATTGGTGGGAGTGTA  
TCTGCAGGATTTAGTAATTCGAATTCAAGTACGGTCGCAATTGATCATTCACT  
ATCTCTAGCAGGGGAAAGAACTTGGGC  
TGAAACAATGGGTTTAAATACCGCTGATACAGCAAGATTAAATGCCAATATT  
AGATATGTAAATACTGGGACGGCTCCAA  
TCTACAACGTGTTACCAACGACTTCGTTAGTGTTAGGAAAAAATCAAACACT  
CGCGACAATTAAAGCTAAGGAAAACCAA  
TTAAGTCAAATACTTGCACCTAATAATTATTATCCTTCTAAAAACTTGGCGCC  
AATCGCATTAATGCACAAGACGATT  
CAGTTCTACTCCAATTACAATGAATTACAATCAATTTCTTGAGTTAGAAAAAA  
CGAAACAATTAAAGATTAGATACGGATC  
AAGTATATGGGAATATAGCAACATACAATTTTGAAAATGGAAGAGTGAGGGT  
GGATACAGGCTCGAACTGGAGTGAAGTG  
TTACCGCAAATTCAAGAAACAACCTGCACGTATCATTTTTAATGGAAAAGATTT  
AAATCTGGTAGAAAGGCGGATAGCGGC  
GGTTAATCCTAGTGATCCATTAGAAACGACTAAACCGGATATGACATTAAAA  
GAAGCCCTTAAAAATAGCATTTGGATTTA  
ACGAACCGAATGGAACTTACAATATCAAGGGAAAGACATAACCGAATTTG  
ATTTTAATTTTCGATCAACAAACATCTCAA  
AATATCAAGAATCAGTTAGCGGAATTAACGCAACTAACATATATACTGTAT  
TAGATAAAATCAAATTAAATGCAAAAAT

FIG. 14 (CONTINUED)

GAATATTTTAATAAGAGATAAACGTTTTTCATTATGATAGAAATAACATAGCA  
GTTGGGGCGGATGAGTCAGTAGTTAAAGG  
AGGCTCATAGAGAGTAATTAAATTCGTCAACAGAGGGATTATTGTTAAATAT  
TGATAAGGATATAAGAAAAATATTATCA  
GGTTATATTGTAGAAATTGAAGATACTGAAGGGCTTAAAGAAAGTTATAAATG  
ACAGATATGATATGTTGAATATTTCTAG  
TTACGGCAAGATGGAAAAACATTTATAGATTTTAAAAAAATATAATGATAAA  
TTACCGTTATATATAAGTAATCCCAAT  
ATAAGGTAATGTATATGCTGTTACTAAAGAAACACTATTATTAAATCCTAGT  
GAGAAATGGGGATACTAGTACCAACGGG  
ATCAAGAAAAATTTTAATCTTTTCTAAAAAAGGCTATGAGATAGGATAA

PA 137  
cdADPRT 172  
cpiote 170  
cpiote 165  
cpiote 140  
VIP1 131

β10 β11

PA 191  
cdADPRT 234  
cpiote 233  
cpiote 237  
cpiote 201  
VIP1 195

β12 β13 α1 TT TT α2 TT α3 TT α4 TT

PA 261  
cdADPRT 299  
cpiote 298  
cpiote 302  
cpiote 266  
VIP1 260

β14 β15

PA 330  
cdADPRT 363  
cpiote 362  
cpiote 366  
cpiote 334  
VIP1 321

β16 TT β17 β18 TTT β19 TT

PA 400  
cdADPRT 428  
cpiote 427  
cpiote 431  
cpiote 401  
VIP1 392

β20 TT β21 TT β22 α4 β23 β24

PA 470  
cdADPRT 496  
cpiote 495  
cpiote 499  
cpiote 469  
VIP1 450

β25 α5 β26 TTT β27 α6 TT

PA 530  
cdADPRT 562  
cpiote 561  
cpiote 565  
cpiote 536  
VIP1 517

β28 β29 α7 β30 α8 β31 β32 TT β33 TT

PA 595  
cdADPRT 626  
cpiote 625  
cpiote 629  
cpiote 600  
VIP1 1086

β32 TT β33 α8 β34 β35 α9 β36 TT β37 TT



## FIG. 16

FA

FA  
cdADPRT  
cpicta  
csicta  
cba2  
VIP1  
MKRKEGR LPMVSKKQLQVVTNT VLLSTVTFSE SLNNEVIRAEQLNINSQSKYT NLQNLKITEKVEETREBK

FA

FA  
cdADPRT  
cpicta  
csicta  
cba2  
VIP1  
EKANZWGRKEKEKWKLTATEGRKMNIPLDKNDIKINYEITF SIAGSPEDZ IKDLKEIDRMFDEKTNLSN

FA

FA  
cdADPRT  
cpicta  
csicta  
cba2  
VIP1  
SITTYKIVVEFTT IGFHKSLTEGHT INSLAKAQPKQQLDRDKKPSYLDTHLTACQVSSKZKVELKVTVP

FA

FA  
cdADPRT  
cpicta  
csicta  
cba2  
VIP1  
SGKGSITFTKAGVILNHSYRKLLDNGYMVHVRKVSQVVRGVZCLOEGTLKKSLEFKNDINAEANSHG

FA

FA  
cdADPRT  
cpicta  
csicta  
cba2  
VIP1  
MKNVBEWAKDLTDSQREALDGYARQDYKEINUNLKNCGGSGNEKLDQAQIKNI SDALGKXIFENITVYRN

FA

FA  
cdADPRT  
cpicta  
csicta  
cba2  
VIP1  
CGMTEPGYQISDFLPS LKDFEEQFLNTIKEDNGYKSTSLSSERLAAPGSKKEILRLQVFKGSGTAYLSAI

FA

FA  
cdADPRT  
cpicta  
csicta  
cba2  
VIP1  
GGPASEDKILLDLKSKYHIDKVTVEVINGVKRYVVDATLLTNSRGPTSTFTFSPSTFTFSDICSTKRTN

FA

FA  
cdADPRT  
cpicta  
csicta  
cba2  
VIP1  
VNRKEDRLLESESSSQGLUQYQSSD LNECAFNVVPSSTT QHLSIFSSQDQMTFSE.n QVPSSTISST  
SHKRLGEIVNEDELFPMNCGQYQSSD LNECAFNVVPSSTT QHLSIFSSQDQMTFSE.n QVPSSTISST  
THCRLEETINEBITLSNCGQYQSSD LNECAFNVVPSSTT QHLSIFSSQDQMTFSE.n QVPSSTISST  
DNCMEBTNEKTVSSNCGQYQSSD LNECAFNVVPSSTT QHLSIFSSQDQMTFSE.n QVPSSTISST  
EN.SMKHSNKNYFTINCGQYQSSD LNECAFNVVPSSTT QHLSIFSSQDQMTFSE.n QVPSSTISST  
QISLTKKQCKEMLEKCGQYQSSD LNECAFNVVPSSTT QHLSIFSSQDQMTFSE.n QVPSSTISST

FA

FA  
cdADPRT  
cpicta  
csicta  
cba2  
VIP1  
VRRSLGEYTFATSAHNNHVTMNVDPQZVINNA SpSHRIPILFRRGLYCTIQDQ. .REN. .FTFEGDLPFRQW  
FSRLGEYTLSTTRD.DVLMQVM. .TESTISHMLRVNFKRGRKRVVRELQ. .LRLILGSIDNLSSTFRQW  
FSRLGEYTLSTTRD.DVLMQIM. .ARGLIABTLRVNFKRQA YHILREIQ. .LRLILGSIDNLSSTFRQW  
FSRLGEYTLSTTRD.DVLMQIM. .ARGLIABTLRVNFKRQA YHILREIQ. .LRLILGSIDNLSSTFRQW  
FSRLGEYTLSTTRD.DVLMQIM. .ARGLIABTLRVNFKRQA YHILREIQ. .LRLILGSIDNLSSTFRQW  
SRITGEYTLSTTRD.DVLMQIM. .ARGLIABTLRVNFKRQA YHILREIQ. .LRLILGSIDNLSSTFRQW

FIG. 16 (CONTINUED)





FIG. 16 (CONTINUED)



## SEQUENCE LISTING

<110> President and Fellows of Harvard College et al.

<120> Compounds and Methods for the Treatment  
and Prevention of Bacterial Infection

<130> 00742/072003

<150> US 60/424,987

<151> 2002-11-08

<160> 38

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 735

<212> PRT

<213> Bacillus anthracis

<400> 1

Glu	Val	Lys	Gln	Glu	Asn	Arg	Leu	Leu	Asn	Glu	Ser	Glu	Ser	Ser	Ser		
1				5					10					15			
Gln	Gly	Leu	Leu	Gly	Tyr	Tyr	Phe	Ser	Asp	Leu	Asn	Phe	Gln	Ala	Pro		
		20						25					30				
Met	Val	Val	Thr	Ser	Ser	Thr	Thr	Gly	Asp	Leu	Ser	Ile	Pro	Ser	Ser		
		35					40					45					
Glu	Leu	Glu	Asn	Ile	Pro	Ser	Glu	Asn	Gln	Tyr	Phe	Gln	Ser	Ala	Ile		
	50					55					60						
Trp	Ser	Gly	Phe	Ile	Lys	Val	Lys	Lys	Ser	Asp	Glu	Tyr	Thr	Phe	Ala		
65				70						75					80		
Thr	Ser	Ala	Asp	Asn	His	Val	Thr	Met	Trp	Val	Asp	Asp	Gln	Glu	Val		
				85					90					95			
Ile	Asn	Lys	Ala	Ser	Asn	Ser	Asn	Lys	Ile	Arg	Leu	Glu	Lys	Gly	Arg		
			100					105						110			
Leu	Tyr	Gln	Ile	Lys	Ile	Gln	Tyr	Gln	Arg	Glu	Asn	Pro	Thr	Glu	Lys		
		115					120						125				
Gly	Leu	Asp	Phe	Lys	Leu	Tyr	Trp	Thr	Asp	Ser	Gln	Asn	Lys	Lys	Glu		
	130					135					140						
Val	Ile	Ser	Ser	Asp	Asn	Leu	Gln	Leu	Pro	Glu	Leu	Lys	Gln	Lys	Ser		
145					150					155					160		
Ser	Asn	Ser	Arg	Lys	Lys	Arg	Ser	Thr	Ser	Ala	Gly	Pro	Thr	Val	Pro		
				165					170					175			
Asp	Arg	Asp	Asn	Asp	Gly	Ile	Pro	Asp	Ser	Leu	Glu	Val	Glu	Gly	Tyr		
			180					185					190				
Thr	Val	Asp	Val	Lys	Asn	Lys	Arg	Thr	Phe	Leu	Ser	Pro	Trp	Ile	Ser		
		195					200						205				
Asn	Ile	His	Glu	Lys	Lys	Gly	Leu	Thr	Lys	Tyr	Lys	Ser	Ser	Pro	Glu		
	210					215						220					
Lys	Trp	Ser	Thr	Ala	Ser	Asp	Pro	Tyr	Ser	Asp	Phe	Glu	Lys	Val	Thr		
225					230					235					240		
Gly	Arg	Ile	Asp	Lys	Asn	Val	Ser	Pro	Glu	Ala	Arg	His	Pro	Leu	Val		
				245					250					255			
Ala	Ala	Tyr	Pro	Ile	Val	His	Val	Asp	Met	Glu	Asn	Ile	Ile	Leu	Ser		
			260					265					270				
Lys	Asn	Glu	Asp	Gln	Ser	Thr	Gln	Asn	Thr	Asp	Ser	Glu	Thr	Arg	Thr		
		275					280					285					
Ile	Ser	Lys	Asn	Thr	Ser	Thr	Ser	Arg	Thr	His	Thr	Ser	Glu	Val	His		
	290					295					300						
Gly	Asn	Ala	Glu	Val	His	Ala	Ser	Phe	Phe	Asp	Ile	Gly	Gly	Ser	Val		



```

305          310          315          320
Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His
          325          330          335
Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
          340          345          350
Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
          355          360          365
Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
          370          375          380
Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Ala Glu Asn Gln
385          390          395          400
Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
          405          410          415
Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
          420          425          430
Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
          435          440          445
Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450          455          460
Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val
465          470          475          480
Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
          485          490          495
Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
          500          505          510
Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
          515          520          525
Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
          530          535          540
Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln
545          550          555          560
Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
          565          570          575
Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
          580          585          590
Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
          595          600          605
Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
          610          615          620
Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser
625          630          635          640
Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
          645          650          655
Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
          660          665          670
Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
          675          680          685
Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
          690          695          700
Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly
705          710          715          720
Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly
          725          730          735

```

&lt;210&gt; 2

&lt;211&gt; 735

&lt;212&gt; PRT

&lt;213&gt; Bacillus anthracis

&lt;400&gt; 2

```

Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser
1          5          10          15

```

Gln	Gly	Leu	Leu	Gly	Tyr	Tyr	Phe	Ser	Asp	Leu	Asn	Phe	Gln	Ala	Pro		
			20					25					30				
Met	Val	Val	Thr	Ser	Ser	Thr	Thr	Gly	Asp	Leu	Ser	Ile	Pro	Ser	Ser		
		35					40					45					
Glu	Leu	Glu	Asn	Ile	Pro	Ser	Glu	Asn	Gln	Tyr	Phe	Gln	Ser	Ala	Ile		
	50					55					60						
Trp	Ser	Gly	Phe	Ile	Lys	Val	Lys	Lys	Ser	Asp	Glu	Tyr	Thr	Phe	Ala		
65					70					75					80		
Thr	Ser	Ala	Asp	Asn	His	Val	Thr	Met	Trp	Val	Asp	Asp	Gln	Glu	Val		
				85					90					95			
Ile	Asn	Lys	Ala	Ser	Asn	Ser	Asn	Lys	Ile	Arg	Leu	Glu	Lys	Gly	Arg		
			100					105					110				
Leu	Tyr	Gln	Ile	Lys	Ile	Gln	Tyr	Gln	Arg	Glu	Asn	Pro	Thr	Glu	Lys		
		115					120					125					
Gly	Leu	Asp	Phe	Lys	Leu	Tyr	Trp	Thr	Asp	Ser	Gln	Asn	Lys	Lys	Glu		
	130					135					140						
Val	Ile	Ser	Ser	Asp	Asn	Leu	Gln	Leu	Pro	Glu	Leu	Lys	Gln	Lys	Ser		
145					150					155					160		
Ser	Asn	Ser	Arg	Lys	Lys	Arg	Ser	Thr	Ser	Ala	Gly	Pro	Thr	Val	Pro		
				165					170					175			
Asp	Arg	Asp	Asn	Asp	Gly	Ile	Pro	Asp	Ser	Leu	Glu	Val	Glu	Gly	Tyr		
			180					185					190				
Thr	Val	Asp	Val	Lys	Asn	Lys	Arg	Thr	Phe	Leu	Ser	Pro	Trp	Ile	Ser		
		195					200					205					
Asn	Ile	His	Glu	Lys	Lys	Gly	Leu	Thr	Lys	Tyr	Lys	Ser	Ser	Pro	Glu		
	210					215					220						
Lys	Trp	Ser	Thr	Ala	Ser	Asp	Pro	Tyr	Ser	Asp	Phe	Glu	Lys	Val	Thr		
225					230					235				240			
Gly	Arg	Ile	Asp	Lys	Asn	Val	Ser	Pro	Glu	Ala	Arg	His	Pro	Leu	Val		
				245					250					255			
Ala	Ala	Tyr	Pro	Ile	Val	His	Val	Asp	Met	Glu	Asn	Ile	Ile	Leu	Ser		
			260					265					270				
Lys	Asn	Glu	Asp	Gln	Ser	Thr	Gln	Asn	Thr	Asp	Ser	Glu	Thr	Arg	Thr		
		275					280					285					
Ile	Ser	Lys	Asn	Thr	Ser	Thr	Ser	Arg	Thr	His	Thr	Ser	Glu	Val	His		
	290					295					300						
Gly	Asn	Ala	Glu	Val	His	Ala	Ser	Phe	Phe	Asp	Ile	Gly	Gly	Ser	Val		
305					310					315					320		
Ser	Ala	Gly	Phe	Ser	Asn	Ser	Asn	Ser	Ser	Thr	Val	Ala	Ile	Asp	His		
				325					330					335			
Ser	Leu	Ser	Leu	Ala	Gly	Glu	Arg	Thr	Trp	Ala	Glu	Thr	Met	Gly	Leu		
			340					345					350				
Asn	Thr	Ala	Asp	Thr	Ala	Arg	Leu	Asn	Ala	Asn	Ile	Arg	Tyr	Val	Asn		
		355					360					365					
Thr	Gly	Thr	Ala	Pro	Ile	Tyr	Asn	Val	Leu	Pro	Thr	Thr	Ser	Leu	Val		
	370					375					380						
Leu	Gly	Lys	Asn	Gln	Thr	Leu	Ala	Thr	Ile	Lys	Ala	Asp	Glu	Asn	Gln		
385					390					395					400		
Leu	Ser	Gln	Ile	Leu	Ala	Pro	Asn	Asn	Tyr	Tyr	Pro	Ser	Lys	Asn	Leu		
				405					410					415			
Ala	Pro	Ile	Ala	Leu	Asn	Ala	Gln	Asp	Asp	Phe	Ser	Ser	Thr	Pro	Ile		
			420					425					430				
Thr	Met	Asn	Tyr	Asn	Gln	Phe	Leu	Glu	Leu	Glu	Lys	Thr	Lys	Gln	Leu		
		435					440					445					
Arg	Leu	Asp	Thr	Asp	Gln	Val	Tyr	Gly	Asn	Ile	Ala	Thr	Tyr	Asn	Phe		
	450					455					460						
Glu	Asn	Gly	Arg	Val	Arg	Val	Asp	Thr	Gly	Ser	Asn	Trp	Ser	Glu	Val		
465					470					475				480			
Leu	Pro	Gln	Ile	Gln	Glu	Thr	Thr	Ala	Arg	Ile	Ile	Phe	Asn	Gly	Lys		
				485					490					495			
Asp	Leu	Asn	Leu	Val	Glu	Arg	Arg	Ile	Ala	Ala	Val	Asn	Pro	Ser	Asp		
			500					505					510				
Pro	Leu	Glu	Thr	Thr	Lys	Pro	Asp	Met	Thr	Leu	Lys	Glu	Ala	Leu	Lys		

Ile	Ala	Phe	Gly	Phe	Asn	Glu	Pro	Asn	Gly	Asn	Leu	Gln	Tyr	Gln	Gly
	530					535					540				
Lys	Asp	Ile	Thr	Glu	Phe	Asp	Phe	Asn	Phe	Asp	Gln	Gln	Thr	Ser	Gln
545					550					555					560
Asn	Ile	Lys	Asn	Gln	Leu	Ala	Glu	Leu	Asn	Ala	Thr	Asn	Ile	Tyr	Thr
			565						570					575	
Val	Leu	Asp	Lys	Ile	Lys	Leu	Asn	Ala	Lys	Met	Asn	Ile	Leu	Ile	Arg
			580					585					590		
Asp	Lys	Arg	Phe	His	Tyr	Asp	Arg	Asn	Asn	Ile	Ala	Val	Gly	Ala	Asp
		595					600					605			
Glu	Ser	Val	Val	Lys	Glu	Ala	His	Arg	Glu	Val	Ile	Asn	Ser	Ser	Thr
	610					615					620				
Glu	Gly	Leu	Leu	Leu	Asn	Ile	Asp	Lys	Asp	Ile	Arg	Lys	Ile	Leu	Ser
625					630					635					640
Gly	Tyr	Ile	Val	Glu	Ile	Glu	Asp	Thr	Glu	Gly	Leu	Lys	Glu	Val	Ile
			645						650					655	
Asn	Asp	Arg	Tyr	Asp	Met	Leu	Asn	Ile	Ser	Ser	Leu	Arg	Gln	Asp	Gly
			660					665					670		
Lys	Thr	Phe	Ile	Asp	Phe	Lys	Lys	Tyr	Asn	Asp	Lys	Leu	Pro	Leu	Tyr
		675					680					685			
Ile	Ser	Asn	Pro	Asn	Tyr	Lys	Val	Asn	Val	Tyr	Ala	Val	Thr	Lys	Glu
	690					695					700				
Asn	Thr	Ile	Ile	Asn	Pro	Ser	Glu	Asn	Gly	Asp	Thr	Ser	Thr	Asn	Gly
705					710					715					720
Ile	Lys	Lys	Ile	Leu	Ile	Phe	Ser	Lys	Lys	Gly	Tyr	Glu	Ile	Gly	
			725						730					735	

&lt;210&gt; 3

&lt;211&gt; 735

&lt;212&gt; PRT

&lt;213&gt; Bacillus anthracis

&lt;400&gt; 3

Glu	Val	Lys	Gln	Glu	Asn	Arg	Leu	Leu	Asn	Glu	Ser	Glu	Ser	Ser	Ser
1				5					10					15	
Gln	Gly	Leu	Leu	Gly	Tyr	Tyr	Phe	Ser	Asp	Leu	Asn	Phe	Gln	Ala	Pro
		20						25					30		
Met	Val	Val	Thr	Ser	Ser	Thr	Thr	Gly	Asp	Leu	Ser	Ile	Pro	Ser	Ser
		35					40					45			
Glu	Leu	Glu	Asn	Ile	Pro	Ser	Glu	Asn	Gln	Tyr	Phe	Gln	Ser	Ala	Ile
	50					55				60					
Trp	Ser	Gly	Phe	Ile	Lys	Val	Lys	Lys	Ser	Asp	Glu	Tyr	Thr	Phe	Ala
65				70						75					80
Thr	Ser	Ala	Asp	Asn	His	Val	Thr	Met	Trp	Val	Asp	Asp	Gln	Glu	Val
				85					90					95	
Ile	Asn	Lys	Ala	Ser	Asn	Ser	Asn	Lys	Ile	Arg	Leu	Glu	Lys	Gly	Arg
			100					105					110		
Leu	Tyr	Gln	Ile	Lys	Ile	Gln	Tyr	Gln	Arg	Glu	Asn	Pro	Thr	Glu	Lys
		115					120					125			
Gly	Leu	Asp	Phe	Lys	Leu	Tyr	Trp	Thr	Asp	Ser	Gln	Asn	Lys	Lys	Glu
	130					135					140				
Val	Ile	Ser	Ser	Asp	Asn	Leu	Gln	Leu	Pro	Glu	Leu	Lys	Gln	Lys	Ser
145					150					155					160
Ser	Asn	Ser	Arg	Lys	Lys	Arg	Ser	Thr	Ser	Ala	Gly	Pro	Thr	Val	Pro
				165					170					175	
Asp	Arg	Asp	Asn	Asp	Gly	Ile	Pro	Asp	Ser	Leu	Glu	Val	Glu	Gly	Tyr
			180					185					190		
Thr	Val	Asp	Val	Lys	Asn	Lys	Arg	Thr	Phe	Leu	Ser	Pro	Trp	Ile	Ser
		195					200					205			
Asn	Ile	His	Glu	Lys	Lys	Gly	Leu	Thr	Lys	Tyr	Lys	Ser	Ser	Pro	Glu
	210					215						220			

Lys	Trp	Ser	Thr	Ala	Ser	Asp	Pro	Tyr	Ser	Asp	Phe	Glu	Lys	Val	Thr
225					230					235					240
Gly	Arg	Ile	Asp	Lys	Asn	Val	Ser	Pro	Glu	Ala	Arg	His	Pro	Leu	Val
				245					250					255	
Ala	Ala	Tyr	Pro	Ile	Val	His	Val	Asp	Met	Glu	Asn	Ile	Ile	Leu	Ser
			260					265					270		
Lys	Asn	Glu	Asp	Gln	Ser	Thr	Gln	Asn	Thr	Asp	Ser	Glu	Thr	Arg	Thr
		275					280					285			
Ile	Ser	Lys	Asn	Thr	Ser	Thr	Ser	Arg	Thr	His	Thr	Ser	Glu	Val	His
	290					295					300				
Gly	Asn	Ala	Glu	Val	His	Ala	Ser	Phe	Phe	Asp	Ile	Gly	Gly	Ser	Val
305					310					315					320
Ser	Ala	Gly	Phe	Ser	Asn	Ser	Asn	Ser	Ser	Thr	Val	Ala	Ile	Asp	His
				325					330					335	
Ser	Leu	Ser	Leu	Ala	Gly	Glu	Arg	Thr	Trp	Ala	Glu	Thr	Met	Gly	Leu
			340					345					350		
Asn	Thr	Ala	Asp	Thr	Ala	Arg	Leu	Asn	Ala	Asn	Ile	Arg	Tyr	Val	Asn
		355					360					365			
Thr	Gly	Thr	Ala	Pro	Ile	Tyr	Asn	Val	Leu	Pro	Thr	Thr	Ser	Leu	Val
	370					375					380				
Leu	Gly	Lys	Asn	Gln	Thr	Leu	Ala	Thr	Ile	Lys	Ala	Cys	Glu	Asn	Gln
385					390					395					400
Leu	Ser	Gln	Ile	Leu	Ala	Pro	Asn	Asn	Tyr	Tyr	Pro	Ser	Lys	Asn	Leu
				405					410					415	
Ala	Pro	Ile	Ala	Leu	Asn	Ala	Gln	Asp	Asp	Phe	Ser	Ser	Thr	Pro	Ile
			420					425					430		
Thr	Met	Asn	Tyr	Asn	Gln	Phe	Leu	Glu	Leu	Glu	Lys	Thr	Lys	Gln	Leu
		435					440					445			
Arg	Leu	Asp	Thr	Asp	Gln	Val	Tyr	Gly	Asn	Ile	Ala	Thr	Tyr	Asn	Phe
	450					455					460				
Glu	Asn	Gly	Arg	Val	Arg	Val	Asp	Thr	Gly	Ser	Asn	Trp	Ser	Glu	Val
465					470					475					480
Leu	Pro	Gln	Ile	Gln	Glu	Thr	Thr	Ala	Arg	Ile	Ile	Phe	Asn	Gly	Lys
				485					490					495	
Asp	Leu	Asn	Leu	Val	Glu	Arg	Arg	Ile	Ala	Ala	Val	Asn	Pro	Ser	Asp
			500					505					510		
Pro	Leu	Glu	Thr	Thr	Lys	Pro	Asp	Met	Thr	Leu	Lys	Glu	Ala	Leu	Lys
		515					520					525			
Ile	Ala	Phe	Gly	Phe	Asn	Glu	Pro	Asn	Gly	Asn	Leu	Gln	Tyr	Gln	Gly
	530					535					540				
Lys	Asp	Ile	Thr	Glu	Phe	Asp	Phe	Asn	Phe	Asp	Gln	Gln	Thr	Ser	Gln
545					550					555					560
Asn	Ile	Lys	Asn	Gln	Leu	Ala	Glu	Leu	Asn	Ala	Thr	Asn	Ile	Tyr	Thr
				565					570					575	
Val	Leu	Asp	Lys	Ile	Lys	Leu	Asn	Ala	Lys	Met	Asn	Ile	Leu	Ile	Arg
			580					585					590		
Asp	Lys	Arg	Phe	His	Tyr	Asp	Arg	Asn	Asn	Ile	Ala	Val	Gly	Ala	Asp
		595					600					605			
Glu	Ser	Val	Val	Lys	Glu	Ala	His	Arg	Glu	Val	Ile	Asn	Ser	Ser	Thr
		610				615					620				
Glu	Gly	Leu	Leu	Leu	Asn	Ile	Asp	Lys	Asp	Ile	Arg	Lys	Ile	Leu	Ser
625					630					635					640
Gly	Tyr	Ile	Val	Glu	Ile	Glu	Asp	Thr	Glu	Gly	Leu	Lys	Glu	Val	Ile
				645					650					655	
Asn	Asp	Arg	Tyr	Asp	Met	Leu	Asn	Ile	Ser	Ser	Leu	Arg	Gln	Asp	Gly
			660					665					670		
Lys	Thr	Phe	Ile	Asp	Phe	Lys	Lys	Tyr	Asn	Asp	Lys	Leu	Pro	Leu	Tyr
		675					680					685			
Ile	Ser	Asn	Pro	Asn	Tyr	Lys	Val	Asn	Val	Tyr	Ala	Val	Thr	Lys	Glu
	690					695					700				
Asn	Thr	Ile	Ile	Asn	Pro	Ser	Glu	Asn	Gly	Asp	Thr	Ser	Thr	Asn	Gly
705					710					715					720
Ile	Lys	Lys	Ile	Leu	Ile	Phe	Ser	Lys	Lys	Gly	Tyr	Glu	Ile	Gly	

725

730

735

<210> 4  
 <211> 735  
 <212> PRT  
 <213> Bacillus anthracis

<400> 4  
 Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser  
 1 5 10 15  
 Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro  
 20 25 30  
 Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser  
 35 40 45  
 Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile  
 50 55 60  
 Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala  
 65 70 75 80  
 Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val  
 85 90 95  
 Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg  
 100 105 110  
 Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys  
 115 120 125  
 Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu  
 130 135 140  
 Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser  
 145 150 155 160  
 Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro  
 165 170 175  
 Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr  
 180 185 190  
 Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser  
 195 200 205  
 Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu  
 210 215 220  
 Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr  
 225 230 235 240  
 Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val  
 245 250 255  
 Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser  
 260 265 270  
 Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr  
 275 280 285  
 Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His  
 290 295 300  
 Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val  
 305 310 315 320  
 Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His  
 325 330 335  
 Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu  
 340 345 350  
 Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn  
 355 360 365  
 Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val  
 370 375 380  
 Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Gln Glu Asn Gln  
 385 390 395 400  
 Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu  
 405 410 415  
 Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile  
 420 425 430

Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu  
 435 440 445  
 Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe  
 450 455 460  
 Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val  
 465 470 475 480  
 Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys  
 485 490 495  
 Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp  
 500 505 510  
 Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys  
 515 520 525  
 Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly  
 530 535 540  
 Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln  
 545 550 555 560  
 Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr  
 565 570 575  
 Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg  
 580 585 590  
 Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp  
 595 600 605  
 Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr  
 610 615 620  
 Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser  
 625 630 635 640  
 Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile  
 645 650 655  
 Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly  
 660 665 670  
 Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr  
 675 680 685  
 Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu  
 690 695 700  
 Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly  
 705 710 715 720  
 Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly  
 725 730 735

&lt;210&gt; 5

&lt;211&gt; 735

&lt;212&gt; PRT

<213> *Bacillus anthracis*

&lt;400&gt; 5

Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser  
 1 5 10 15  
 Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro  
 20 25 30  
 Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser  
 35 40 45  
 Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile  
 50 55 60  
 Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala  
 65 70 75 80  
 Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val  
 85 90 95  
 Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg  
 100 105 110  
 Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys  
 115 120 125  
 Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu

130	135	140
Val Ile Ser Ser Asp	Asn Leu Gln Leu Pro	Glu Leu Lys Gln Lys Ser
145	150	155
Ser Asn Ser Arg Lys	Lys Arg Ser Thr Ser	Ala Gly Pro Thr Val Pro
165	170	175
Asp Arg Asp Asn Asp	Gly Ile Pro Asp Ser	Leu Glu Val Glu Gly Tyr
180	185	190
Thr Val Asp Val Lys	Asn Lys Arg Thr Phe	Leu Ser Pro Trp Ile Ser
195	200	205
Asn Ile His Glu Lys	Lys Gly Leu Thr Lys Tyr	Lys Ser Ser Pro Glu
210	215	220
Lys Trp Ser Thr Ala	Ser Asp Pro Tyr Ser	Phe Glu Lys Val Thr
225	230	235
Gly Arg Ile Asp Lys	Asn Val Ser Pro Glu	Ala Arg His Pro Leu Val
245	250	255
Ala Ala Tyr Pro Ile	Val His Val Asp Met	Glu Asn Ile Ile Leu Ser
260	265	270
Lys Asn Glu Asp Gln	Ser Thr Gln Asn Thr	Asp Ser Glu Thr Arg Thr
275	280	285
Ile Ser Lys Asn Thr	Ser Thr Ser Arg Thr	His Thr Ser Glu Val His
290	295	300
Gly Asn Ala Glu Val	His Ala Ser Phe Phe	Asp Ile Gly Gly Ser Val
305	310	315
Ser Ala Gly Phe Ser	Asn Ser Asn Ser Ser	Thr Val Ala Ile Asp His
325	330	335
Ser Leu Ser Leu Ala	Gly Glu Arg Thr Trp	Ala Glu Thr Met Gly Leu
340	345	350
Asn Thr Ala Asp Thr	Ala Arg Leu Asn Ala	Asn Ile Arg Tyr Val Asn
355	360	365
Thr Gly Thr Ala Pro	Ile Tyr Asn Val Leu	Pro Thr Thr Ser Leu Val
370	375	380
Leu Gly Lys Asn Gln	Thr Leu Ala Thr Ile	Lys Ala Lys Glu Asn Gln
385	390	395
Leu Ser Gln Ile Leu	Ala Pro Asn Asn Tyr	Tyr Pro Ser Lys Asn Leu
405	410	415
Ala Pro Ile Ala Leu	Asn Ala Gln Ala Asp	Phe Ser Ser Thr Pro Ile
420	425	430
Thr Met Asn Tyr Asn	Gln Phe Leu Glu Leu	Glu Lys Thr Lys Gln Leu
435	440	445
Arg Leu Asp Thr Asp	Gln Val Tyr Gly Asn	Ile Ala Thr Tyr Asn Phe
450	455	460
Glu Asn Gly Arg Val	Arg Val Asp Thr Gly	Ser Asn Trp Ser Glu Val
465	470	475
Leu Pro Gln Ile Gln	Glu Thr Thr Ala Arg	Ile Ile Phe Asn Gly Lys
485	490	495
Asp Leu Asn Leu Val	Glu Arg Arg Ile Ala	Ala Val Asn Pro Ser Asp
500	505	510
Pro Leu Glu Thr Thr	Lys Pro Asp Met Thr	Leu Lys Glu Ala Leu Lys
515	520	525
Ile Ala Phe Gly Phe	Asn Glu Pro Asn Gly	Asn Leu Gln Tyr Gln Gly
530	535	540
Lys Asp Ile Thr Glu	Phe Asp Phe Asn Phe	Asp Gln Gln Thr Ser Gln
545	550	555
Asn Ile Lys Asn Gln	Leu Ala Glu Leu Asn	Ala Thr Asn Ile Tyr Thr
565	570	575
Val Leu Asp Lys Ile	Lys Leu Asn Ala Lys	Met Asn Ile Leu Ile Arg
580	585	590
Asp Lys Arg Phe His	Tyr Asp Arg Asn Asn	Ile Ala Val Gly Ala Asp
595	600	605
Glu Ser Val Val Lys	Glu Ala His Arg Glu	Val Ile Asn Ser Ser Thr
610	615	620
Glu Gly Leu Leu Leu	Asn Ile Asp Lys Asp	Ile Arg Lys Ile Leu Ser
625	630	635
		640

Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile  
                                 645                                650                                655  
 Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly  
                                 660                                665                                670  
 Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr  
                                 675                                680                                685  
 Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu  
                                 690                                695                                700  
 Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly  
 705                                710                                715                                720  
 Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly  
                                 725                                730                                735

&lt;210&gt; 6

&lt;211&gt; 735

&lt;212&gt; PRT

&lt;213&gt; Bacillus anthracis

&lt;400&gt; 6

Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser  
 1                                5                                10                                15  
 Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro  
                                 20                                25                                30  
 Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser  
                                 35                                40                                45  
 Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile  
                                 50                                55                                60  
 Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala  
 65                                70                                75                                80  
 Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val  
                                 85                                90                                95  
 Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg  
                                 100                                105                                110  
 Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys  
                                 115                                120                                125  
 Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu  
                                 130                                135                                140  
 Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser  
 145                                150                                155                                160  
 Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro  
                                 165                                170                                175  
 Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr  
                                 180                                185                                190  
 Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser  
                                 195                                200                                205  
 Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu  
                                 210                                215                                220  
 Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr  
 225                                230                                235                                240  
 Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val  
                                 245                                250                                255  
 Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser  
                                 260                                265                                270  
 Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr  
                                 275                                280                                285  
 Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His  
                                 290                                295                                300  
 Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val  
 305                                310                                315                                320  
 Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His  
                                 325                                330                                335  
 Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu



```

          340          345          350
Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
          355          360          365
Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val
          370          375          380
Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln
385          390          395          400
Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
          405          410          415
Ala Pro Ile Ala Leu Asn Ala Gln Asn Asp Phe Ser Ser Thr Pro Ile
          420          425          430
Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
          435          440          445
Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
450          455          460
Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val
465          470          475          480
Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
          485          490          495
Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp
          500          505          510
Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
          515          520          525
Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
          530          535          540
Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln
545          550          555          560
Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
          565          570          575
Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
          580          585          590
Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
          595          600          605
Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
          610          615          620
Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser
625          630          635          640
Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
          645          650          655
Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
          660          665          670
Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
          675          680          685
Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690          695          700
Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly
705          710          715          720
Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly
          725          730          735

```

&lt;210&gt; 7

&lt;211&gt; 735

&lt;212&gt; PRT

&lt;213&gt; Bacillus anthracis

&lt;400&gt; 7

```

Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser
 1          5          10          15
Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
          20          25          30
Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
          35          40          45

```

Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile  
 50 55 60  
 Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala  
 65 70 75 80  
 Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val  
 85 90 95  
 Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg  
 100 105 110  
 Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys  
 115 120 125  
 Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu  
 130 135 140  
 Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser  
 145 150 155 160  
 Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro  
 165 170 175  
 Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr  
 180 185 190  
 Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser  
 195 200 205  
 Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu  
 210 215 220  
 Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr  
 225 230 235 240  
 Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val  
 245 250 255  
 Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser  
 260 265 270  
 Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr  
 275 280 285  
 Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His  
 290 295 300  
 Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val  
 305 310 315 320  
 Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His  
 325 330 335  
 Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu  
 340 345 350  
 Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn  
 355 360 365  
 Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val  
 370 375 380  
 Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln  
 385 390 395 400  
 Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu  
 405 410 415  
 Ala Pro Ile Ala Leu Asn Ala Gln Glu Asp Phe Ser Ser Thr Pro Ile  
 420 425 430  
 Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu  
 435 440 445  
 Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe  
 450 455 460  
 Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val  
 465 470 475 480  
 Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys  
 485 490 495  
 Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp  
 500 505 510  
 Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys  
 515 520 525  
 Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly  
 530 535 540  
 Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln

```

545          550          555          560
Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser
Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly
Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly
          725          730          735

```

```

<210> 8
<211> 735
<212> PRT
<213> Bacillus anthracis

```

```

<400> 8
Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser
1          5          10          15
Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20          25          30
Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35          40          45
Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50          55          60
Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala
65          70          75          80
Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85          90          95
Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100          105          110
Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115          120          125
Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130          135          140
Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser
145          150          155          160
Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165          170          175
Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180          185          190
Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195          200          205
Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210          215          220
Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr
225          230          235          240
Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245          250          255

```

Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser  
 260 265 270  
 Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr  
 275 280 285  
 Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His  
 290 295 300  
 Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val  
 305 310 315 320  
 Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His  
 325 330 335  
 Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu  
 340 345 350  
 Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn  
 355 360 365  
 Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val  
 370 375 380  
 Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln  
 385 390 395 400  
 Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu  
 405 410 415  
 Ala Pro Ile Ala Leu Asn Ala Gln Lys Asp Phe Ser Ser Thr Pro Ile  
 420 425 430  
 Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu  
 435 440 445  
 Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe  
 450 455 460  
 Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val  
 465 470 475 480  
 Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys  
 485 490 495  
 Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp  
 500 505 510  
 Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys  
 515 520 525  
 Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly  
 530 535 540  
 Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln  
 545 550 555 560  
 Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr  
 565 570 575  
 Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg  
 580 585 590  
 Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp  
 595 600 605  
 Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr  
 610 615 620  
 Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser  
 625 630 635 640  
 Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile  
 645 650 655  
 Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly  
 660 665 670  
 Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr  
 675 680 685  
 Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu  
 690 695 700  
 Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly  
 705 710 715 720  
 Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly  
 725 730 735

<211> 735  
 <212> PRT  
 <213> Bacillus anthracis

<400> 9  
 Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser  
 1 5 10 15  
 Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro  
 20 25 30  
 Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser  
 35 40 45  
 Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile  
 50 55 60  
 Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala  
 65 70 75 80  
 Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val  
 85 90 95  
 Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg  
 100 105 110  
 Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys  
 115 120 125  
 Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu  
 130 135 140  
 Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser  
 145 150 155 160  
 Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro  
 165 170 175  
 Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr  
 180 185 190  
 Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser  
 195 200 205  
 Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu  
 210 215 220  
 Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr  
 225 230 235 240  
 Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val  
 245 250 255  
 Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser  
 260 265 270  
 Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr  
 275 280 285  
 Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His  
 290 295 300  
 Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val  
 305 310 315 320  
 Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His  
 325 330 335  
 Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu  
 340 345 350  
 Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn  
 355 360 365  
 Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val  
 370 375 380  
 Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln  
 385 390 395 400  
 Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu  
 405 410 415  
 Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Ala Ser Ser Thr Pro Ile  
 420 425 430  
 Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu  
 435 440 445  
 Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe  
 450 455 460

Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val  
 465 470 475 480  
 Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys  
 485 490 495  
 Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp  
 500 505 510  
 Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys  
 515 520 525  
 Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly  
 530 535 540  
 Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln  
 545 550 555 560  
 Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr  
 565 570 575  
 Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg  
 580 585 590  
 Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp  
 595 600 605  
 Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr  
 610 615 620  
 Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser  
 625 630 635 640  
 Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile  
 645 650 655  
 Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly  
 660 665 670  
 Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr  
 675 680 685  
 Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu  
 690 695 700  
 Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly  
 705 710 715 720  
 Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly  
 725 730 735

&lt;210&gt; 10

&lt;211&gt; 735

&lt;212&gt; PRT

&lt;213&gt; Bacillus anthracis

&lt;400&gt; 10

Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser  
 1 5 10 15  
 Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro  
 20 25 30  
 Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser  
 35 40 45  
 Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile  
 50 55 60  
 Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala  
 65 70 75 80  
 Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val  
 85 90 95  
 Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg  
 100 105 110  
 Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys  
 115 120 125  
 Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu  
 130 135 140  
 Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser  
 145 150 155 160  
 Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro

				165					170					175			
Asp	Arg	Asp	Asn	Asp	Gly	Ile	Pro	Asp	Ser	Leu	Glu	Val	Glu	Gly	Tyr		
			180					185					190				
Thr	Val	Asp	Val	Lys	Asn	Lys	Arg	Thr	Phe	Leu	Ser	Pro	Trp	Ile	Ser		
		195					200					205					
Asn	Ile	His	Glu	Lys	Lys	Gly	Leu	Thr	Lys	Tyr	Lys	Ser	Ser	Pro	Glu		
	210					215					220						
Lys	Trp	Ser	Thr	Ala	Ser	Asp	Pro	Tyr	Ser	Asp	Phe	Glu	Lys	Val	Thr		
225					230					235					240		
Gly	Arg	Ile	Asp	Lys	Asn	Val	Ser	Pro	Glu	Ala	Arg	His	Pro	Leu	Val		
				245					250					255			
Ala	Ala	Tyr	Pro	Ile	Val	His	Val	Asp	Met	Glu	Asn	Ile	Ile	Leu	Ser		
			260					265					270				
Lys	Asn	Glu	Asp	Gln	Ser	Thr	Gln	Asn	Thr	Asp	Ser	Glu	Thr	Arg	Thr		
	275						280					285					
Ile	Ser	Lys	Asn	Thr	Ser	Thr	Ser	Arg	Thr	His	Thr	Ser	Glu	Val	His		
	290					295					300						
Gly	Asn	Ala	Glu	Val	His	Ala	Ser	Phe	Phe	Asp	Ile	Gly	Gly	Ser	Val		
305					310					315					320		
Ser	Ala	Gly	Phe	Ser	Asn	Ser	Asn	Ser	Ser	Thr	Val	Ala	Ile	Asp	His		
				325					330					335			
Ser	Leu	Ser	Leu	Ala	Gly	Glu	Arg	Thr	Trp	Ala	Glu	Thr	Met	Gly	Leu		
			340					345					350				
Asn	Thr	Ala	Asp	Thr	Ala	Arg	Leu	Asn	Ala	Asn	Ile	Arg	Tyr	Val	Asn		
	355						360					365					
Thr	Gly	Thr	Ala	Pro	Ile	Tyr	Asn	Val	Leu	Pro	Thr	Thr	Ser	Leu	Val		
	370					375					380						
Leu	Gly	Lys	Asn	Gln	Thr	Leu	Ala	Thr	Ile	Lys	Ala	Asp	Glu	Asn	Gln		
385					390					395					400		
Leu	Ser	Gln	Ile	Leu	Ala	Pro	Asn	Asn	Tyr	Tyr	Pro	Ser	Lys	Asn	Leu		
			405						410					415			
Ala	Pro	Ile	Ala	Leu	Asn	Ala	Gln	Lys	Asp	Phe	Ser	Ser	Thr	Pro	Ile		
			420					425					430				
Thr	Met	Asn	Tyr	Asn	Gln	Phe	Leu	Glu	Leu	Glu	Lys	Thr	Lys	Gln	Leu		
	435						440					445					
Arg	Leu	Asp	Thr	Asp	Gln	Val	Tyr	Gly	Asn	Ile	Ala	Thr	Tyr	Asn	Phe		
	450					455					460						
Glu	Asn	Gly	Arg	Val	Arg	Val	Asp	Thr	Gly	Ser	Asn	Trp	Ser	Glu	Val		
465					470					475				480			
Leu	Pro	Gln	Ile	Gln	Glu	Thr	Thr	Ala	Arg	Ile	Ile	Phe	Asn	Gly	Lys		
				485					490					495			
Asp	Leu	Asn	Leu	Val	Glu	Arg	Arg	Ile	Ala	Ala	Val	Asn	Pro	Ser	Asp		
			500					505					510				
Pro	Leu	Glu	Thr	Thr	Lys	Pro	Asp	Met	Thr	Leu	Lys	Glu	Ala	Leu	Lys		
	515						520					525					
Ile	Ala	Phe	Gly	Phe	Asn	Glu	Pro	Asn	Gly	Asn	Leu	Gln	Tyr	Gln	Gly		
	530					535					540						
Lys	Asp	Ile	Thr	Glu	Phe	Asp	Phe	Asn	Phe	Asp	Gln	Gln	Thr	Ser	Gln		
545					550					555				560			
Asn	Ile	Lys	Asn	Gln	Leu	Ala	Glu	Leu	Asn	Ala	Thr	Asn	Ile	Tyr	Thr		
				565					570					575			
Val	Leu	Asp	Lys	Ile	Lys	Leu	Asn	Ala	Lys	Met	Asn	Ile	Leu	Ile	Arg		
			580					585					590				
Asp	Lys	Arg	Phe	His	Tyr	Asp	Arg	Asn	Asn	Ile	Ala	Val	Gly	Ala	Asp		
	595						600					605					
Glu	Ser	Val	Val	Lys	Glu	Ala	His	Arg	Glu	Val	Ile	Asn	Ser	Ser	Thr		
	610					615						620					
Glu	Gly	Leu	Leu	Leu	Asn	Ile	Asp	Lys	Asp	Ile	Arg	Lys	Ile	Leu	Ser		
625					630					635				640			
Gly	Tyr	Ile	Val	Glu	Ile	Glu	Asp	Thr	Glu	Gly	Leu	Lys	Glu	Val	Ile		
				645					650					655			
Asn	Asp	Arg	Tyr	Asp	Met	Leu	Asn	Ile	Ser	Ser	Leu	Arg	Gln	Asp	Gly		
			660					665					670				

Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr  
 675 680 685  
 Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu  
 690 695 700  
 Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly  
 705 710 715 720  
 Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly  
 725 730 735

<210> 11  
 <211> 735  
 <212> PRT  
 <213> Bacillus anthracis

<400> 11  
 Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser  
 1 5 10 15  
 Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro  
 20 25 30  
 Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser  
 35 40 45  
 Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile  
 50 55 60  
 Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala  
 65 70 75 80  
 Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val  
 85 90 95  
 Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg  
 100 105 110  
 Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys  
 115 120 125  
 Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu  
 130 135 140  
 Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser  
 145 150 155 160  
 Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro  
 165 170 175  
 Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr  
 180 185 190  
 Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser  
 195 200 205  
 Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu  
 210 215 220  
 Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr  
 225 230 235 240  
 Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val  
 245 250 255  
 Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser  
 260 265 270  
 Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr  
 275 280 285  
 Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His  
 290 295 300  
 Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val  
 305 310 315 320  
 Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His  
 325 330 335  
 Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu  
 340 345 350  
 Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn  
 355 360 365  
 Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val



370	Leu Gly Lys Asn Gln Thr	375	Leu Ala Thr Ile Asp	380	Ala Asp Glu Asn Gln
385	Leu Ser Gln Ile Leu	390	Ala Pro Asn Asn Tyr	395	Tyr Pro Ser Lys Asn
	405	410	Lys Phe Ser Ser Thr	415	Pro Ile
Ala Pro Ile	420	425	Glu Leu Glu Lys Thr	430	Lys Gln Leu
Thr Met Asn	435	440	Val Tyr Gly Asn Ile	445	Thr Tyr Asn Phe
Arg Leu Asp	450	455	Val Asp Thr Gly Ser	460	Asn Trp Ser Glu Val
Glu Asn Gly	465	470	Ala Arg Ile Ile Phe	475	Asn Gly Lys
Leu Pro Gln	485	490	Ala Val Asn Pro Ser	495	Asp
Asp Leu Asn	500	505	Ala Val Asn Pro Ser	510	Asp
Pro Leu Glu	515	520	Met Thr Leu Lys Glu	525	Ala Leu Lys
Ile Ala Phe	530	535	Asn Gly Asn Leu Gln	540	Tyr Gln Gly
Lys Asp Ile	545	550	Phe Asn Phe Asp	555	Gln Thr Ser Gln
Asn Ile Lys	565	570	Ala Thr Asn Ile Tyr	575	Thr
Val Leu Asp	580	585	Lys Met Asn Ile Leu	590	Ile Arg
Asp Lys Arg	595	600	Asn Asn Ile Ala Val	605	Gly Ala Asp
Glu Ser Val	610	615	His Arg Glu Val Ile	620	Asn Ser Ser Thr
Glu Gly Leu	625	630	Asn Ile Asp Lys Asp	635	Ile Arg Lys Ile Leu
Gly Tyr Ile	645	650	Glu Asp Thr Glu Gly	655	Leu Lys Glu Val Ile
Asn Asp Arg	660	665	Met Leu Asn Ile Ser	670	Ser Leu Arg Gln Asp
Lys Thr Phe	675	680	Lys Tyr Asn Asp Lys	685	Leu Pro Leu Tyr
Ile Ser Asn	690	695	Val Asn Val Tyr Ala	700	Val Thr Lys Glu
Asn Thr Ile	705	710	Pro Ser Glu Asn Gly	715	Asp Thr Ser Thr Asn
Ile Lys Lys	725	730	Phe Ser Lys Lys Gly	735	Tyr Glu Ile Gly

&lt;210&gt; 12

&lt;211&gt; 711

&lt;212&gt; PRT

&lt;213&gt; Bacillus anthracis

&lt;400&gt; 12

Glu Val Lys	Gln Glu Asn Arg	Leu Leu Asn	Glu Ser Glu	Ser Ser Ser
1	5	10	15	
Gln Gly Leu	Leu Gly Tyr Tyr	Phe Ser Asp	Leu Asn Phe	Gln Ala Pro
	20	25	30	
Met Val Val	Thr Ser Ser Thr	Thr Gly Asp	Leu Ser Ile	Pro Ser Ser
	35	40	45	
Glu Leu Glu	Asn Ile Pro Ser	Glu Asn Gln	Tyr Phe Gln	Ser Ala Ile
	50	55	60	
Trp Ser Gly	Phe Ile Lys Val	Lys Lys Ser	Asp Glu Tyr	Thr Phe Ala
65	70	75	80	

Thr	Ser	Ala	Asp	Asn	His	Val	Thr	Met	Trp	Val	Asp	Asp	Gln	Glu	Val
				85					90					95	
Ile	Asn	Lys	Ala	Ser	Asn	Ser	Asn	Lys	Ile	Arg	Leu	Glu	Lys	Gly	Arg
			100					105					110		
Leu	Tyr	Gln	Ile	Lys	Ile	Gln	Tyr	Gln	Arg	Glu	Asn	Pro	Thr	Glu	Lys
		115					120					125			
Gly	Leu	Asp	Phe	Lys	Leu	Tyr	Trp	Thr	Asp	Ser	Gln	Asn	Lys	Lys	Glu
	130					135					140				
Val	Ile	Ser	Ser	Asp	Asn	Leu	Gln	Leu	Pro	Glu	Leu	Lys	Gln	Lys	Ser
145					150					155					160
Ser	Asn	Ser	Arg	Lys	Lys	Arg	Ser	Thr	Ser	Ala	Gly	Pro	Thr	Val	Pro
				165					170					175	
Asp	Arg	Asp	Asn	Asp	Gly	Ile	Pro	Asp	Ser	Leu	Glu	Val	Glu	Gly	Tyr
				180				185					190		
Thr	Val	Asp	Val	Lys	Asn	Lys	Arg	Thr	Phe	Leu	Ser	Pro	Trp	Ile	Ser
		195					200					205			
Asn	Ile	His	Glu	Lys	Lys	Gly	Leu	Thr	Lys	Tyr	Lys	Ser	Ser	Pro	Glu
	210					215					220				
Lys	Trp	Ser	Thr	Ala	Ser	Asp	Pro	Tyr	Ser	Asp	Phe	Glu	Lys	Val	Thr
225					230					235					240
Gly	Arg	Ile	Asp	Lys	Asn	Val	Ser	Pro	Glu	Ala	Arg	His	Pro	Leu	Val
				245					250					255	
Ala	Ala	Tyr	Pro	Ile	Val	His	Val	Asp	Met	Glu	Asn	Ile	Ile	Leu	Ser
			260					265					270		
Lys	Asn	Glu	Asp	Gln	Ser	Thr	Gln	Asn	Thr	Asp	Ser	Glu	Thr	Arg	Thr
			275				280					285			
Ile	Ser	Lys	Asn	Thr	Ser	Thr	Ser	Arg	Thr	His	Thr	Ser	Asn	Ser	Asn
	290					295					300				
Ser	Ser	Thr	Val	Ala	Ile	Asp	His	Ser	Leu	Ser	Leu	Ala	Gly	Glu	Arg
305					310					315					320
Thr	Trp	Ala	Glu	Thr	Met	Gly	Leu	Asn	Thr	Ala	Asp	Thr	Ala	Arg	Leu
			325						330					335	
Asn	Ala	Asn	Ile	Arg	Tyr	Val	Asn	Thr	Gly	Thr	Ala	Pro	Ile	Tyr	Asn
			340					345					350		
Val	Leu	Pro	Thr	Thr	Ser	Leu	Val	Leu	Gly	Lys	Asn	Gln	Thr	Leu	Ala
		355					360					365			
Thr	Ile	Lys	Ala	Lys	Glu	Asn	Gln	Leu	Ser	Gln	Ile	Leu	Ala	Pro	Asn
	370					375					380				
Asn	Tyr	Tyr	Pro	Ser	Lys	Asn	Leu	Ala	Pro	Ile	Ala	Leu	Asn	Ala	Gln
385					390					395					400
Asp	Asp	Phe	Ser	Ser	Thr	Pro	Ile	Thr	Met	Asn	Tyr	Asn	Gln	Phe	Leu
				405					410					415	
Glu	Leu	Glu	Lys	Thr	Lys	Gln	Leu	Arg	Leu	Asp	Thr	Asp	Gln	Val	Tyr
			420					425					430		
Gly	Asn	Ile	Ala	Thr	Tyr	Asn	Phe	Glu	Asn	Gly	Arg	Val	Arg	Val	Asp
		435					440					445			
Thr	Gly	Ser	Asn	Trp	Ser	Glu	Val	Leu	Pro	Gln	Ile	Gln	Glu	Thr	Thr
	450					455					460				
Ala	Arg	Ile	Ile	Phe	Asn	Gly	Lys	Asp	Leu	Asn	Leu	Val	Glu	Arg	Arg
465					470					475					480
Ile	Ala	Ala	Val	Asn	Pro	Ser	Asp	Pro	Leu	Glu	Thr	Thr	Lys	Pro	Asp
				485					490					495	
Met	Thr	Leu	Lys	Glu	Ala	Leu	Lys	Ile	Ala	Phe	Gly	Phe	Asn	Glu	Pro
			500					505					510		
Asn	Gly	Asn	Leu	Gln	Tyr	Gln	Gly	Lys	Asp	Ile	Thr	Glu	Phe	Asp	Phe
		515					520					525			
Asn	Phe	Asp	Gln	Gln	Thr	Ser	Gln	Asn	Ile	Lys	Asn	Gln	Leu	Ala	Glu
	530					535					540				
Leu	Asn	Ala	Thr	Asn	Ile	Tyr	Thr	Val	Leu	Asp	Lys	Ile	Lys	Leu	Asn
545					550					555					560
Ala	Lys	Met	Asn	Ile	Leu	Ile	Arg	Asp	Lys	Arg	Phe	His	Tyr	Asp	Arg
				565					570					575	
Asn	Asn	Ile	Ala	Val	Gly	Ala	Asp	Glu	Ser	Val	Val	Lys	Glu	Ala	His

```

          580          585          590
Arg Glu Val Ile Asn Ser Ser Thr Glu Gly Leu Leu Leu Asn Ile Asp
          595          600          605
Lys Asp Ile Arg Lys Ile Leu Ser Gly Tyr Ile Val Glu Ile Glu Asp
          610          615          620
Thr Glu Gly Leu Lys Glu Val Ile Asn Asp Arg Tyr Asp Met Leu Asn
625          630          635          640
Ile Ser Ser Leu Arg Gln Asp Gly Lys Thr Phe Ile Asp Phe Lys Lys
          645          650          655
Tyr Asn Asp Lys Leu Pro Leu Tyr Ile Ser Asn Pro Asn Tyr Lys Val
          660          665          670
Asn Val Tyr Ala Val Thr Lys Glu Asn Thr Ile Ile Asn Pro Ser Glu
          675          680          685
Asn Gly Asp Thr Ser Thr Asn Gly Ile Lys Lys Ile Leu Ile Phe Ser
          690          695          700
Lys Lys Gly Tyr Glu Ile Gly
705          710

```

<210> 13  
 <211> 735  
 <212> PRT  
 <213> Bacillus anthracis

```

<400> 13
Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser
 1          5          10          15
Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
          20          25          30
Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
          35          40          45
Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
          50          55          60
Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala
65          70          75          80
Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
          85          90          95
Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
          100          105          110
Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
          115          120          125
Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
          130          135          140
Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser
145          150          155          160
Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
          165          170          175
Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
          180          185          190
Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
          195          200          205
Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
          210          215          220
Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr
225          230          235          240
Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
          245          250          255
Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
          260          265          270
Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
          275          280          285
Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
290          295          300

```

Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val  
 305 310 315 320  
 Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His  
 325 330 335  
 Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu  
 340 345 350  
 Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn  
 355 360 365  
 Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val  
 370 375 380  
 Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Asp Glu Asn Gln  
 385 390 395 400  
 Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu  
 405 410 415  
 Ala Pro Ile Ala Leu Asn Ala Gln Lys Asp Ala Ser Ser Thr Pro Ile  
 420 425 430  
 Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu  
 435 440 445  
 Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe  
 450 455 460  
 Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val  
 465 470 475 480  
 Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys  
 485 490 495  
 Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp  
 500 505 510  
 Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys  
 515 520 525  
 Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly  
 530 535 540  
 Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln  
 545 550 555 560  
 Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr  
 565 570 575  
 Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg  
 580 585 590  
 Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp  
 595 600 605  
 Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr  
 610 615 620  
 Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser  
 625 630 635 640  
 Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile  
 645 650 655  
 Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly  
 660 665 670  
 Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr  
 675 680 685  
 Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu  
 690 695 700  
 Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly  
 705 710 715 720  
 Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly  
 725 730 735

&lt;210&gt; 14

&lt;211&gt; 711

&lt;212&gt; PRT

&lt;213&gt; Bacillus anthracis

&lt;400&gt; 14

Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser

1				5				10				15			
Gln	Gly	Leu	Leu	Gly	Tyr	Tyr	Phe	Ser	Asp	Leu	Asn	Phe	Gln	Ala	Pro
			20					25					30		
Met	Val	Val	Thr	Ser	Ser	Thr	Thr	Gly	Asp	Leu	Ser	Ile	Pro	Ser	Ser
		35					40					45			
Glu	Leu	Glu	Asn	Ile	Pro	Ser	Glu	Asn	Gln	Tyr	Phe	Gln	Ser	Ala	Ile
	50					55					60				
Trp	Ser	Gly	Phe	Ile	Lys	Val	Lys	Lys	Ser	Asp	Glu	Tyr	Thr	Phe	Ala
65					70					75				80	
Thr	Ser	Ala	Asp	Asn	His	Val	Thr	Met	Trp	Val	Asp	Asp	Gln	Glu	Val
				85					90				95		
Ile	Asn	Lys	Ala	Ser	Asn	Ser	Asn	Lys	Ile	Arg	Leu	Glu	Lys	Gly	Arg
			100					105					110		
Leu	Tyr	Gln	Ile	Lys	Ile	Gln	Tyr	Gln	Arg	Glu	Asn	Pro	Thr	Glu	Lys
		115					120					125			
Gly	Leu	Asp	Phe	Lys	Leu	Tyr	Trp	Thr	Asp	Ser	Gln	Asn	Lys	Lys	Glu
	130					135					140				
Val	Ile	Ser	Ser	Asp	Asn	Leu	Gln	Leu	Pro	Glu	Leu	Lys	Gln	Lys	Ser
145					150					155				160	
Ser	Asn	Ser	Arg	Lys	Lys	Arg	Ser	Thr	Ser	Ala	Gly	Pro	Thr	Val	Pro
				165					170				175		
Asp	Arg	Asp	Asn	Asp	Gly	Ile	Pro	Asp	Ser	Leu	Glu	Val	Glu	Gly	Tyr
			180					185					190		
Thr	Val	Asp	Val	Lys	Asn	Lys	Arg	Thr	Phe	Leu	Ser	Pro	Trp	Ile	Ser
	195						200					205			
Asn	Ile	His	Glu	Lys	Lys	Gly	Leu	Thr	Lys	Tyr	Lys	Ser	Ser	Pro	Glu
	210					215					220				
Lys	Trp	Ser	Thr	Ala	Ser	Asp	Pro	Tyr	Ser	Asp	Phe	Glu	Lys	Val	Thr
225					230					235				240	
Gly	Arg	Ile	Asp	Lys	Asn	Val	Ser	Pro	Glu	Ala	Arg	His	Pro	Leu	Val
				245					250				255		
Ala	Ala	Tyr	Pro	Ile	Val	His	Val	Asp	Met	Glu	Asn	Ile	Ile	Leu	Ser
			260					265					270		
Lys	Asn	Glu	Asp	Gln	Ser	Thr	Gln	Asn	Thr	Asp	Ser	Glu	Thr	Arg	Thr
	275						280					285			
Ile	Ser	Lys	Asn	Thr	Ser	Thr	Ser	Arg	Thr	His	Thr	Ser	Asn	Ser	Asn
	290					295					300				
Ser	Ser	Thr	Val	Ala	Ile	Asp	His	Ser	Leu	Ser	Leu	Ala	Gly	Glu	Arg
305					310				315					320	
Thr	Trp	Ala	Glu	Thr	Met	Gly	Leu	Asn	Thr	Ala	Asp	Thr	Ala	Arg	Leu
				325					330				335		
Asn	Ala	Asn	Ile	Arg	Tyr	Val	Asn	Thr	Gly	Thr	Ala	Pro	Ile	Tyr	Asn
			340					345					350		
Val	Leu	Pro	Thr	Thr	Ser	Leu	Val	Leu	Gly	Lys	Asn	Gln	Thr	Leu	Ala
	355						360					365			
Thr	Ile	Lys	Ala	Lys	Glu	Asn	Gln	Leu	Ser	Gln	Ile	Leu	Ala	Pro	Asn
	370					375					380				
Asn	Tyr	Tyr	Pro	Ser	Lys	Asn	Leu	Ala	Pro	Ile	Ala	Leu	Asn	Ala	Gln
385					390					395				400	
Asp	Asp	Ala	Ser	Ser	Thr	Pro	Ile	Thr	Met	Asn	Tyr	Asn	Gln	Phe	Leu
				405					410					415	
Glu	Leu	Glu	Lys	Thr	Lys	Gln	Leu	Arg	Leu	Asp	Thr	Asp	Gln	Val	Tyr
			420					425					430		
Gly	Asn	Ile	Ala	Thr	Tyr	Asn	Phe	Glu	Asn	Gly	Arg	Val	Arg	Val	Asp
			435				440					445			
Thr	Gly	Ser	Asn	Trp	Ser	Glu	Val	Leu	Pro	Gln	Ile	Gln	Glu	Thr	Thr
	450					455					460				
Ala	Arg	Ile	Ile	Phe	Asn	Gly	Lys	Asp	Leu	Asn	Leu	Val	Glu	Arg	Arg
465					470					475				480	
Ile	Ala	Ala	Val	Asn	Pro	Ser	Asp	Pro	Leu	Glu	Thr	Thr	Lys	Pro	Asp
				485					490					495	
Met	Thr	Leu	Lys	Glu	Ala	Leu	Lys	Ile	Ala	Phe	Gly	Phe	Asn	Glu	Pro
			500					505					510		

Asn Gly Asn Leu Gln Tyr Gln Gly Lys Asp Ile Thr Glu Phe Asp Phe  
           515  520                  525  
 Asn Phe Asp Gln Gln Thr Ser Gln Asn Ile Lys Asn Gln Leu Ala Glu  
           530  535                  540  
 Leu Asn Ala Thr Asn Ile Tyr Thr Val Leu Asp Lys Ile Lys Leu Asn  
 545  550                  555                  560  
 Ala Lys Met Asn Ile Leu Ile Arg Asp Lys Arg Phe His Tyr Asp Arg  
   565                  570                  575  
 Asn Asn Ile Ala Val Gly Ala Asp Glu Ser Val Val Lys Glu Ala His  
   580                  585                  590  
 Arg Glu Val Ile Asn Ser Ser Thr Glu Gly Leu Leu Leu Asn Ile Asp  
   595                  600                  605  
 Lys Asp Ile Arg Lys Ile Leu Ser Gly Tyr Ile Val Glu Ile Glu Asp  
           610  615                  620  
 Thr Glu Gly Leu Lys Glu Val Ile Asn Asp Arg Tyr Asp Met Leu Asn  
 625  630                  635                  640  
 Ile Ser Ser Leu Arg Gln Asp Gly Lys Thr Phe Ile Asp Phe Lys Lys  
   645                  650                  655  
 Tyr Asn Asp Lys Leu Pro Leu Tyr Ile Ser Asn Pro Asn Tyr Lys Val  
   660                  665                  670  
 Asn Val Tyr Ala Val Thr Lys Glu Asn Thr Ile Ile Asn Pro Ser Glu  
   675                  680                  685  
 Asn Gly Asp Thr Ser Thr Asn Gly Ile Lys Lys Ile Leu Ile Phe Ser  
           690  695                  700  
 Lys Lys Gly Tyr Glu Ile Gly  
 705  710

&lt;210&gt; 15

&lt;211&gt; 711

&lt;212&gt; PRT

&lt;213&gt; Bacillus anthracis

&lt;400&gt; 15

Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser  
   1  5                  10                  15  
 Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro  
   20                  25                  30  
 Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser  
   35                  40                  45  
 Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile  
           50  55                  60  
 Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala  
 65  70                  75                  80  
 Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val  
   85                  90                  95  
 Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg  
   100                  105                  110  
 Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys  
   115                  120                  125  
 Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu  
           130  135                  140  
 Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser  
 145  150                  155                  160  
 Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro  
   165                  170                  175  
 Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr  
   180                  185                  190  
 Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser  
   195                  200                  205  
 Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu  
           210  215                  220  
 Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr

-24-

<210> 16  
 <211> 711  
 <212> PRT  
 <213> Bacillus anthracis

<400> 16  
 Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser  
 1 5 10 15  
 Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro  
 20 25 30  
 Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser  
 35 40 45  
 Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile  
 50 55 60  
 Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala  
 65 70 75 80  
 Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val  
 85 90 95  
 Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg  
 100 105 110  
 Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys  
 115 120 125  
 Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu  
 130 135 140  
 Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser  
 145 150 155 160  
 Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro  
 165 170 175  
 Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr  
 180 185 190  
 Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser  
 195 200 205  
 Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu  
 210 215 220  
 Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr  
 225 230 235 240  
 Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val  
 245 250 255  
 Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser  
 260 265 270  
 Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr  
 275 280 285  
 Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Asn Ser Asn  
 290 295 300  
 Ser Ser Thr Val Ala Ile Asp His Ser Leu Ser Leu Ala Gly Glu Arg  
 305 310 315 320  
 Thr Trp Ala Glu Thr Met Gly Leu Asn Thr Ala Asp Thr Ala Arg Leu  
 325 330 335  
 Asn Ala Asn Ile Arg Tyr Val Asn Thr Gly Thr Ala Pro Ile Tyr Asn  
 340 345 350  
 Val Leu Pro Thr Thr Ser Leu Val Leu Gly Lys Asn Gln Thr Leu Ala  
 355 360 365  
 Thr Ile Lys Ala Asp Glu Asn Gln Leu Ser Gln Ile Leu Ala Pro Asn  
 370 375 380  
 Asn Tyr Tyr Pro Ser Lys Asn Leu Ala Pro Ile Ala Leu Asn Ala Gln  
 385 390 395 400  
 Lys Asp Ala Ser Ser Thr Pro Ile Thr Met Asn Tyr Asn Gln Phe Leu  
 405 410 415  
 Glu Leu Glu Lys Thr Lys Gln Leu Arg Leu Asp Thr Asp Gln Val Tyr  
 420 425 430  
 Gly Asn Ile Ala Thr Tyr Asn Phe Glu Asn Gly Arg Val Arg Val Asp  
 435 440 445  
 Thr Gly Ser Asn Trp Ser Glu Val Leu Pro Gln Ile Gln Glu Thr Thr



```

      450              455              460
Ala Arg Ile Ile Phe Asn Gly Lys Asp Leu Asn Leu Val Glu Arg Arg
465              470              475              480
Ile Ala Ala Val Asn Pro Ser Asp Pro Leu Glu Thr Thr Lys Pro Asp
      485              490
Met Thr Leu Lys Glu Ala Leu Lys Ile Ala Phe Gly Phe Asn Glu Pro
      500              505              510
Asn Gly Asn Leu Gln Tyr Gln Gly Lys Asp Ile Thr Glu Phe Asp Phe
      515              520              525
Asn Phe Asp Gln Gln Thr Ser Gln Asn Ile Lys Asn Gln Leu Ala Glu
      530              535              540
Leu Asn Ala Thr Asn Ile Tyr Thr Val Leu Asp Lys Ile Lys Leu Asn
545              550              555              560
Ala Lys Met Asn Ile Leu Ile Arg Asp Lys Arg Phe His Tyr Asp Arg
      565              570              575
Asn Asn Ile Ala Val Gly Ala Asp Glu Ser Val Val Lys Glu Ala His
      580              585              590
Arg Glu Val Ile Asn Ser Ser Thr Glu Gly Leu Leu Leu Asn Ile Asp
      595              600              605
Lys Asp Ile Arg Lys Ile Leu Ser Gly Tyr Ile Val Glu Ile Glu Asp
      610              615              620
Thr Glu Gly Leu Lys Glu Val Ile Asn Asp Arg Tyr Asp Met Leu Asn
625              630              635              640
Ile Ser Ser Leu Arg Gln Asp Gly Lys Thr Phe Ile Asp Phe Lys Lys
      645              650              655
Tyr Asn Asp Lys Leu Pro Leu Tyr Ile Ser Asn Pro Asn Tyr Lys Val
      660              665              670
Asn Val Tyr Ala Val Thr Lys Glu Asn Thr Ile Ile Asn Pro Ser Glu
      675              680              685
Asn Gly Asp Thr Ser Thr Asn Gly Ile Lys Lys Ile Leu Ile Phe Ser
      690              695              700
Lys Lys Gly Tyr Glu Ile Gly
705              710

```

<210> 17  
 <211> 735  
 <212> PRT  
 <213> Bacillus anthracis

```

<400> 17
Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser
  1              5              10              15
Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
      20              25              30
Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
      35              40              45
Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
      50              55              60
Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala
65              70              75              80
Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
      85              90              95
Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
      100              105              110
Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
      115              120              125
Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
      130              135              140
Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser
145              150              155              160
Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
      165              170              175

```

Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr  
 180 185 190  
 Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser  
 195 200 205  
 Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu  
 210 215 220  
 Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr  
 225 230 235 240  
 Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val  
 245 250 255  
 Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser  
 260 265 270  
 Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr  
 275 280 285  
 Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His  
 290 295 300  
 Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val  
 305 310 315 320  
 Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His  
 325 330 335  
 Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu  
 340 345 350  
 Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn  
 355 360 365  
 Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val  
 370 375 380  
 Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln  
 385 390 395 400  
 Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu  
 405 410 415  
 Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Asp Ser Ser Thr Pro Ile  
 420 425 430  
 Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu  
 435 440 445  
 Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe  
 450 455 460  
 Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val  
 465 470 475 480  
 Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys  
 485 490 495  
 Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp  
 500 505 510  
 Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys  
 515 520 525  
 Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly  
 530 535 540  
 Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln  
 545 550 555 560  
 Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr  
 565 570 575  
 Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg  
 580 585 590  
 Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp  
 595 600 605  
 Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr  
 610 615 620  
 Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser  
 625 630 635 640  
 Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile  
 645 650 655  
 Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly  
 660 665 670  
 Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr

		675					680					685			
Ile	Ser	Asn	Pro	Asn	Tyr	Lys	Val	Asn	Val	Tyr	Ala	Val	Thr	Lys	Glu
	690					695					700				
Asn	Thr	Ile	Ile	Asn	Pro	Ser	Glu	Asn	Gly	Asp	Thr	Ser	Thr	Asn	Gly
705					710					715					720
Ile	Lys	Lys	Ile	Leu	Ile	Phe	Ser	Lys	Lys	Gly	Tyr	Glu	Ile	Gly	
				725					730					735	

&lt;210&gt; 18

&lt;211&gt; 735

&lt;212&gt; PRT

&lt;213&gt; Bacillus anthracis

&lt;400&gt; 18

Glu	Val	Lys	Gln	Glu	Asn	Arg	Leu	Leu	Asn	Glu	Ser	Glu	Ser	Ser	Ser
1				5					10					15	
Gln	Gly	Leu	Leu	Gly	Tyr	Tyr	Phe	Ser	Asp	Leu	Asn	Phe	Gln	Ala	Pro
		20					25					30			
Met	Val	Val	Thr	Ser	Ser	Thr	Thr	Gly	Asp	Leu	Ser	Ile	Pro	Ser	Ser
		35				40						45			
Glu	Leu	Glu	Asn	Ile	Pro	Ser	Glu	Asn	Gln	Tyr	Phe	Gln	Ser	Ala	Ile
	50					55				60					
Trp	Ser	Gly	Phe	Ile	Lys	Val	Lys	Lys	Ser	Asp	Glu	Tyr	Thr	Phe	Ala
65				70					75						80
Thr	Ser	Ala	Asp	Asn	His	Val	Thr	Met	Trp	Val	Asp	Asp	Gln	Glu	Val
				85				90					95		
Ile	Asn	Lys	Ala	Ser	Asn	Ser	Asn	Lys	Ile	Arg	Leu	Glu	Lys	Gly	Arg
			100					105					110		
Leu	Tyr	Gln	Ile	Lys	Ile	Gln	Tyr	Gln	Arg	Glu	Asn	Pro	Thr	Glu	Lys
		115				120						125			
Gly	Leu	Asp	Phe	Lys	Leu	Tyr	Trp	Thr	Asp	Ser	Gln	Asn	Lys	Lys	Glu
	130					135					140				
Val	Ile	Ser	Ser	Asp	Asn	Leu	Gln	Leu	Pro	Glu	Leu	Lys	Gln	Lys	Ser
145				150					155						160
Ser	Asn	Ser	Arg	Lys	Lys	Arg	Ser	Thr	Ser	Ala	Gly	Pro	Thr	Val	Pro
			165					170						175	
Asp	Arg	Asp	Asn	Asp	Gly	Ile	Pro	Asp	Ser	Leu	Glu	Val	Glu	Gly	Tyr
			180					185					190		
Thr	Val	Asp	Val	Lys	Asn	Lys	Arg	Thr	Phe	Leu	Ser	Pro	Trp	Ile	Ser
		195					200					205			
Asn	Ile	His	Glu	Lys	Lys	Gly	Leu	Thr	Lys	Tyr	Lys	Ser	Ser	Pro	Glu
	210					215					220				
Lys	Trp	Ser	Thr	Ala	Ser	Asp	Pro	Tyr	Ser	Asp	Phe	Glu	Lys	Val	Thr
225					230					235					240
Gly	Arg	Ile	Asp	Lys	Asn	Val	Ser	Pro	Glu	Ala	Arg	His	Pro	Leu	Val
				245					250					255	
Ala	Ala	Tyr	Pro	Ile	Val	His	Val	Asp	Met	Glu	Asn	Ile	Ile	Leu	Ser
			260					265					270		
Lys	Asn	Glu	Asp	Gln	Ser	Thr	Gln	Asn	Thr	Asp	Ser	Glu	Thr	Arg	Thr
		275					280					285			
Ile	Ser	Lys	Asn	Thr	Ser	Thr	Ser	Arg	Thr	His	Thr	Ser	Glu	Val	His
	290					295					300				
Gly	Asn	Ala	Glu	Val	His	Ala	Ser	Phe	Phe	Asp	Ile	Gly	Gly	Ser	Val
305					310					315					320
Ser	Ala	Gly	Phe	Ser	Asn	Ser	Asn	Ser	Ser	Thr	Val	Ala	Ile	Asp	His
				325					330					335	
Ser	Leu	Ser	Leu	Ala	Gly	Glu	Arg	Thr	Trp	Ala	Glu	Thr	Met	Gly	Leu
			340				345						350		
Asn	Thr	Ala	Asp	Thr	Ala	Arg	Leu	Asn	Ala	Asn	Ile	Arg	Tyr	Val	Asn
		355				360						365			
Thr	Gly	Thr	Ala	Pro	Ile	Tyr	Asn	Val	Leu	Pro	Thr	Thr	Ser	Leu	Val
	370					375					380				

Leu	Gly	Lys	Asn	Gln	Thr	Leu	Ala	Thr	Ile	Lys	Ala	Lys	Glu	Asn	Gln
385					390					395					400
Leu	Ser	Gln	Ile	Leu	Ala	Pro	Asn	Asn	Tyr	Tyr	Pro	Ser	Lys	Asn	Leu
				405					410					415	
Ala	Pro	Ile	Ala	Leu	Asn	Ala	Gln	Asp	Asp	Lys	Ser	Ser	Thr	Pro	Ile
			420					425					430		
Thr	Met	Asn	Tyr	Asn	Gln	Phe	Leu	Glu	Leu	Glu	Lys	Thr	Lys	Gln	Leu
		435					440					445			
Arg	Leu	Asp	Thr	Asp	Gln	Val	Tyr	Gly	Asn	Ile	Ala	Thr	Tyr	Asn	Phe
	450					455					460				
Glu	Asn	Gly	Arg	Val	Arg	Val	Asp	Thr	Gly	Ser	Asn	Trp	Ser	Glu	Val
465					470					475					480
Leu	Pro	Gln	Ile	Gln	Glu	Thr	Thr	Ala	Arg	Ile	Ile	Phe	Asn	Gly	Lys
				485					490					495	
Asp	Leu	Asn	Leu	Val	Glu	Arg	Arg	Ile	Ala	Ala	Val	Asn	Pro	Ser	Asp
			500					505					510		
Pro	Leu	Glu	Thr	Thr	Lys	Pro	Asp	Met	Thr	Leu	Lys	Glu	Ala	Leu	Lys
		515					520					525			
Ile	Ala	Phe	Gly	Phe	Asn	Glu	Pro	Asn	Gly	Asn	Leu	Gln	Tyr	Gln	Gly
	530					535					540				
Lys	Asp	Ile	Thr	Glu	Phe	Asp	Phe	Asn	Phe	Asp	Gln	Gln	Thr	Ser	Gln
545					550					555					560
Asn	Ile	Lys	Asn	Gln	Leu	Ala	Glu	Leu	Asn	Ala	Thr	Asn	Ile	Tyr	Thr
				565					570					575	
Val	Leu	Asp	Lys	Ile	Lys	Leu	Asn	Ala	Lys	Met	Asn	Ile	Leu	Ile	Arg
			580					585					590		
Asp	Lys	Arg	Phe	His	Tyr	Asp	Arg	Asn	Asn	Ile	Ala	Val	Gly	Ala	Asp
		595					600					605			
Glu	Ser	Val	Val	Lys	Glu	Ala	His	Arg	Glu	Val	Ile	Asn	Ser	Ser	Thr
	610					615					620				
Glu	Gly	Leu	Leu	Leu	Asn	Ile	Asp	Lys	Asp	Ile	Arg	Lys	Ile	Leu	Ser
625					630					635					640
Gly	Tyr	Ile	Val	Glu	Ile	Glu	Asp	Thr	Glu	Gly	Leu	Lys	Glu	Val	Ile
				645					650					655	
Asn	Asp	Arg	Tyr	Asp	Met	Leu	Asn	Ile	Ser	Ser	Leu	Arg	Gln	Asp	Gly
			660					665					670		
Lys	Thr	Phe	Ile	Asp	Phe	Lys	Lys	Tyr	Asn	Asp	Lys	Leu	Pro	Leu	Tyr
		675					680					685			
Ile	Ser	Asn	Pro	Asn	Tyr	Lys	Val	Asn	Val	Tyr	Ala	Val	Thr	Lys	Glu
	690					695					700				
Asn	Thr	Ile	Ile	Asn	Pro	Ser	Glu	Asn	Gly	Asp	Thr	Ser	Thr	Asn	Gly
705				710						715					720
Ile	Lys	Lys	Ile	Leu	Ile	Phe	Ser	Lys	Lys	Gly	Tyr	Glu	Ile	Gly	
				725					730					735	

&lt;210&gt; 19

&lt;211&gt; 735

&lt;212&gt; PRT

&lt;213&gt; Bacillus anthracis

&lt;220&gt;

&lt;221&gt; VARIANT

&lt;222&gt; 397

&lt;223&gt; Xaa = any amino acid except Lys

&lt;400&gt; 19

Glu	Val	Lys	Gln	Glu	Asn	Arg	Leu	Leu	Asn	Glu	Ser	Glu	Ser	Ser	Ser
1				5					10					15	
Gln	Gly	Leu	Leu	Gly	Tyr	Tyr	Phe	Ser	Asp	Leu	Asn	Phe	Gln	Ala	Pro
			20					25					30		
Met	Val	Val	Thr	Ser	Ser	Thr	Thr	Gly	Asp	Leu	Ser	Ile	Pro	Ser	Ser
		35					40						45		

Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile  
 50 55 60  
 Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala  
 65 70 75 80  
 Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val  
 85 90 95  
 Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg  
 100 105 110  
 Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys  
 115 120 125  
 Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu  
 130 135 140  
 Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser  
 145 150 155 160  
 Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro  
 165 170 175  
 Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr  
 180 185 190  
 Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser  
 195 200 205  
 Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu  
 210 215 220  
 Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr  
 225 230 235 240  
 Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val  
 245 250 255  
 Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser  
 260 265 270  
 Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr  
 275 280 285  
 Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His  
 290 295 300  
 Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val  
 305 310 315 320  
 Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His  
 325 330 335  
 Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu  
 340 345 350  
 Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn  
 355 360 365  
 Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val  
 370 375 380  
 Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Xaa Glu Asn Gln  
 385 390 395 400  
 Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu  
 405 410 415  
 Ala Pro Ile Ala Leu Asn Ala Gln Asp Phe Ser Ser Thr Pro Ile  
 420 425 430  
 Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu  
 435 440 445  
 Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe  
 450 455 460  
 Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val  
 465 470 475 480  
 Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys  
 485 490 495  
 Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp  
 500 505 510  
 Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys  
 515 520 525  
 Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly  
 530 535 540  
 Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln

```

545          550          555          560
Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
565          570          575
Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
580          585          590
Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
595          600          605
Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
610          615          620
Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser
625          630          635
Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
645          650          655
Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
660          665          670
Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
675          680          685
Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
690          695          700
Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly
705          710          715          720
Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly
725          730          735

```

<210> 20  
 <211> 735  
 <212> PRT  
 <213> Bacillus anthracis

```

<400> 20
Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser
1          5          10          15
Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20          25          30
Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35          40          45
Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50          55          60
Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala
65          70          75          80
Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85          90          95
Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100          105          110
Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115          120          125
Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130          135          140
Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser
145          150          155          160
Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165          170          175
Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180          185          190
Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195          200          205
Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210          215          220
Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr
225          230          235          240
Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245          250          255

```

Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser  
 260 265 270  
 Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr  
 275 280 285  
 Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His  
 290 295 300  
 Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val  
 305 310 315 320  
 Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His  
 325 330 335  
 Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu  
 340 345 350  
 Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn  
 355 360 365  
 Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val  
 370 375 380  
 Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln  
 385 390 395 400  
 Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu  
 405 410 415  
 Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile  
 420 425 430  
 Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu  
 435 440 445  
 Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe  
 450 455 460  
 Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val  
 465 470 475 480  
 Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys  
 485 490 495  
 Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp  
 500 505 510  
 Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys  
 515 520 525  
 Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly  
 530 535 540  
 Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln  
 545 550 555 560  
 Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr  
 565 570 575  
 Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg  
 580 585 590  
 Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp  
 595 600 605  
 Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr  
 610 615 620  
 Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser  
 625 630 635 640  
 Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile  
 645 650 655  
 Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly  
 660 665 670  
 Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr  
 675 680 685  
 Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu  
 690 695 700  
 Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly  
 705 710 715 720  
 Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly  
 725 730 735

&lt;210&gt; 21

<211> 735  
 <212> PRT  
 <213> Bacillus anthracis

<400> 21

Glu	Val	Lys	Gln	Glu	Asn	Arg	Leu	Leu	Asn	Glu	Ser	Glu	Ser	Ser	Ser	
1				5					10					15		
Gln	Gly	Leu	Leu	Gly	Tyr	Tyr	Phe	Ser	Asp	Leu	Asn	Phe	Gln	Ala	Pro	
		20						25					30			
Met	Val	Val	Thr	Ser	Ser	Thr	Thr	Gly	Asp	Leu	Ser	Ile	Pro	Ser	Ser	
		35					40					45				
Glu	Leu	Glu	Asn	Ile	Pro	Ser	Glu	Asn	Gln	Tyr	Phe	Gln	Ser	Ala	Ile	
	50					55					60					
Trp	Ser	Gly	Phe	Ile	Lys	Val	Lys	Lys	Ser	Asp	Glu	Tyr	Thr	Phe	Ala	
65					70					75					80	
Thr	Ser	Ala	Asp	Asn	His	Val	Thr	Met	Trp	Val	Asp	Asp	Gln	Glu	Val	
				85					90				95			
Ile	Asn	Lys	Ala	Ser	Asn	Ser	Asn	Lys	Ile	Arg	Leu	Glu	Lys	Gly	Arg	
		100						105					110			
Leu	Tyr	Gln	Ile	Lys	Ile	Gln	Tyr	Gln	Arg	Glu	Asn	Pro	Thr	Glu	Lys	
		115					120					125				
Gly	Leu	Asp	Phe	Lys	Leu	Tyr	Trp	Thr	Asp	Ser	Gln	Asn	Lys	Lys	Glu	
	130					135					140					
Val	Ile	Ser	Ser	Asp	Asn	Leu	Gln	Leu	Pro	Glu	Leu	Lys	Gln	Lys	Ser	
145					150					155					160	
Ser	Asn	Ser	Arg	Lys	Lys	Arg	Ser	Thr	Ser	Ala	Gly	Pro	Thr	Val	Pro	
				165					170					175		
Asp	Arg	Asp	Asn	Asp	Gly	Ile	Pro	Asp	Ser	Leu	Glu	Val	Glu	Gly	Tyr	
			180					185					190			
Thr	Val	Asp	Val	Lys	Asn	Lys	Arg	Thr	Phe	Leu	Ser	Pro	Trp	Ile	Ser	
		195					200					205				
Asn	Ile	His	Glu	Lys	Lys	Gly	Leu	Thr	Lys	Tyr	Lys	Ser	Ser	Pro	Glu	
	210					215					220					
Lys	Trp	Ser	Thr	Ala	Ser	Asp	Pro	Tyr	Ser	Asp	Phe	Glu	Lys	Val	Thr	
225					230					235					240	
Gly	Arg	Ile	Asp	Lys	Asn	Val	Ser	Pro	Glu	Ala	Arg	His	Pro	Leu	Val	
				245					250					255		
Ala	Ala	Tyr	Pro	Ile	Val	His	Val	Asp	Met	Glu	Asn	Ile	Ile	Leu	Ser	
		260						265					270			
Lys	Asn	Glu	Asp	Gln	Ser	Thr	Gln	Asn	Thr	Asp	Ser	Glu	Thr	Arg	Thr	
		275						280					285			
Ile	Ser	Lys	Asn	Thr	Ser	Thr	Ser	Arg	Thr	His	Thr	Ser	Glu	Val	His	
	290					295					300					
Gly	Asn	Ala	Glu	Val	His	Ala	Ser	Phe	Phe	Asp	Ile	Gly	Gly	Ser	Val	
305					310					315					320	
Ser	Ala	Gly	Phe	Ser	Asn	Ser	Asn	Ser	Ser	Thr	Val	Ala	Ile	Asp	His	
				325					330					335		
Ser	Leu	Ser	Leu	Ala	Gly	Glu	Arg	Thr	Trp	Ala	Glu	Thr	Met	Gly	Leu	
		340						345					350			
Asn	Thr	Ala	Asp	Thr	Ala	Arg	Leu	Asn	Ala	Asn	Ile	Arg	Tyr	Val	Asn	
		355					360						365			
Thr	Gly	Thr	Ala	Pro	Ile	Tyr	Asn	Val	Leu	Pro	Thr	Thr	Ser	Leu	Val	
	370					375						380				
Leu	Gly	Lys	Asn	Gln	Thr	Leu	Ala	Thr	Ile	Lys	Ala	Lys	Glu	Asn	Gln	
385					390					395					400	
Leu	Ser	Gln	Ile	Leu	Ala	Pro	Asn	Asn	Tyr	Tyr	Pro	Ser	Lys	Asn	Leu	
				405					410					415		
Ala	Pro	Ile	Ala	Leu	Asn	Ala	Gln	Asp	Asp	Phe	Ser	Ser	Thr	Pro	Ile	
			420					425					430			
Thr	Met	Asn	Tyr	Asn	Gln	Phe	Leu	Glu	Leu	Glu	Lys	Thr	Lys	Gln	Leu	
		435					440					445				
Arg	Leu	Asp	Thr	Asp	Gln	Val	Tyr	Gly	Asn	Ile	Ala	Thr	Tyr	Asn	Phe	
	450					455						460				



Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val  
 465 470 475 480  
 Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys  
 485 490 495  
 Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp  
 500 505 510  
 Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys  
 515 520 525  
 Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly  
 530 535 540  
 Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln  
 545 550 555 560  
 Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr  
 565 570 575  
 Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg  
 580 585 590  
 Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp  
 595 600 605  
 Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr  
 610 615 620  
 Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser  
 625 630 635 640  
 Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile  
 645 650 655  
 Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly  
 660 665 670  
 Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr  
 675 680 685  
 Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu  
 690 695 700  
 Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly  
 705 710 715 720  
 Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly  
 725 730 735

&lt;210&gt; 22

&lt;211&gt; 2208

&lt;212&gt; DNA

<213> *Bacillus anthracis*

&lt;400&gt; 22

gaagttaaacc aggagaaccg gttatttaaatt gaatcagaat caagttccca ggggttacta 60  
 ggatactatt ttagtgattt gaattttcaa gcacccatgg tggttaccto ttctactaca 120  
 ggggatttat ctattcctag ttctgagtta gaaaatattc catcggaata ccaatatatt 180  
 caatctgcta tttggtcagg atttatcaaa gttaagaaga gtgatgaata tacatttgct 240  
 acttccgctg ataatcatgt aacaatgtgg gtagatgacc aagaagtgat taataaagct 300  
 tctaattcta acaaaatcag attagaaaaa ggaagattat atcaaataaa aattcaatat 360  
 caacgagaaa atcctactga aaaaggattg gatttcaagt tgtactggac cgatttctcaa 420  
 aataaaaaag aagtgatttc tagtgataac ttacaattgc cagaattaaa acaaaaatct 480  
 tcgaactcaa gaaaaaagcg aagtacaagt gctggacctt cggttccaga ccgtgacaat 540  
 gatggaatcc ctgattcatt agaggtagaa ggatatacgg ttgatgtcaa aaataaaaaga 600  
 acttttcttt caccatggat ttctaataatt catgaaaaga aaggattaac caaatataaa 660  
 tcatctcctg aaaaatggag cacggcttct gatccgtaca gtgatttcga aaaggttaca 720  
 ggacggattg ataagaatgt atcaccagag gcaagacacc cccttggtggc agcttatccg 780  
 attgtacatg tagatatgga gaatattatt ctctcaaaaa atgaggatca atccacacag 840  
 aatactgata gtgaaacgag aacaataagt aaaaatactt ctacaagtag gacacatact 900  
 agtgaagtac atggaaatgc agaagtgcac gcgtcgttct ttgatattgg tgggagtgtg 960  
 tctgcaggat ttagtaattc gaattcaagt acggctcgcaa ttgatcattc actatctcta 1020  
 gcaggggaaa gaacttgggc tgaaacaatg ggtttaaata ccgctgatac agcaagatta 1080  
 aatgcccaata ttagatatgt aaatactggg acggctccaa tctacaacgt gttaccaacg 1140  
 acttcgttag tgttaggaaa aaatcaaaaa ctgcgcgacaa ttaaagctaa ggaaaaccaa 1200  
 ttaagtcaaa tacttgcacc taataattat tatccttcta aaaacttggc gccaatcgca 1260

```

ttaaattgcac aagacgattt cagtttctact ccaattacaa tgaattacaa tcaattttctt 1320
gagtttagaaa aaacgaaaca attaagatta gatacggatc aagtatatgg gaatatagca 1380
acatacaatt ttgaaaatgg aagagtgagg gtggatacag gctcgaactg gagtgaagtg 1440
ttaccgcaaa ttcaagaaac aactgcacgt atcatttttta atggaaaaga tttaaatctg 1500
gtagaaaggc ggatagcggc ggtaaatcct agtgatccat tagaaacgac taaaccggat 1560
atgacattaa aagaagccct taaaatagca tttggattta acgaaccgaa tggaaactta 1620
caatatcaag ggaaagacat aaccgaattt gatttttaatt tccgatcaaca aacatctcaa 1680
aatatcaaga atcagtttagc ggaattaaac gcaactaaca tatatactgt attagataaa 1740
atcaaattaa atgcaaaaat gaatattttta ataagagata aacgtttttca ttatgataga 1800
aataacatag cagttggggc ggatgagtc gtagttaagg aggctcatag agaagtaatt 1860
aattcgtcaa cagagggatt attgttaaat attgataagg atataagaaa aatattatca 1920
ggttatatgg tagaaattga agatactgaa gggcttaaag aagttataaa tgacagatat 1980
gatatgttga atattttctag tttacggcaa gatggaaaaa catttataga ttttaaaaaa 2040
tataatgata aattaccgtt atataataagt aatcccaatt ataaggtaaa tgtatatgct 2100
gttactaaag aaaacactat tattaatcct agtgagaatg gggatactag taccaacggg 2160
atcaagaaaa ttttaattct ttctaaaaaa ggctatgaga taggataa 2208

```

&lt;210&gt; 23

&lt;211&gt; 735

&lt;212&gt; PRT

<213> *Bacillus anthracis*

&lt;220&gt;

&lt;221&gt; VARIANT

&lt;222&gt; 427

&lt;223&gt; Xaa = any amino acid except Phe

&lt;400&gt; 23

```

Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser
1          5          10          15
Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20          25          30
Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35          40          45
Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50          55          60
Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala
65          70          75          80
Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85          90          95
Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100          105          110
Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115          120          125
Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130          135          140
Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser
145          150          155          160
Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165          170          175
Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
180          185          190
Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
195          200          205
Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
210          215          220
Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr
225          230          235          240
Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
245          250          255
Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
260          265          270
Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr

```

		275					280				285				
Ile	Ser	Lys	Asn	Thr	Ser	Thr	Ser	Arg	Thr	His	Thr	Ser	Glu	Val	His
	290					295					300				
Gly	Asn	Ala	Glu	Val	His	Ala	Ser	Phe	Phe	Asp	Ile	Gly	Gly	Ser	Val
305					310					315					320
Ser	Ala	Gly	Phe	Ser	Asn	Ser	Asn	Ser	Ser	Thr	Val	Ala	Ile	Asp	His
				325					330					335	
Ser	Leu	Ser	Leu	Ala	Gly	Glu	Arg	Thr	Trp	Ala	Glu	Thr	Met	Gly	Leu
			340					345					350		
Asn	Thr	Ala	Asp	Thr	Ala	Arg	Leu	Asn	Ala	Asn	Ile	Arg	Tyr	Val	Asn
		355					360					365			
Thr	Gly	Thr	Ala	Pro	Ile	Tyr	Asn	Val	Leu	Pro	Thr	Thr	Ser	Leu	Val
	370				375						380				
Leu	Gly	Lys	Asn	Gln	Thr	Leu	Ala	Thr	Ile	Lys	Ala	Lys	Glu	Asn	Gln
385				390						395					400
Leu	Ser	Gln	Ile	Leu	Ala	Pro	Asn	Asn	Tyr	Tyr	Pro	Ser	Lys	Asn	Leu
				405					410					415	
Ala	Pro	Ile	Ala	Leu	Asn	Ala	Gln	Asp	Asp	Xaa	Ser	Ser	Thr	Pro	Ile
			420					425					430		
Thr	Met	Asn	Tyr	Asn	Gln	Phe	Leu	Glu	Leu	Glu	Lys	Thr	Lys	Gln	Leu
		435					440					445			
Arg	Leu	Asp	Thr	Asp	Gln	Val	Tyr	Gly	Asn	Ile	Ala	Thr	Tyr	Asn	Phe
	450				455						460				
Glu	Asn	Gly	Arg	Val	Arg	Val	Asp	Thr	Gly	Ser	Asn	Trp	Ser	Glu	Val
465				470						475					480
Leu	Pro	Gln	Ile	Gln	Glu	Thr	Thr	Ala	Arg	Ile	Ile	Phe	Asn	Gly	Lys
				485					490					495	
Asp	Leu	Asn	Leu	Val	Glu	Arg	Arg	Ile	Ala	Ala	Val	Asn	Pro	Ser	Asp
			500					505					510		
Pro	Leu	Glu	Thr	Thr	Lys	Pro	Asp	Met	Thr	Leu	Lys	Glu	Ala	Leu	Lys
		515					520					525			
Ile	Ala	Phe	Gly	Phe	Asn	Glu	Pro	Asn	Gly	Asn	Leu	Gln	Tyr	Gln	Gly
	530				535						540				
Lys	Asp	Ile	Thr	Glu	Phe	Asp	Phe	Asn	Phe	Asp	Gln	Gln	Thr	Ser	Gln
545				550						555					560
Asn	Ile	Lys	Asn	Gln	Leu	Ala	Glu	Leu	Asn	Ala	Thr	Asn	Ile	Tyr	Thr
			565						570					575	
Val	Leu	Asp	Lys	Ile	Lys	Leu	Asn	Ala	Lys	Met	Asn	Ile	Leu	Ile	Arg
			580					585					590		
Asp	Lys	Arg	Phe	His	Tyr	Asp	Arg	Asn	Asn	Ile	Ala	Val	Gly	Ala	Asp
		595				600						605			
Glu	Ser	Val	Val	Lys	Glu	Ala	His	Arg	Glu	Val	Ile	Asn	Ser	Ser	Thr
	610				615						620				
Glu	Gly	Leu	Leu	Leu	Asn	Ile	Asp	Lys	Asp	Ile	Arg	Lys	Ile	Leu	Ser

```
<210> 24
<211> 599
<212> PRT
<213> Bacillus anthracis
```

```

<400> 24
Thr Asp Ser Gln Asn Lys Lys Glu Val Ile Ser Ser Asp Asn Leu Gln
1      5      10      15
Leu Pro Glu Leu Lys Gln Lys Ser Ser Asn Ser Arg Lys Lys Arg Ser
20      25      30
Thr Ser Ala Gly Pro Thr Val Pro Asp Arg Asp Asn Asp Gly Ile Pro
35      40      45
Asp Ser Leu Glu Val Glu Gly Tyr Thr Val Asp Val Lys Asn Lys Arg
50      55      60
Thr Phe Leu Ser Pro Trp Ile Ser Asn Ile His Glu Lys Lys Gly Leu
65      70      75      80
Thr Lys Tyr Lys Ser Ser Pro Glu Lys Trp Ser Thr Ala Ser Asp Pro
85      90      95
Tyr Ser Asp Phe Glu Lys Val Thr Gly Arg Ile Asp Lys Asn Val Ser
100     105     110
Pro Glu Ala Arg His Pro Leu Val Ala Ala Tyr Pro Ile Val His Val
115     120     125
Asp Met Glu Asn Ile Ile Leu Ser Lys Asn Glu Asp Gln Ser Thr Gln
130     135     140
Asn Thr Asp Ser Gln Thr Arg Thr Ile Ser Lys Asn Thr Ser Thr Ser
145     150     155     160
Arg Thr His Thr Ser Glu Val His Gly Asn Ala Glu Val His Ala Ser
165     170     175
Phe Phe Asp Ile Gly Gly Ser Val Ser Ala Gly Phe Ser Asn Ser Asn
180     185     190
Ser Ser Thr Val Ala Ile Asp His Ser Leu Ser Leu Ala Gly Glu Arg
195     200     205
Thr Trp Ala Glu Thr Met Gly Leu Asn Thr Ala Asp Thr Ala Arg Leu
210     215     220
Asn Ala Asn Ile Arg Tyr Val Asn Thr Gly Thr Ala Pro Ile Tyr Asn
225     230     235     240
Val Leu Pro Thr Thr Ser Leu Val Leu Gly Lys Asn Gln Thr Leu Ala
245     250     255
Thr Ile Lys Ala Lys Glu Asn Gln Leu Ser Gln Ile Leu Ala Pro Asn
260     265     270
Asn Tyr Tyr Pro Ser Lys Asn Leu Ala Pro Ile Ala Leu Asn Ala Gln
275     280     285
Asp Asp Phe Ser Ser Thr Pro Ile Thr Met Asn Tyr Asn Gln Phe Leu
290     295     300
Glu Leu Glu Lys Thr Lys Gln Leu Arg Leu Asp Thr Asp Gln Val Tyr
305     310     315     320
Gly Asn Ile Ala Thr Tyr Asn Phe Glu Asn Gly Arg Val Arg Val Asp
325     330     335
Thr Gly Ser Asn Trp Ser Glu Val Leu Pro Gln Ile Gln Glu Thr Thr
340     345     350
Ala Arg Ile Ile Phe Asn Gly Lys Asp Leu Asn Leu Val Glu Arg Arg
355     360     365
Ile Ala Ala Val Asn Pro Ser Asp Pro Leu Glu Thr Thr Lys Pro Asp
370     375     380
Met Thr Leu Lys Glu Ala Leu Lys Ile Ala Phe Gly Phe Asn Glu Pro
385     390     395     400
Asn Gly Asn Leu Gln Tyr Gln Gly Lys Asp Ile Thr Glu Phe Asp Phe
405     410     415
Asn Phe Asp Gln Gln Thr Ser Gln Asn Ile Lys Asn Gln Leu Ala Glu
420     425     430
Leu Asn Val Thr Asn Ile Tyr Thr Val Leu Asp Lys Ile Lys Leu Asn
435     440     445
Ala Lys Met Asn Ile Leu Ile Arg Asp Lys Arg Phe His Tyr Asp Arg
450     455     460
Asn Asn Ile Ala Val Gly Ala Asp Glu Ser Val Val Lys Glu Ala His
465     470     475     480
Arg Glu Val Ile Asn Ser Ser Thr Glu Gly Leu Leu Leu Asn Ile Asp
485     490     495

```

Lys Asp Ile Arg Lys Ile Leu Ser Gly Tyr Ile Val Glu Ile Glu Asp  
 500 505 510  
 Thr Glu Gly Leu Lys Glu Val Ile Asn Asp Arg Tyr Asp Met Leu Asn  
 515 520 525  
 Ile Ser Ser Leu Arg Gln Asp Gly Lys Thr Phe Ile Asp Phe Lys Lys  
 530 535 540  
 Tyr Asn Asp Lys Leu Pro Leu Tyr Ile Ser Asn Pro Asn Tyr Lys Val  
 545 550 555 560  
 Asn Val Tyr Ala Val Thr Lys Glu Asn Thr Ile Ile Asn Pro Ser Glu  
 565 570 575  
 Asn Gly Asp Thr Ser Thr Asn Gly Ile Lys Lys Ile Leu Ile Phe Ser  
 580 585 590  
 Lys Lys Gly Tyr Glu Ile Gly  
 595

&lt;210&gt; 25

&lt;211&gt; 705

&lt;212&gt; PRT

&lt;213&gt; Clostridium difficile

&lt;400&gt; 25

Glu Leu Asp Gly Met Lys Lys Ile Ile Pro Glu Glu Asn Leu Phe Leu  
 1 5 10 15  
 Arg Asp Tyr Ser Asn Ile Glu Lys Asp Asp Pro Phe Ile Pro Asn Asn  
 20 25 30  
 Asn Phe Phe Asp Pro Lys Leu Met Ser Asp Trp Glu Asp Glu Asp Leu  
 35 40 45  
 Asp Thr Asp Asn Asp Asn Ile Pro Asp Ser Tyr Glu Arg Asn Gly Tyr  
 50 55 60  
 Thr Ile Lys Asp Leu Ile Ala Val Lys Trp Glu Asp Ser Phe Ala Glu  
 65 70 75 80  
 Gln Gly Tyr Lys Lys Tyr Val Ser Asn Tyr Leu Glu Ser Asn Thr Ala  
 85 90 95  
 Gly Asp Pro Tyr Thr Asp Tyr Glu Lys Ala Ser Gly Ser Phe Asp Lys  
 100 105 110  
 Ala Ile Lys Thr Glu Ala Arg Asp Pro Leu Val Ala Ala Tyr Pro Ile  
 115 120 125  
 Val Gly Val Gly Met Glu Lys Leu Ile Ile Ser Thr Asn Glu His Ala  
 130 135 140  
 Ser Thr Asp Gln Gly Lys Thr Val Ser Arg Ala Thr Thr Asn Ser Lys  
 145 150 155 160  
 Thr Glu Ser Asn Thr Ala Gly Val Ser Val Asn Val Gly Tyr Gln Asn  
 165 170 175  
 Gly Phe Thr Ala Asn Val Thr Thr Asn Tyr Ser His Thr Thr Asp Asn  
 180 185 190  
 Ser Thr Ala Val Gln Asp Ser Asn Gly Glu Ser Trp Asn Thr Gly Leu  
 195 200 205  
 Ser Ile Asn Lys Gly Glu Ser Ala Tyr Ile Asn Ala Asn Val Arg Tyr  
 210 215 220  
 Tyr Asn Thr Gly Thr Ala Pro Met Tyr Lys Val Thr Pro Thr Thr Asn  
 225 230 235 240  
 Leu Val Leu Asp Gly Asp Thr Leu Ser Thr Ile Lys Ala Gln Glu Asn  
 245 250 255  
 Gln Ile Gly Asn Asn Leu Ser Pro Gly Asp Thr Tyr Pro Lys Lys Gly  
 260 265 270  
 Leu Ser Pro Leu Ala Leu Asn Thr Met Asp Gln Phe Ser Ser Arg Leu  
 275 280 285  
 Ile Pro Ile Asn Tyr Asp Gln Leu Lys Lys Leu Asp Ala Gly Lys Gln  
 290 295 300  
 Ile Lys Leu Glu Thr Thr Gln Val Ser Gly Asn Phe Gly Thr Lys Asn  
 305 310 315 320  
 Ser Ser Gly Gln Ile Val Thr Glu Gly Asn Ser Trp Ser Asp Tyr Ile

```

          325          330          335
Ser Gln Ile Asp Ser Ile Ser Ala Ser Ile Ile Leu Asp Thr Glu Asn
          340          345          350
Glu Ser Tyr Glu Arg Arg Val Thr Ala Lys Asn Leu Gln Asp Pro Glu
          355          360          365
Asp Lys Thr Pro Glu Leu Thr Ile Gly Glu Ala Ile Glu Lys Ala Phe
          370          375          380
Gly Ala Thr Lys Lys Asp Gly Leu Leu Tyr Phe Asn Asp Ile Pro Ile
385          390          395          400
Asp Glu Ser Cys Val Glu Leu Ile Phe Asp Asp Asn Thr Ala Asn Lys
          405          410          415
Ile Lys Asp Ser Leu Lys Thr Leu Ser Asp Lys Lys Ile Tyr Asn Val
          420          425          430
Lys Leu Glu Arg Gly Met Asn Ile Leu Ile Lys Thr Pro Thr Tyr Phe
          435          440          445
Thr Asn Phe Asp Asp Tyr Asn Asn Tyr Pro Ser Thr Trp Ser Asn Val
          450          455          460
Asn Thr Thr Asn Gln Asp Gly Leu Gln Gly Ser Ala Asn Lys Leu Asn
465          470          475          480
Gly Glu Thr Lys Ile Lys Ile Pro Met Ser Glu Leu Lys Pro Tyr Lys
          485          490          495
Arg Tyr Val Phe Ser Gly Tyr Ser Lys Asp Pro Leu Thr Ser Asn Ser
          500          505          510
Ile Ile Val Lys Ile Lys Ala Lys Glu Glu Lys Thr Asp Tyr Leu Val
          515          520          525
Pro Glu Gln Gly Tyr Thr Lys Phe Ser Tyr Glu Phe Glu Thr Thr Glu
          530          535          540
Lys Asp Ser Ser Asn Ile Glu Ile Thr Leu Ile Gly Ser Gly Thr Thr
545          550          555          560
Tyr Leu Asp Asn Leu Ser Ile Thr Glu Leu Asn Ser Thr Pro Glu Ile
          565          570          575
Leu Asp Glu Pro Glu Val Lys Ile Pro Thr Asp Gln Glu Ile Met Asp
          580          585          590
Ala His Lys Ile Tyr Phe Ala Asp Leu Asn Phe Asn Pro Ser Thr Gly
          595          600          605
Asn Thr Tyr Ile Asn Gly Met Tyr Phe Ala Pro Thr Gln Thr Asn Lys
          610          615          620
Glu Ala Leu Asp Tyr Ile Gln Lys Tyr Arg Val Glu Ala Thr Leu Gln
625          630          635          640
Tyr Ser Gly Phe Lys Asp Ile Gly Thr Lys Asp Lys Glu Met Arg Asn
          645          650          655
Tyr Leu Gly Asp Pro Asn Gln Pro Lys Thr Asn Tyr Val Asn Leu Arg
          660          665          670
Ser Tyr Phe Thr Gly Gly Glu Asn Ile Met Thr Tyr Lys Lys Leu Arg
          675          680          685
Ile Tyr Ala Ile Thr Pro Asp Asp Arg Glu Leu Leu Val Leu Ser Val
          690          695          700
Asp
705

```

&lt;210&gt; 26

&lt;211&gt; 706

&lt;212&gt; PRT

&lt;213&gt; Clostridium perfringens

&lt;400&gt; 26

```

Glu Leu Asn Gly Asn Lys Thr Val Ile Pro Glu Glu Asn Leu Phe Phe
1          5          10          15
Arg Asp Tyr Ser Lys Ile Asp Glu Asn Asp Pro Phe Ile Pro Asn Asn
20          25          30
Asn Phe Phe Asp Val Arg Phe Phe Ser Ala Ala Trp Glu Asp Glu Asp
35          40          45

```

Leu Asp Thr Asp Asn Asp Asn Ile Pro Asp Ala Tyr Glu Lys Asn Gly  
 50 55 60  
 Tyr Thr Ile Lys Asp Ser Ile Ala Val Lys Trp Asn Asp Ser Phe Ala  
 65 70 75 80  
 Glu Gln Gly Tyr Lys Lys Tyr Val Ser Ser Tyr Leu Glu Ser Asn Thr  
 85 90 95  
 Ala Gly Asp Pro Tyr Thr Asp Tyr Gln Lys Ala Ser Gly Ser Ile Asp  
 100 105 110  
 Lys Ala Ile Lys Leu Glu Ala Arg Asp Pro Leu Val Ala Ala Tyr Pro  
 115 120 125  
 Val Val Gly Val Gly Met Glu Asn Leu Ile Ile Ser Thr Asn Glu His  
 130 135 140  
 Ala Ser Ser Asp Gln Gly Lys Thr Val Ser Arg Ala Thr Thr Asn Ser  
 145 150 155 160  
 Lys Thr Asp Ala Asn Thr Val Gly Val Ser Ile Ser Ala Gly Tyr Gln  
 165 170 175  
 Asn Gly Phe Thr Gly Asn Ile Thr Thr Ser Tyr Ser His Thr Thr Asp  
 180 185 190  
 Asn Ser Thr Ala Val Gln Asp Ser Asn Gly Glu Ser Trp Asn Thr Gly  
 195 200 205  
 Leu Ser Ile Asn Lys Gly Glu Ser Ala Tyr Ile Asn Ala Asn Val Arg  
 210 215 220  
 Tyr Tyr Asn Thr Gly Thr Ala Pro Met Tyr Lys Val Thr Pro Thr Thr  
 225 230 235 240  
 Asn Leu Val Leu Asp Gly Glu Thr Leu Ala Thr Ile Lys Ala Gln Asp  
 245 250 255  
 Asn Gln Ile Gly Asn Asn Leu Ser Pro Asn Glu Thr Tyr Pro Lys Lys  
 260 265 270  
 Gly Leu Ser Pro Leu Ala Leu Asn Thr Met Asp Gln Phe Asn Ala Arg  
 275 280 285  
 Leu Ile Pro Ile Asn Tyr Asp Gln Leu Lys Lys Leu Asp Ser Gly Lys  
 290 295 300  
 Gln Ile Lys Leu Glu Thr Thr Gln Val Ser Gly Asn Tyr Gly Thr Lys  
 305 310 315 320  
 Asn Ser Gln Gly Gln Ile Ile Thr Glu Gly Asn Ser Trp Ser Asn Tyr  
 325 330 335  
 Ile Ser Gln Ile Asp Ser Val Ser Ala Ser Ile Ile Leu Asp Thr Gly  
 340 345 350  
 Ser Gln Thr Phe Glu Arg Arg Val Ala Ala Lys Glu Gln Gly Asn Pro  
 355 360 365  
 Glu Asp Lys Thr Pro Glu Ile Thr Ile Gly Glu Ala Ile Lys Lys Ala  
 370 375 380  
 Phe Ser Ala Thr Lys Asn Gly Glu Leu Leu Tyr Phe Asn Gly Ile Pro  
 385 390 395 400  
 Ile Asp Glu Ser Cys Val Glu Leu Ile Phe Asp Asp Asn Thr Ser Glu  
 405 410 415  
 Ile Ile Lys Glu Gln Leu Lys Tyr Leu Asp Asp Lys Lys Ile Tyr Asn  
 420 425 430  
 Val Lys Leu Glu Arg Gly Met Asn Ile Leu Ile Lys Val Pro Ser Tyr  
 435 440 445  
 Phe Thr Asn Phe Asp Glu Tyr Asn Asn Phe Pro Ala Ser Trp Ser Asn  
 450 455 460  
 Ile Asp Thr Lys Asn Gln Asp Gly Leu Gln Ser Val Ala Asn Lys Leu  
 465 470 475 480  
 Ser Gly Glu Thr Lys Ile Ile Ile Pro Met Ser Lys Leu Lys Pro Tyr  
 485 490 495  
 Lys Arg Tyr Val Phe Ser Gly Tyr Ser Lys Asp Pro Ser Thr Ser Asn  
 500 505 510  
 Ser Ile Thr Val Asn Ile Lys Ser Lys Glu Gln Lys Thr Asp Tyr Leu  
 515 520 525  
 Val Pro Glu Lys Asp Tyr Thr Lys Phe Ser Tyr Glu Phe Glu Thr Thr  
 530 535 540  
 Gly Lys Asp Ser Ser Asp Ile Glu Ile Thr Leu Thr Ser Ser Gly Val

```

545      550      555      560
Ile Phe Leu Asp Asn Leu Ser Ile Thr Glu Leu Asn Ser Thr Pro Glu
      565      570      575
Ile Leu Lys Glu Pro Glu Ile Lys Val Pro Ser Asp Gln Glu Ile Leu
      580      585      590
Asp Ala His Asn Lys Tyr Tyr Ala Asp Ile Lys Leu Asp Thr Asn Thr
      595      600      605
Gly Asn Thr Tyr Ile Asp Gly Ile Tyr Phe Glu Pro Thr Gln Thr Asn
      610      615      620
Lys Glu Ala Leu Asp Tyr Ile Gln Lys Tyr Arg Val Glu Ala Thr Leu
625      630      635      640
Gln Tyr Ser Gly Phe Lys Asp Ile Gly Thr Lys Asp Lys Glu Ile Arg
      645      650      655
Asn Tyr Leu Gly Asp Gln Asn Gln Pro Lys Thr Asn Tyr Ile Asn Phe
      660      665      670
Arg Ser Tyr Phe Thr Ser Gly Glu Asn Val Met Thr Tyr Lys Lys Leu
      675      680      685
Arg Ile Tyr Ala Val Thr Pro Asp Asn Arg Glu Leu Leu Val Leu Ser
      690      695      700
Val Asn
705

```

&lt;210&gt; 27

&lt;211&gt; 712

&lt;212&gt; PRT

&lt;213&gt; Clostridium spiroforme

&lt;400&gt; 27

```

Glu Leu Asn Gly Asp Lys Thr Leu Ile Pro Glu Lys Asn Leu Phe Leu
1      5      10      15
Arg Asp Tyr Ser Lys Ile Asp Glu Asn Asp Pro Phe Ile Pro Lys Asp
20      25      30
Asn Phe Phe Asp Leu Lys Leu Lys Ser Arg Ser Ala Arg Leu Ala Ser
35      40      45
Gly Trp Gly Asp Glu Asp Leu Asp Thr Asp Asn Asp Asn Ile Pro Asp
50      55      60
Ala Tyr Glu Lys Asn Gly Tyr Thr Ile Lys Asp Ser Ile Ala Val Lys
65      70      75      80
Trp Glu Asp Ser Phe Ala Gln Gln Gly Tyr Lys Lys Tyr Leu Ser Ser
85      90      95
Tyr Leu Glu Ser Asn Thr Ala Gly Asp Pro Tyr Thr Asp Tyr Gln Lys
100      105      110
Ala Ser Gly Ser Phe Asp Lys Ala Ile Lys Ala Glu Ala Arg Asp Pro
115      120      125
Leu Val Ala Ala Tyr Pro Val Val Gly Val Gly Met Glu Lys Leu Ile
130      135      140
Ile Ser Thr Asn Glu His Ala Ser Thr Asp Gln Gly Lys Thr Val Ser
145      150      155      160
Arg Asn Thr Thr Asn Ser Lys Thr Asp Ala Asn Thr Ala Gly Val Ala
165      170      175
Ile Asn Ile Ala Tyr Gln Asn Gly Phe Thr Gly Ser Ile Thr Thr Asn
180      185      190
Tyr Ser His Thr Thr Glu Asn Ser Thr Ala Val Gln Asn Ser Asn Gly
195      200      205
Glu Ser Trp Asn Thr Ser Leu Ser Ile Asn Lys Gly Glu Ser Ala Tyr
210      215      220
Ile Asn Ala Asn Val Arg Tyr Tyr Asn Thr Gly Thr Ala Pro Met Tyr
225      230      235      240
Lys Val Thr Pro Thr Thr Asn Leu Val Leu Asp Gly Asp Thr Leu Thr
245      250      255
Thr Ile Lys Ala Gln Asp Asn Gln Ile Gly Asn Asn Leu Ser Pro Asn
260      265      270

```



Glu Thr Tyr Pro Lys Lys Gly Leu Ser Pro Leu Ala Leu Asn Thr Met  
 275 280 285  
 Asp Gln Phe Ser Ser Arg Leu Ile Pro Ile Asn Tyr Asp Gln Leu Lys  
 290 295 300  
 Lys Leu Asp Ala Gly Lys Gln Ile Lys Leu Glu Thr Thr Gln Val Ser  
 305 310 315 320  
 Gly Asn Tyr Gly Ile Lys Asn Ser Gln Gly Gln Ile Ile Thr Glu Gly  
 325 330 335  
 Asn Ser Trp Ser Asp Tyr Ile Ser Gln Ile Asp Ser Leu Ser Ala Ser  
 340 345 350  
 Ile Ile Leu Asp Thr Gly Ser Asp Val Phe Glu Arg Arg Val Thr Ala  
 355 360 365  
 Lys Asp Ser Ser Asn Pro Glu Asp Lys Thr Pro Val Leu Thr Ile Gly  
 370 375 380  
 Glu Ala Ile Glu Lys Ala Phe Gly Ala Thr Lys Asn Gly Glu Ile Leu  
 385 390 395 400  
 Tyr Phe Asn Gly Met Pro Ile Asp Glu Ser Cys Val Glu Leu Ile Phe  
 405 410 415  
 Asp Gly Asn Thr Ala Asn Leu Ile Lys Glu Arg Leu Asn Ala Leu Asn  
 420 425 430  
 Asp Lys Lys Ile Tyr Asn Val Gln Leu Glu Arg Gly Met Lys Ile Leu  
 435 440 445  
 Ile Lys Thr Ser Thr Tyr Phe Asn Asn Phe Asp Gly Tyr Asn Asn Phe  
 450 455 460  
 Pro Ser Ser Trp Ser Asn Val Asp Ser Asn Asn Gln Asp Gly Leu Gln  
 465 470 475 480  
 Asn Ala Ala Asn Lys Leu Ser Gly Glu Thr Lys Ile Val Ile Pro Met  
 485 490 495  
 Ser Lys Leu Asn Pro Tyr Lys Arg Tyr Val Phe Ser Gly Tyr Leu Lys  
 500 505 510  
 Asn Ser Ser Thr Ser Asn Pro Ile Thr Val Asn Ile Lys Ala Lys Glu  
 515 520 525  
 Gln Lys Thr Tyr Asn Leu Val Ser Glu Asn Asp Tyr Lys Lys Phe Ser  
 530 535 540  
 Tyr Glu Phe Glu Thr Ile Gly Arg Asp Ala Ser Asn Ile Glu Ile Thr  
 545 550 555 560  
 Leu Thr Ser Ser Gly Thr Ile Phe Leu Asp Asn Leu Ser Ile Thr Glu  
 565 570 575  
 Leu Asn Ser Thr Pro Glu Ile Leu Lys Glu Pro Asp Ile Lys Val Pro  
 580 585 590  
 Ser Asp Gln Glu Ile Ile Asp Ala His Lys Lys Tyr Tyr Ala Asp Leu  
 595 600 605  
 Ser Phe Asn Gln Ser Thr Ala Asn Tyr Tyr Leu Asp Gly Leu Tyr Phe  
 610 615 620  
 Glu Pro Thr Gln Thr Asn Lys Glu Val Leu Asp Tyr Ile Gln Lys Tyr  
 625 630 635 640  
 Lys Val Glu Ala Thr Leu Glu Tyr Ser Gly Phe Lys Asp Ile Gly Thr  
 645 650 655  
 Lys Asp Lys Glu Leu Arg Asn Tyr Thr Gly Asp Ser Asn Gln Pro Lys  
 660 665 670  
 Thr Asn Tyr Val Asn Phe Arg Ser Tyr Phe Thr Ser Gly Glu Asn Val  
 675 680 685  
 Met Pro Tyr Lys Lys Leu Arg Ile Tyr Ala Ile Thr Pro Glu Asn Lys  
 690 695 700  
 Glu Leu Leu Val Leu Ser Ile Asn  
 705 710

&lt;210&gt; 28

&lt;211&gt; 582

&lt;212&gt; PRT

&lt;213&gt; Clostridium botulinum

&lt;400&gt; 28

Glu Thr Ser Asp Ile Ile Lys Glu Ile Ile Pro Ser Glu Val Leu Leu  
 1 5 10 15  
 Lys Pro Asn Tyr Ser Asn Thr Asn Glu Lys Ser Lys Phe Ile Pro Asn  
 20 25 30  
 Asn Thr Leu Phe Ser Asn Ala Lys Leu Lys Ala Asn Ala Asn Arg Asp  
 35 40 45  
 Thr Asp Arg Asp Gly Ile Pro Asp Glu Trp Glu Ile Asn Gly Tyr Thr  
 50 55 60  
 Val Met Asn Gln Lys Ala Val Ala Trp Asp Asp Lys Phe Ala Ala Asn  
 65 70 75 80  
 Gly Tyr Lys Lys Tyr Val Ser Asn Pro Phe Lys Pro Cys Thr Ala Asn  
 85 90 95  
 Asp Pro Tyr Thr Asp Phe Glu Lys Val Ser Gly Gln Ile Asp Pro Ser  
 100 105 110  
 Val Ser Met Val Ala Arg Asp Pro Met Ile Ser Ala Tyr Pro Ile Val  
 115 120 125  
 Gly Val Gln Met Glu Arg Leu Val Val Ser Lys Ser Glu Thr Ile Thr  
 130 135 140  
 Gly Asp Ser Thr Lys Ser Met Ser Lys Ser Thr Ser His Ser Ser Thr  
 145 150 155 160  
 Asn Ile Asn Thr Val Gly Ala Glu Val Ser Gly Ser Leu Gln Leu Ala  
 165 170 175  
 Gly Gly Ile Phe Pro Val Phe Ser Met Ser Ala Ser Ala Asn Tyr Ser  
 180 185 190  
 His Thr Trp Gln Asn Thr Ser Thr Val Asp Asp Thr Thr Gly Glu Ser  
 195 200 205  
 Phe Ser Gln Gly Leu Ser Ile Asn Thr Gly Glu Ser Ala Tyr Ile Asn  
 210 215 220  
 Pro Asn Ile Arg Tyr Tyr Asn Thr Gly Thr Ala Pro Val Tyr Asn Val  
 225 230 235 240  
 Thr Pro Thr Thr Thr Ile Val Ile Asp Lys Gln Ser Val Ala Thr Ile  
 245 250 255  
 Lys Gly Gln Glu Ser Leu Ile Gly Asp Tyr Leu Asn Pro Gly Gly Thr  
 260 265 270  
 Tyr Pro Ile Ile Gly Glu Pro Pro Met Ala Leu Asn Thr Met Asp Gln  
 275 280 285  
 Phe Ser Ser Arg Leu Ile Pro Ile Asn Tyr Asn Gln Leu Lys Ser Ile  
 290 295 300  
 Asp Asn Gly Gly Thr Val Met Leu Ser Thr Ser Gln Phe Thr Gly Asn  
 305 310 315 320  
 Phe Ala Lys Tyr Asn Ser Asn Gly Asn Leu Val Thr Asp Gly Asn Asn  
 325 330 335  
 Trp Gly Pro Tyr Leu Gly Thr Ile Lys Ser Thr Thr Ala Ser Leu Thr  
 340 345 350  
 Leu Ser Phe Ser Gly Gln Thr Thr Gln Val Ala Val Val Ala Pro Asn  
 355 360 365  
 Phe Ser Asp Pro Glu Asp Lys Thr Pro Lys Leu Thr Leu Glu Gln Ala  
 370 375 380  
 Leu Val Lys Ala Phe Ala Leu Glu Lys Lys Asn Gly Lys Phe Tyr Phe  
 385 390 395 400  
 His Gly Leu Glu Ile Ser Lys Asn Glu Lys Ile Gln Val Phe Leu Asp  
 405 410 415  
 Ser Asn Thr Asn Asn Asp Phe Glu Asn Gln Leu Lys Asn Thr Ala Asp  
 420 425 430  
 Lys Asp Ile Met His Cys Ile Ile Lys Arg Asn Met Asn Ile Leu Val  
 435 440 445  
 Lys Val Ile Thr Phe Lys Glu Asn Ile Ser Ser Ile Asn Ile Ile Asn  
 450 455 460  
 Asp Thr Asn Phe Gly Val Gln Ser Met Thr Gly Leu Ser Asn Arg Ser  
 465 470 475 480  
 Lys Gly Gln Asp Gly Ile Tyr Arg Ala Ala Thr Thr Ala Phe Ser Phe  
 485 490 495

Lys Ser Lys Glu Leu Lys Tyr Pro Glu Gly Arg Tyr Arg Met Arg Phe  
                   500                                  505                                  510  
 Val Ile Gln Ser Tyr Glu Pro Phe Thr Cys Asn Phe Lys Leu Phe Asn  
                   515                                  520                                  525  
 Asn Leu Ile Tyr Ser Ser Ser Phe Asp Lys Gly Tyr Tyr Asp Glu Phe  
                   530                                  535                                  540  
 Phe Tyr Phe Tyr Tyr Asn Gly Ser Lys Ser Phe Phe Asn Ile Ser Cys  
                   545                                  550                                  555                                  560  
 Asp Ile Ile Asn Ser Ile Asn Arg Leu Ser Gly Val Phe Leu Ile Glu  
                                   565                                  570                                  575  
 Leu Asp Lys Leu Ile Ile  
                                   580

<210> 29  
 <211> 708  
 <212> PRT  
 <213> Bacillus cereus

<400> 29  
 Ile Asp Ser Gln Asn Gln Pro Gln Gln Val Gln Gln Asp Glu Leu Arg  
   1                  5                                  10                                  15  
 Asn Pro Glu Phe Asn Lys Lys Glu Ser Gln Glu Phe Leu Ala Lys Pro  
                   20                                  25                                  30  
 Ser Lys Ile Asn Leu Phe Thr Gln Gln Met Lys Arg Glu Ile Asp Glu  
                   35                                  40                                  45  
 Asp Thr Asp Thr Asp Gly Asp Ser Ile Pro Asp Leu Trp Glu Glu Asn  
                   50                                  55                                  60  
 Gly Tyr Thr Ile Gln Asn Arg Ile Ala Val Lys Trp Asp Asp Ser Leu  
                   65                                  70                                  75                                  80  
 Ala Ser Lys Gly Tyr Thr Lys Phe Val Ser Asn Pro Leu Glu Ser His  
                                   85                                  90                                  95  
 Thr Val Gly Asp Pro Tyr Thr Asp Tyr Glu Lys Ala Ala Arg Asp Leu  
                   100                                  105                                  110  
 Asp Leu Ser Asn Ala Lys Glu Thr Phe Asn Pro Leu Val Ala Ala Phe  
                   115                                  120                                  125  
 Pro Ser Val Asn Val Ser Met Glu Lys Val Ile Leu Ser Pro Asn Glu  
                   130                                  135                                  140  
 Asn Leu Ser Asn Ser Val Glu Ser His Ser Ser Thr Asn Trp Ser Tyr  
                   145                                  150                                  155                                  160  
 Thr Asn Thr Glu Gly Ala Ser Val Glu Ala Gly Ile Gly Pro Lys Gly  
                                   165                                  170                                  175  
 Ile Ser Phe Gly Val Ser Val Asn Tyr Gln His Ser Glu Thr Val Ala  
                   180                                  185                                  190  
 Gln Glu Trp Gly Thr Ser Thr Gly Asn Thr Ser Gln Phe Asn Thr Ala  
                   195                                  200                                  205  
 Ser Ala Gly Tyr Leu Asn Ala Asn Val Arg Tyr Asn Asn Val Gly Thr  
                   210                                  215                                  220  
 Gly Ala Ile Tyr Asp Val Lys Pro Thr Thr Ser Phe Val Leu Asn Asn  
                   225                                  230                                  235                                  240  
 Asp Thr Ile Ala Thr Ile Thr Ala Lys Ser Asn Ser Thr Ala Leu Asn  
                                   245                                  250                                  255  
 Ile Ser Pro Gly Glu Ser Tyr Pro Lys Lys Gly Gln Asn Gly Ile Ala  
                                   260                                  265                                  270  
 Ile Thr Ser Met Asp Asp Phe Asn Ser His Pro Ile Thr Leu Asn Lys  
                   275                                  280                                  285  
 Lys Gln Val Asp Asn Leu Leu Asn Asn Lys Pro Met Met Leu Glu Thr  
                   290                                  295                                  300  
 Asn Gln Thr Asp Gly Val Tyr Lys Ile Lys Asp Thr His Gly Asn Ile  
                   305                                  310                                  315                                  320  
 Val Thr Gly Gly Glu Trp Asn Gly Val Ile Gln Gln Ile Lys Ala Lys  
                                   325                                  330                                  335  
 Thr Ala Ser Ile Ile Val Asp Asp Gly Glu Arg Val Ala Glu Lys Arg

			340					345					350				
Val	Ala	Ala	Lys	Asp	Tyr	Glu	Asn	Pro	Glu	Asp	Lys	Thr	Pro	Ser	Leu		
		355					360					365					
Thr	Leu	Lys	Asp	Ala	Leu	Lys	Leu	Ser	Tyr	Pro	Asp	Glu	Ile	Lys	Glu		
	370					375					380						
Ile	Glu	Gly	Leu	Leu	Tyr	Tyr	Lys	Asn	Lys	Pro	Ile	Tyr	Glu	Ser	Ser		
385					390					395					400		
Val	Met	Thr	Tyr	Leu	Asp	Glu	Asn	Thr	Ala	Lys	Glu	Val	Thr	Lys	Gln		
			405						410					415			
Leu	Asn	Asp	Thr	Thr	Gly	Lys	Phe	Lys	Asp	Val	Ser	His	Leu	Tyr	Asp		
			420					425					430				
Val	Lys	Leu	Thr	Pro	Lys	Met	Asn	Val	Thr	Ile	Lys	Leu	Ser	Ile	Leu		
		435					440					445					
Tyr	Asp	Asn	Ala	Glu	Ser	Asn	Asp	Asn	Ser	Ile	Gly	Lys	Trp	Thr	Asn		
	450					455					460						
Thr	Asn	Ile	Val	Ser	Gly	Gly	Asn	Asn	Gly	Lys	Lys	Gln	Tyr	Ser	Ser		
465					470					475					480		
Asn	Asn	Pro	Asp	Ala	Asn	Leu	Thr	Leu	Asn	Thr	Asp	Ala	Gln	Glu	Lys		
			485					490					495				
Leu	Asn	Lys	Asn	Arg	Asp	Tyr	Tyr	Ile	Ser	Leu	Tyr	Met	Lys	Ser	Glu		
			500					505					510				
Lys	Asn	Thr	Gln	Cys	Glu	Ile	Thr	Ile	Asp	Gly	Glu	Ile	Tyr	Pro	Ile		
		515					520					525					
Thr	Thr	Lys	Thr	Val	Asn	Val	Asn	Lys	Asp	Asn	Tyr	Lys	Arg	Leu	Asp		
	530					535					540						
Ile	Ile	Ala	His	Asn	Ile	Lys	Ser	Asn	Pro	Ile	Ser	Ser	Leu	His	Ile		
545					550					555					560		
Lys	Thr	Asn	Asp	Glu	Ile	Thr	Leu	Phe	Trp	Asp	Asp	Ile	Ser	Ile	Thr		
			565					570					575				
Asp	Val	Ala	Ser	Ile	Lys	Pro	Glu	Asn	Leu	Thr	Asp	Ser	Glu	Ile	Lys		
		580						585					590				
Gln	Ile	Tyr	Ser	Arg	Tyr	Gly	Ile	Lys	Leu	Glu	Asp	Gly	Ile	Leu	Ile		
		595				600						605					
Asp	Lys	Lys	Gly	Gly	Ile	His	Tyr	Gly	Glu	Phe	Ile	Asn	Glu	Ala	Ser		
	610					615					620						
Phe	Asn	Ile	Glu	Pro	Leu	Gln	Asn	Tyr	Val	Thr	Lys	Tyr	Glu	Val	Thr		
625					630					635					640		
Tyr	Ser	Ser	Glu	Leu	Gly	Pro	Asn	Val	Ser	Asp	Thr	Leu	Glu	Ser	Asp		
			645					650					655				
Lys	Ile	Tyr	Lys	Asp	Gly	Thr	Ile	Lys	Phe	Asp	Phe	Thr	Lys	Tyr	Ser		
			660					665					670				
Lys	Asn	Glu	Gln	Gly	Leu	Phe	Tyr	Asp	Ser	Gly	Leu	Asn	Trp	Asp	Phe		
		675					680					685					
Lys	Ile	Asn	Ala	Ile	Thr	Tyr	Asp	Gly	Lys	Glu	Met	Asn	Val	Phe	His		
	690					695					700						
Arg	Tyr	Asn	Lys														
705																	

&lt;210&gt; 30

&lt;211&gt; 735

&lt;212&gt; PRT

&lt;213&gt; Bacillus anthracis

&lt;400&gt; 30

Glu	Val	Lys	Gln	Glu	Asn	Arg	Leu	Leu	Asn	Glu	Ser	Glu	Ser	Ser	Ser		
1			5					10					15				
Gln	Gly	Leu	Leu	Gly	Tyr	Tyr	Phe	Ser	Asp	Leu	Asn	Phe	Gln	Ala	Pro		
			20					25					30				
Met	Val	Val	Thr	Ser	Ser	Thr	Thr	Gly	Asp	Leu	Ser	Ile	Pro	Ser	Ser		
		35				40						45					
Glu	Leu	Glu	Asn	Ile	Pro	Ser	Glu	Asn	Gln	Tyr	Phe	Gln	Ser	Ala	Ile		
	50					55					60						

Trp	Ser	Gly	Phe	Ile	Lys	Val	Lys	Lys	Ser	Asp	Glu	Tyr	Thr	Phe	Ala
65					70					75					80
Thr	Ser	Ala	Asp	Asn	His	Val	Thr	Met	Trp	Val	Asp	Asp	Gln	Glu	Val
				85					90					95	
Ile	Asn	Lys	Ala	Ser	Asn	Ser	Asn	Lys	Ile	Arg	Leu	Glu	Lys	Gly	Arg
			100					105					110		
Leu	Tyr	Gln	Ile	Lys	Ile	Gln	Tyr	Gln	Arg	Glu	Asn	Pro	Thr	Glu	Lys
		115					120					125			
Gly	Leu	Asp	Phe	Lys	Leu	Tyr	Trp	Thr	Asp	Ser	Gln	Asn	Lys	Lys	Glu
	130					135					140				
Val	Ile	Ser	Ser	Asp	Asn	Leu	Gln	Leu	Pro	Glu	Leu	Lys	Gln	Lys	Ser
145					150					155					160
Ser	Asn	Ser	Arg	Lys	Lys	Arg	Ser	Thr	Ser	Ala	Gly	Pro	Thr	Val	Pro
				165					170					175	
Asp	Arg	Asp	Asn	Asp	Gly	Ile	Pro	Asp	Ser	Leu	Glu	Val	Glu	Gly	Tyr
			180					185					190		
Thr	Val	Asp	Val	Lys	Asn	Lys	Arg	Thr	Phe	Leu	Ser	Pro	Trp	Ile	Ser
		195					200					205			
Asn	Ile	His	Glu	Lys	Lys	Gly	Leu	Thr	Lys	Tyr	Lys	Ser	Ser	Pro	Glu
	210					215					220				
Lys	Trp	Ser	Thr	Ala	Ser	Asp	Pro	Tyr	Ser	Asp	Phe	Glu	Lys	Val	Thr
225					230					235					240
Gly	Arg	Ile	Asp	Lys	Asn	Val	Ser	Pro	Glu	Ala	Arg	His	Pro	Leu	Val
				245					250					255	
Ala	Ala	Tyr	Pro	Ile	Val	His	Val	Asp	Met	Glu	Asn	Ile	Ile	Leu	Ser
			260					265					270		
Lys	Asn	Glu	Asp	Gln	Ser	Thr	Gln	Asn	Thr	Asp	Ser	Gln	Thr	Arg	Thr
		275					280					285			
Ile	Ser	Lys	Asn	Thr	Ser	Thr	Ser	Arg	Thr	His	Thr	Ser	Glu	Val	His
	290					295					300				
Gly	Asn	Ala	Glu	Val	His	Ala	Ser	Phe	Phe	Asp	Ile	Gly	Gly	Ser	Val
305					310					315					320
Ser	Ala	Gly	Phe	Ser	Asn	Ser	Asn	Ser	Ser	Thr	Val	Ala	Ile	Asp	His
				325					330					335	
Ser	Leu	Ser	Leu	Ala	Gly	Glu	Arg	Thr	Trp	Ala	Glu	Thr	Met	Gly	Leu
			340					345					350		
Asn	Thr	Ala	Asp	Thr	Ala	Arg	Leu	Asn	Ala	Asn	Ile	Arg	Tyr	Val	Asn
		355					360					365			
Thr	Gly	Thr	Ala	Pro	Ile	Tyr	Asn	Val	Leu	Pro	Thr	Thr	Ser	Leu	Val
	370					375					380				
Leu	Gly	Lys	Asn	Gln	Thr	Leu	Ala	Thr	Ile	Lys	Ala	Lys	Glu	Asn	Gln
385					390					395					400
Leu	Ser	Gln	Ile	Leu	Ala	Pro	Asn	Asn	Tyr	Tyr	Pro	Ser	Lys	Asn	Leu
				405					410					415	
Ala	Pro	Ile	Ala	Leu	Asn	Ala	Gln	Asp	Asp	Phe	Ser	Ser	Thr	Pro	Ile
			420					425					430		
Thr	Met	Asn	Tyr	Asn	Gln	Phe	Leu	Glu	Leu	Glu	Lys	Thr	Lys	Gln	Leu
		435					440					445			
Arg	Leu	Asp	Thr	Asp	Gln	Val	Tyr	Gly	Asn	Ile	Ala	Thr	Tyr	Asn	Phe
	450					455					460				
Glu	Asn	Gly	Arg	Val	Arg	Val	Asp	Thr	Gly	Ser	Asn	Trp	Ser	Glu	Val
465					470					475					480
Leu	Pro	Gln	Ile	Gln	Glu	Thr	Thr	Ala	Arg	Ile	Ile	Phe	Asn	Gly	Lys
				485					490					495	
Asp	Leu	Asn	Leu	Val	Glu	Arg	Arg	Ile	Ala	Ala	Val	Asn	Pro	Ser	Asp
			500					505					510		
Pro	Leu	Glu	Thr	Thr	Lys	Pro	Asp	Met	Thr	Leu	Lys	Glu	Ala	Leu	Lys
		515					520					525			
Ile	Ala	Phe	Gly	Phe	Asn	Glu	Pro	Asn	Gly	Asn	Leu	Gln	Tyr	Gln	Gly
	530					535					540				
Lys	Asp	Ile	Thr	Glu	Phe	Asp	Phe	Asn	Phe	Asp	Gln	Gln	Thr	Ser	Gln
545					550					555					560
Asn	Ile	Lys	Asn	Gln	Leu	Ala	Glu	Leu	Asn	Val	Thr	Asn	Ile	Tyr	Thr

```
<210> 31
<211> 876
<212> PRT
<213> Clostridium difficile
```

Met Lys Ile Gln Met Arg Asn Lys Lys Val Leu Ser Phe Leu Thr Leu															
1				5					10					15	
Thr	Ala	Ile	Val	Ser	Gln	Ala	Leu	Val	Tyr	Pro	Val	Tyr	Ala	Gln	Thr
			20					25					30		
Ser	Thr	Ser	Asn	His	Ser	Asn	Lys	Lys	Lys	Glu	Ile	Val	Asn	Glu	Asp
		35					40					45			
Ile	Leu	Pro	Asn	Asn	Gly	Leu	Met	Gly	Tyr	Tyr	Phe	Ser	Asp	Glu	His
	50				55						60				
Phe	Lys	Asp	Leu	Lys	Leu	Met	Ala	Pro	Ile	Lys	Asp	Gly	Asn	Leu	Lys
65				70						75					80
Phe	Glu	Glu	Lys	Lys	Val	Asp	Lys	Leu	Leu	Asp	Lys	Asp	Lys	Ser	Asp
				85					90					95	
Val	Lys	Ser	Ile	Arg	Trp	Thr	Gly	Arg	Ile	Ile	Pro	Ser	Lys	Asp	Gly
			100					105					110		
Glu	Tyr	Thr	Leu	Ser	Thr	Asp	Arg	Asp	Asp	Val	Leu	Met	Gln	Val	Asn
		115					120					125			
Thr	Glu	Ser	Thr	Ile	Ser	Asn	Thr	Leu	Lys	Val	Asn	Met	Lys	Lys	Gly
	130					135					140				
Lys	Glu	Tyr	Lys	Val	Arg	Ile	Glu	Leu	Gln	Asp	Lys	Asn	Leu	Gly	Ser
145				150						155				160	
Ile	Asp	Asn	Leu	Ser	Ser	Pro	Asn	Leu	Tyr	Trp	Glu	Leu	Asp	Gly	Met
			165						170				175		
Lys	Lys	Ile	Ile	Pro	Glu	Glu	Asn	Leu	Phe	Leu	Arg	Asp	Tyr	Ser	Asn
			180					185					190		
Ile	Glu	Lys	Asp	Asp	Pro	Phe	Ile	Pro	Asn	Asn	Asn	Phe	Phe	Asp	Pro
		195					200					205			
Lys	Leu	Met	Ser	Asp	Trp	Glu	Asp	Glu	Asp	Leu	Asp	Thr	Asp	Asn	Asp
	210					215					220				
Asn	Ile	Pro	Asp	Ser	Tyr	Glu	Arg	Asn	Gly	Tyr	Thr	Ile	Lys	Asp	Leu
225				230						235					240
Ile	Ala	Val	Lys	Trp	Glu	Asp	Ser	Phe	Ala	Glu	Gln	Gly	Tyr	Lys	Lys
			245						250				255		
Tyr	Val	Ser	Asn	Tyr	Leu	Glu	Ser	Asn	Thr	Ala	Gly	Asp	Pro	Tyr	Thr
			260					265					270		

Asp	Tyr	Glu	Lys	Ala	Ser	Gly	Ser	Phe	Asp	Lys	Ala	Ile	Lys	Thr	Glu
		275					280					285			
Ala	Arg	Asp	Pro	Leu	Val	Ala	Ala	Tyr	Pro	Ile	Val	Gly	Val	Gly	Met
	290					295					300				
Glu	Lys	Leu	Ile	Ile	Ser	Thr	Asn	Glu	His	Ala	Ser	Thr	Asp	Gln	Gly
305					310					315					320
Lys	Thr	Val	Ser	Arg	Ala	Thr	Thr	Asn	Ser	Lys	Thr	Glu	Ser	Asn	Thr
				325					330					335	
Ala	Gly	Val	Ser	Val	Asn	Val	Gly	Tyr	Gln	Asn	Gly	Phe	Thr	Ala	Asn
			340					345					350		
Val	Thr	Thr	Asn	Tyr	Ser	His	Thr	Thr	Asp	Asn	Ser	Thr	Ala	Val	Gln
			355				360					365			
Asp	Ser	Asn	Gly	Glu	Ser	Trp	Asn	Thr	Gly	Leu	Ser	Ile	Asn	Lys	Gly
	370					375					380				
Glu	Ser	Ala	Tyr	Ile	Asn	Ala	Asn	Val	Arg	Tyr	Tyr	Asn	Thr	Gly	Thr
385					390					395					400
Ala	Pro	Met	Tyr	Lys	Val	Thr	Pro	Thr	Thr	Asn	Leu	Val	Leu	Asp	Gly
				405					410					415	
Asp	Thr	Leu	Ser	Thr	Ile	Lys	Ala	Gln	Glu	Asn	Gln	Ile	Gly	Asn	Asn
			420					425					430		
Leu	Ser	Pro	Gly	Asp	Thr	Tyr	Pro	Lys	Lys	Gly	Leu	Ser	Pro	Leu	Ala
		435					440					445			
Leu	Asn	Thr	Met	Asp	Gln	Phe	Ser	Ser	Arg	Leu	Ile	Pro	Ile	Asn	Tyr
	450					455					460				
Asp	Gln	Leu	Lys	Lys	Leu	Asp	Ala	Gly	Lys	Gln	Ile	Lys	Leu	Glu	Thr
465					470					475					480
Thr	Gln	Val	Ser	Gly	Asn	Phe	Gly	Thr	Lys	Asn	Ser	Ser	Gly	Gln	Ile
				485					490					495	
Val	Thr	Glu	Gly	Asn	Ser	Trp	Ser	Asp	Tyr	Ile	Ser	Gln	Ile	Asp	Ser
			500					505					510		
Ile	Ser	Ala	Ser	Ile	Ile	Leu	Asp	Thr	Glu	Asn	Glu	Ser	Tyr	Glu	Arg
		515					520					525			
Arg	Val	Thr	Ala	Lys	Asn	Leu	Gln	Asp	Pro	Glu	Asp	Lys	Thr	Pro	Glu
	530					535					540				
Leu	Thr	Ile	Gly	Glu	Ala	Ile	Glu	Lys	Ala	Phe	Gly	Ala	Thr	Lys	Lys
545					550					555					560
Asp	Gly	Leu	Leu	Tyr	Phe	Asn	Asp	Ile	Pro	Ile	Asp	Glu	Ser	Cys	Val
				565					570					575	
Glu	Leu	Ile	Phe	Asp	Asp	Asn	Thr	Ala	Asn	Lys	Ile	Lys	Asp	Ser	Leu
			580					585					590		
Lys	Thr	Leu	Ser	Asp	Lys	Lys	Ile	Tyr	Asn	Val	Lys	Leu	Glu	Arg	Gly
		595					600					605			
Met	Asn	Ile	Leu	Ile	Lys	Thr	Pro	Thr	Tyr	Phe	Thr	Asn	Phe	Asp	Asp
	610					615					620				
Tyr	Asn	Asn	Tyr	Pro	Ser	Thr	Trp	Ser	Asn	Val	Asn	Thr	Thr	Asn	Gln
625					630					635					640
Asp	Gly	Leu	Gln	Gly	Ser	Ala	Asn	Lys	Leu	Asn	Gly	Glu	Thr	Lys	Ile
				645					650					655	
Lys	Ile	Pro	Met	Ser	Glu	Leu	Lys	Pro	Tyr	Lys	Arg	Tyr	Val	Phe	Ser
			660					665					670		
Gly	Tyr	Ser	Lys	Asp	Pro	Leu	Thr	Ser	Asn	Ser	Ile	Ile	Val	Lys	Ile
		675					680					685			
Lys	Ala	Lys	Glu	Glu	Lys	Thr	Asp	Tyr	Leu	Val	Pro	Glu	Gln	Gly	Tyr
	690					695					700				
Thr	Lys	Phe	Ser	Tyr	Glu	Phe	Glu	Thr	Thr	Glu	Lys	Asp	Ser	Ser	Asn
705					710					715					720
Ile	Glu	Ile	Thr	Leu	Ile	Gly	Ser	Gly	Thr	Thr	Tyr	Leu	Asp	Asn	Leu
				725					730					735	
Ser	Ile	Thr	Glu	Leu	Asn	Ser	Thr	Pro	Glu	Ile	Leu	Asp	Glu	Pro	Glu
			740					745					750		
Val	Lys	Ile	Pro	Thr	Asp	Gln	Glu	Ile	Met	Asp	Ala	His	Lys	Ile	Tyr
	755						760					765			
Phe	Ala	Asp	Leu	Asn	Phe	Asn	Pro	Ser	Thr	Gly	Asn	Thr	Tyr	Ile	Asn

770		775		780
Gly Met Tyr Phe Ala Pro Thr Gln Thr Asn Lys Glu Ala Leu Asp Tyr				
785		790		795
Ile Gln Lys Tyr Arg Val Glu Ala Thr Leu Gln Tyr Ser Gly Phe Lys				
	805		810	
Asp Ile Gly Thr Lys Asp Lys Glu Met Arg Asn Tyr Leu Gly Asp Pro				
	820		825	
Asn Gln Pro Lys Thr Asn Tyr Val Asn Leu Arg Ser Tyr Phe Thr Gly				
	835		840	
Gly Glu Asn Ile Met Thr Tyr Lys Lys Leu Arg Ile Tyr Ala Ile Thr				
	850		855	
Pro Asp Asp Arg Glu Leu Leu Val Leu Ser Val Asp				
865		870		875

&lt;210&gt; 32

&lt;211&gt; 875

&lt;212&gt; PRT

&lt;213&gt; Clostridium perfringens

&lt;400&gt; 32

Met Asn Ile Gln Ile Lys Asn Val Phe Ser Phe Leu Thr Leu Thr Ala				
1	5	10	15	
Met Ile Ser Gln Thr Leu Ser Tyr Asn Val Tyr Ala Gln Thr Thr				
	20	25	30	
Gln Asn Asp Thr Asn Gln Lys Glu Glu Ile Thr Asn Glu Asn Thr Leu				
	35	40	45	
Ser Ser Asn Gly Leu Met Gly Tyr Tyr Phe Ala Asp Glu His Phe Lys				
	50	55	60	
Asp Leu Glu Leu Met Ala Pro Ile Lys Asn Gly Asp Leu Lys Phe Glu				
65	70	75	80	
Glu Lys Lys Val Asp Lys Leu Leu Thr Glu Asp Asn Ser Ser Ile Lys				
	85	90	95	
Ser Ile Arg Trp Thr Gly Arg Ile Ile Pro Ser Glu Asp Gly Glu Tyr				
	100	105	110	
Ile Leu Ser Thr Asp Arg Asn Asp Val Leu Met Gln Ile Asn Ala Lys				
	115	120	125	
Gly Asp Ile Ala Lys Thr Leu Lys Val Asn Met Lys Lys Gly Gln Ala				
	130	135	140	
Tyr Asn Ile Arg Ile Glu Ile Gln Asp Lys Asn Leu Gly Ser Ile Asp				
145	150	155	160	
Asn Leu Ser Val Pro Lys Leu Tyr Trp Glu Leu Asn Gly Asn Lys Thr				
	165	170	175	
Val Ile Pro Glu Glu Asn Leu Phe Phe Arg Asp Tyr Ser Lys Ile Asp				
	180	185	190	
Glu Asn Asp Pro Phe Ile Pro Asn Asn Phe Phe Asp Val Arg Phe				
	195	200	205	
Phe Ser Ala Ala Trp Glu Asp Glu Asp Leu Asp Thr Asp Asn Asp Asn				
	210	215	220	
Ile Pro Asp Ala Tyr Glu Lys Asn Gly Tyr Thr Ile Lys Asp Ser Ile				
225	230	235	240	
Ala Val Lys Trp Asn Asp Ser Phe Ala Glu Gln Gly Tyr Lys Lys Tyr				
	245	250	255	
Val Ser Ser Tyr Leu Glu Ser Asn Thr Ala Gly Asp Pro Tyr Thr Asp				
	260	265	270	
Tyr Gln Lys Ala Ser Gly Ser Ile Asp Lys Ala Ile Lys Leu Glu Ala				
	275	280	285	
Arg Asp Pro Leu Val Ala Ala Tyr Pro Val Val Gly Val Gly Met Glu				
	290	295	300	
Asn Leu Ile Ile Ser Thr Asn Glu His Ala Ser Ser Asp Gln Gly Lys				
305	310	315	320	
Thr Val Ser Arg Ala Thr Thr Asn Ser Lys Thr Asp Ala Asn Thr Val				
	325	330	335	



Gly	Val	Ser	Ile	Ser	Ala	Gly	Tyr	Gln	Asn	Gly	Phe	Thr	Gly	Asn	Ile
			340					345					350		
Thr	Thr	Ser	Tyr	Ser	His	Thr	Thr	Asp	Asn	Ser	Thr	Ala	Val	Gln	Asp
		355					360					365			
Ser	Asn	Gly	Glu	Ser	Trp	Asn	Thr	Gly	Leu	Ser	Ile	Asn	Lys	Gly	Glu
	370					375					380				
Ser	Ala	Tyr	Ile	Asn	Ala	Asn	Val	Arg	Tyr	Tyr	Asn	Thr	Gly	Thr	Ala
385					390					395					400
Pro	Met	Tyr	Lys	Val	Thr	Pro	Thr	Thr	Asn	Leu	Val	Leu	Asp	Gly	Glu
				405					410					415	
Thr	Leu	Ala	Thr	Ile	Lys	Ala	Gln	Asp	Asn	Gln	Ile	Gly	Asn	Asn	Leu
			420					425					430		
Ser	Pro	Asn	Glu	Thr	Tyr	Pro	Lys	Lys	Gly	Leu	Ser	Pro	Leu	Ala	Leu
		435				440						445			
Asn	Thr	Met	Asp	Gln	Phe	Asn	Ala	Arg	Leu	Ile	Pro	Ile	Asn	Tyr	Asp
	450					455					460				
Gln	Leu	Lys	Lys	Leu	Asp	Ser	Gly	Lys	Gln	Ile	Lys	Leu	Glu	Thr	Thr
465					470					475					480
Gln	Val	Ser	Gly	Asn	Tyr	Gly	Thr	Lys	Asn	Ser	Gln	Gly	Gln	Ile	Ile
				485					490					495	
Thr	Glu	Gly	Asn	Ser	Trp	Ser	Asn	Tyr	Ile	Ser	Gln	Ile	Asp	Ser	Val
			500					505					510		
Ser	Ala	Ser	Ile	Ile	Leu	Asp	Thr	Gly	Ser	Gln	Thr	Phe	Glu	Arg	Arg
		515					520					525			
Val	Ala	Ala	Lys	Glu	Gln	Gly	Asn	Pro	Glu	Asp	Lys	Thr	Pro	Glu	Ile
	530					535					540				
Thr	Ile	Gly	Glu	Ala	Ile	Lys	Lys	Ala	Phe	Ser	Ala	Thr	Lys	Asn	Gly
545					550					555					560
Glu	Leu	Leu	Tyr	Phe	Asn	Gly	Ile	Pro	Ile	Asp	Glu	Ser	Cys	Val	Glu
				565					570					575	
Leu	Ile	Phe	Asp	Asp	Asn	Thr	Ser	Glu	Ile	Ile	Lys	Glu	Gln	Leu	Lys
			580					585					590		
Tyr	Leu	Asp	Asp	Lys	Lys	Ile	Tyr	Asn	Val	Lys	Leu	Glu	Arg	Gly	Met
		595					600					605			
Asn	Ile	Leu	Ile	Lys	Val	Pro	Ser	Tyr	Phe	Thr	Asn	Phe	Asp	Glu	Tyr
	610					615					620				
Asn	Asn	Phe	Pro	Ala	Ser	Trp	Ser	Asn	Ile	Asp	Thr	Lys	Asn	Gln	Asp
625					630					635					640
Gly	Leu	Gln	Ser	Val	Ala	Asn	Lys	Leu	Ser	Gly	Glu	Thr	Lys	Ile	Ile
				645					650					655	
Ile	Pro	Met	Ser	Lys	Leu	Lys	Pro	Tyr	Lys	Arg	Tyr	Val	Phe	Ser	Gly
			660					665					670		
Tyr	Ser	Lys	Asp	Pro	Ser	Thr	Ser	Asn	Ser	Ile	Thr	Val	Asn	Ile	Lys
		675					680					685			
Ser	Lys	Glu	Gln	Lys	Thr	Asp	Tyr	Leu	Val	Pro	Glu	Lys	Asp	Tyr	Thr
	690					695					700				
Lys	Phe	Ser	Tyr	Glu	Phe	Glu	Thr	Thr	Gly	Lys	Asp	Ser	Ser	Asp	Ile
705					710					715					720
Glu	Ile	Thr	Leu	Thr	Ser	Ser	Gly	Val	Ile	Phe	Leu	Asp	Asn	Leu	Ser
				725					730					735	
Ile	Thr	Glu	Leu	Asn	Ser	Thr	Pro	Glu	Ile	Leu	Lys	Glu	Pro	Glu	Ile
			740					745					750		
Lys	Val	Pro	Ser	Asp	Gln	Glu	Ile	Leu	Asp	Ala	His	Asn	Lys	Tyr	Tyr
		755					760					765			
Ala	Asp	Ile	Lys	Leu	Asp	Thr	Asn	Thr	Gly	Asn	Thr	Tyr	Ile	Asp	Gly
	770					775					780				
Ile	Tyr	Phe	Glu	Pro	Thr	Gln	Thr	Asn	Lys	Glu	Ala	Leu	Asp	Tyr	Ile
785					790					795					800
Gln	Lys	Tyr	Arg	Val	Glu	Ala	Thr	Leu	Gln	Tyr	Ser	Gly	Phe	Lys	Asp
				805					810					815	
Ile	Gly	Thr	Lys	Asp	Lys	Glu	Ile	Arg	Asn	Tyr	Leu	Gly	Asp	Gln	Asn
			820					825					830		
Gln	Pro	Lys	Thr	Asn	Tyr	Ile	Asn	Phe	Arg	Ser	Tyr	Phe	Thr	Ser	Gly

		835					840				845					
Glu	Asn	Val	Met	Thr	Tyr	Lys	Lys	Leu	Arg	Ile	Tyr	Ala	Val	Thr	Pro	
	850					855					860					
Asp	Asn	Arg	Glu	Leu	Leu	Val	Leu	Ser	Val	Asn						
865					870					875						

```
<210> 33
<211> 879
<212> PRT
<213> Clostridium spiroforme
```

<div>400</div>	33														
Met 1	Lys	Asn	Lys	Lys 5	Ile	Leu	Gly	Leu	Leu 10	Thr	Cys	Thr	Val	Leu 15	Val
Gly	Gln	Met	Met	Thr 20	Tyr	Pro	Val	Tyr 25	Ala	Lys	Thr	Ile	Thr 30	Gln	Asn
Tyr	Asp	Asn 35	Gln	Glu	Val	Glu	Thr 40	Thr	Asn	Glu	Lys	Thr 45	Val	Ser	Ser
Asn	Gly 50	Leu	Met	Gly	Tyr	Tyr 55	Phe	Ala	Asp	Glu	His 60	Phe	Lys	Asp	Leu
Glu 65	Leu	Met	Ala	Pro	Val 70	Lys	Asn	Gly	Glu	Leu 75	Lys	Phe	Glu	Lys	Asn 80
Lys	Val	Glu	Lys	Leu 85	Leu	Thr	Glu	Glu	Lys 90	Thr	Asn	Ile	Lys	Ser 95	Ile
Arg	Trp	Thr	Gly 100	Arg	Ile	Ile	Pro	Ser 105	Lys	Asp	Gly	Glu	Tyr 110	Thr	Leu
Ser	Thr	Asp 115	Lys	Asp	Asn	Val	Leu 120	Met	Gln	Ile	Asn	Ala 125	Glu	Gly	Glu
Ile	Ala	Asn 130	Thr	Leu	Lys	Val	Asn 135	Met	Ile	Lys	Gly 140	Gln	Glu	Tyr	Ser
Ile 145	Arg	Ile	Glu	Ile	Gln 150	Asp	Lys	Asp	Ile	Gly 155	Tyr	Val	Asp	Asp	Leu 160
Ser	Ser	Pro	Lys	Leu 165	Tyr	Trp	Glu	Leu	Asn 170	Gly	Asp	Lys	Thr	Leu 175	Ile
Pro	Glu	Lys	Asn 180	Leu	Phe	Leu	Arg	Asp 185	Tyr	Ser	Lys	Ile	Asp 190	Glu	Asn
Asp	Pro	Phe 195	Ile	Pro	Lys	Asp	Asn 200	Phe	Phe	Asp	Leu	Lys 205	Leu	Lys	Ser
Arg	Ser 210	Ala	Arg	Leu	Ala	Ser 215	Gly	Trp	Gly	Asp	Glu 220	Asp	Leu	Asp	Thr
Asp 225	Asn	Asp	Asn	Ile	Pro 230	Asp	Ala	Tyr	Glu	Lys 235	Asn	Gly	Tyr	Thr	Ile 240
Lys	Asp	Ser	Ile	Ala 245	Val	Lys	Trp	Glu	Asp 250	Ser	Phe	Ala	Gln	Gln 255	Gly
Tyr	Lys	Lys	Tyr 260	Leu	Ser	Ser	Tyr	Leu 265	Glu	Ser	Asn	Thr	Ala 270	Gly	Asp
Pro	Tyr 275	Thr	Asp	Tyr	Gln	Lys	Ala 280	Ser	Gly	Ser	Phe	Asp 285	Lys	Ala	Ile
Lys	Ala 290	Glu	Ala	Arg	Asp	Pro 295	Leu	Val	Ala	Ala	Tyr 300	Pro	Val	Val	Gly
Val 305	Gly	Met	Glu	Lys	Leu 310	Ile	Ile	Ser	Thr	Asn	Glu 315	His	Ala	Ser	Thr 320
Asp	Gln	Gly	Lys	Thr 325	Val	Ser	Arg	Asn	Thr 330	Thr	Asn	Ser	Lys	Thr 335	Asp
Ala	Asn	Thr	Ala 340	Gly	Val	Ala	Ile	Asn 345	Ile	Ala	Tyr	Gln	Asn 350	Gly	Phe
Thr	Gly	Ser	Ile	Thr	Thr	Asn	Tyr 360	Ser	His	Thr	Thr	Glu 365	Asn	Ser	Thr
Ala	Val 370	Gln	Asn	Ser	Asn	Gly 375	Glu	Ser	Trp	Asn	Thr 380	Ser	Leu	Ser	Ile
Asn 385	Lys	Gly	Glu	Ser	Ala 390	Tyr	Ile	Asn	Ala	Asn 395	Val	Arg	Tyr	Tyr	Asn 400

Thr Gly Thr Ala Pro Met Tyr Lys Val Thr Pro Thr Thr Asn Leu Val  
 405 410 415  
 Leu Asp Gly Asp Thr Leu Thr Thr Ile Lys Ala Gln Asp Asn Gln Ile  
 420 425 430  
 Gly Asn Asn Leu Ser Pro Asn Glu Thr Tyr Pro Lys Lys Gly Leu Ser  
 435 440 445  
 Pro Leu Ala Leu Asn Thr Met Asp Gln Phe Ser Ser Arg Leu Ile Pro  
 450 455 460  
 Ile Asn Tyr Asp Gln Leu Lys Lys Leu Asp Ala Gly Lys Gln Ile Lys  
 465 470 475 480  
 Leu Glu Thr Thr Gln Val Ser Gly Asn Tyr Gly Ile Lys Asn Ser Gln  
 485 490 495  
 Gly Gln Ile Ile Thr Glu Gly Asn Ser Trp Ser Asp Tyr Ile Ser Gln  
 500 505 510  
 Ile Asp Ser Leu Ser Ala Ser Ile Ile Leu Asp Thr Gly Ser Asp Val  
 515 520 525  
 Phe Glu Arg Arg Val Thr Ala Lys Asp Ser Ser Asn Pro Glu Asp Lys  
 530 535 540  
 Thr Pro Val Leu Thr Ile Gly Glu Ala Ile Glu Lys Ala Phe Gly Ala  
 545 550 555 560  
 Thr Lys Asn Gly Glu Ile Leu Tyr Phe Asn Gly Met Pro Ile Asp Glu  
 565 570 575  
 Ser Cys Val Glu Leu Ile Phe Asp Gly Asn Thr Ala Asn Leu Ile Lys  
 580 585 590  
 Glu Arg Leu Asn Ala Leu Asn Asp Lys Lys Ile Tyr Asn Val Gln Leu  
 595 600 605  
 Glu Arg Gly Met Lys Ile Leu Ile Lys Thr Ser Thr Tyr Phe Asn Asn  
 610 615 620  
 Phe Asp Gly Tyr Asn Asn Phe Pro Ser Ser Trp Ser Asn Val Asp Ser  
 625 630 635 640  
 Asn Asn Gln Asp Gly Leu Gln Asn Ala Ala Asn Lys Leu Ser Gly Glu  
 645 650 655  
 Thr Lys Ile Val Ile Pro Met Ser Lys Leu Asn Pro Tyr Lys Arg Tyr  
 660 665 670  
 Val Phe Ser Gly Tyr Leu Lys Asn Ser Ser Thr Ser Asn Pro Ile Thr  
 675 680 685  
 Val Asn Ile Lys Ala Lys Glu Gln Lys Thr Tyr Asn Leu Val Ser Glu  
 690 695 700  
 Asn Asp Tyr Lys Lys Phe Ser Tyr Glu Phe Glu Thr Ile Gly Arg Asp  
 705 710 715 720  
 Ala Ser Asn Ile Glu Ile Thr Leu Thr Ser Ser Gly Thr Ile Phe Leu  
 725 730 735  
 Asp Asn Leu Ser Ile Thr Glu Leu Asn Ser Thr Pro Glu Ile Leu Lys  
 740 745 750  
 Glu Pro Asp Ile Lys Val Pro Ser Asp Gln Glu Ile Ile Asp Ala His  
 755 760 765  
 Lys Lys Tyr Tyr Ala Asp Leu Ser Phe Asn Gln Ser Thr Ala Asn Tyr  
 770 775 780  
 Tyr Leu Asp Gly Leu Tyr Phe Glu Pro Thr Gln Thr Asn Lys Glu Val  
 785 790 795 800  
 Leu Asp Tyr Ile Gln Lys Tyr Lys Val Glu Ala Thr Leu Glu Tyr Ser  
 805 810 815  
 Gly Phe Lys Asp Ile Gly Thr Lys Asp Lys Glu Leu Arg Asn Tyr Thr  
 820 825 830  
 Gly Asp Ser Asn Gln Pro Lys Thr Asn Tyr Val Asn Phe Arg Ser Tyr  
 835 840 845  
 Phe Thr Ser Gly Glu Asn Val Met Pro Tyr Lys Lys Leu Arg Ile Tyr  
 850 855 860  
 Ala Ile Thr Pro Glu Asn Lys Glu Leu Leu Val Leu Ser Ile Asn  
 865 870 875

&lt;210&gt; 34

&lt;211&gt; 721

&lt;212&gt; PRT

&lt;213&gt; Clostridium botulinum

&lt;400&gt; 34

```

Met Leu Val Ser Lys Phe Glu Asn Ser Val Lys Asn Ser Asn Lys Asn
 1      5      10      15
Tyr Phe Thr Ile Asn Gly Leu Met Gly Tyr Tyr Phe Glu Asn Asp Phe
      20      25      30
Phe Asn Leu Asn Ile Ile Ser Pro Thr Leu Asp Gly Asn Leu Thr Phe
      35      40      45
Ser Lys Glu Asp Ile Asn Ser Ile Leu Gly Asn Lys Ile Ile Lys Ser
      50      55      60
Ala Arg Trp Ile Gly Leu Ile Lys Pro Ser Ile Thr Gly Glu Tyr Ile
      65      70      75      80
Leu Ser Thr Asn Ser Pro Asn Cys Arg Val Glu Leu Asn Gly Glu Ile
      85      90      95
Phe Asn Leu Ser Leu Asn Thr Ser Asn Thr Val Asn Leu Ile Gln Gly
      100      105      110
Asn Val Tyr Asp Ile Arg Ile Glu Gln Leu Met Ser Glu Asn Gln Leu
      115      120      125
Leu Lys Asn Tyr Glu Gly Ile Lys Leu Tyr Trp Glu Thr Ser Asp Ile
      130      135      140
Ile Lys Glu Ile Ile Pro Ser Glu Val Leu Leu Lys Pro Asn Tyr Ser
      145      150      155      160
Asn Thr Asn Glu Lys Ser Lys Phe Ile Pro Asn Asn Thr Leu Phe Ser
      165      170      175
Asn Ala Lys Leu Lys Ala Asn Ala Asn Arg Asp Thr Asp Arg Asp Gly
      180      185      190
Ile Pro Asp Glu Trp Glu Ile Asn Gly Tyr Thr Val Met Asn Gln Lys
      195      200      205
Ala Val Ala Trp Asp Asp Lys Phe Ala Ala Asn Gly Tyr Lys Lys Tyr
      210      215      220
Val Ser Asn Pro Phe Lys Pro Cys Thr Ala Asn Asp Pro Tyr Thr Asp
      225      230      235      240
Phe Glu Lys Val Ser Gly Gln Ile Asp Pro Ser Val Ser Met Val Ala
      245      250      255
Arg Asp Pro Met Ile Ser Ala Tyr Pro Ile Val Gly Val Gln Met Glu
      260      265      270
Arg Leu Val Val Ser Lys Ser Glu Thr Ile Thr Gly Asp Ser Thr Lys
      275      280      285
Ser Met Ser Lys Ser Thr Ser His Ser Ser Thr Asn Ile Asn Thr Val
      290      295      300
Gly Ala Glu Val Ser Gly Ser Leu Gln Leu Ala Gly Gly Ile Phe Pro
      305      310      315      320
Val Phe Ser Met Ser Ala Ser Ala Asn Tyr Ser His Thr Trp Gln Asn
      325      330      335
Thr Ser Thr Val Asp Asp Thr Thr Gly Glu Ser Phe Ser Gln Gly Leu
      340      345      350
Ser Ile Asn Thr Gly Glu Ser Ala Tyr Ile Asn Pro Asn Ile Arg Tyr
      355      360      365
Tyr Asn Thr Gly Thr Ala Pro Val Tyr Asn Val Thr Pro Thr Thr Thr
      370      375      380
Ile Val Ile Asp Lys Gln Ser Val Ala Thr Ile Lys Gly Gln Glu Ser
      385      390      395      400
Leu Ile Gly Asp Tyr Leu Asn Pro Gly Gly Thr Tyr Pro Ile Ile Gly
      405      410      415
Glu Pro Pro Met Ala Leu Asn Thr Met Asp Gln Phe Ser Ser Arg Leu
      420      425      430
Ile Pro Ile Asn Tyr Asn Gln Leu Lys Ser Ile Asp Asn Gly Gly Thr
      435      440      445
Val Met Leu Ser Thr Ser Gln Phe Thr Gly Asn Phe Ala Lys Tyr Asn
      450      455      460

```

Ser Asn Gly Asn Leu Val Thr Asp Gly Asn Asn Trp Gly Pro Tyr Leu  
 465 470 475 480  
 Gly Thr Ile Lys Ser Thr Thr Ala Ser Leu Thr Leu Ser Phe Ser Gly  
 485 490 495  
 Gln Thr Thr Gln Val Ala Val Val Ala Pro Asn Phe Ser Asp Pro Glu  
 500 505 510  
 Asp Lys Thr Pro Lys Leu Thr Leu Glu Gln Ala Leu Val Lys Ala Phe  
 515 520 525  
 Ala Leu Glu Lys Lys Asn Gly Lys Phe Tyr Phe His Gly Leu Glu Ile  
 530 535 540  
 Ser Lys Asn Glu Lys Ile Gln Val Phe Leu Asp Ser Asn Thr Asn Asn  
 545 550 555 560  
 Asp Phe Glu Asn Gln Leu Lys Asn Thr Ala Asp Lys Asp Ile Met His  
 565 570 575  
 Cys Ile Ile Lys Arg Asn Met Asn Ile Leu Val Lys Val Ile Thr Phe  
 580 585 590  
 Lys Glu Asn Ile Ser Ser Ile Asn Ile Ile Asn Asp Thr Asn Phe Gly  
 595 600 605  
 Val Gln Ser Met Thr Gly Leu Ser Asn Arg Ser Lys Gly Gln Asp Gly  
 610 615 620  
 Ile Tyr Arg Ala Ala Thr Thr Ala Phe Ser Phe Lys Ser Lys Glu Leu  
 625 630 635 640  
 Lys Tyr Pro Glu Gly Arg Tyr Arg Met Arg Phe Val Ile Gln Ser Tyr  
 645 650 655  
 Glu Pro Phe Thr Cys Asn Phe Lys Leu Phe Asn Asn Leu Ile Tyr Ser  
 660 665 670  
 Ser Ser Phe Asp Lys Gly Tyr Tyr Asp Glu Phe Phe Tyr Phe Tyr Tyr  
 675 680 685  
 Asn Gly Ser Lys Ser Phe Phe Asn Ile Ser Cys Asp Ile Ile Asn Ser  
 690 695 700  
 Ile Asn Arg Leu Ser Gly Val Phe Leu Ile Glu Leu Asp Lys Leu Ile  
 705 710 715 720  
 Ile

<210> 35  
 <211> 1338  
 <212> PRT  
 <213> *Bacillus cereus*

<400> 35  
 Met Lys Arg Met Glu Gly Lys Leu Phe Met Val Ser Lys Lys Leu Gln  
 1 5 10 15  
 Val Val Thr Lys Thr Val Leu Leu Ser Thr Val Phe Ser Ile Ser Leu  
 20 25 30  
 Leu Asn Asn Glu Val Ile Lys Ala Glu Gln Leu Asn Ile Asn Ser Gln  
 35 40 45  
 Ser Lys Tyr Thr Asn Leu Gln Asn Leu Lys Ile Thr Asp Lys Val Glu  
 50 55 60  
 Asp Phe Lys Glu Asp Lys Glu Lys Ala Lys Glu Trp Gly Lys Glu Lys  
 65 70 75 80  
 Glu Lys Glu Trp Lys Leu Thr Ala Thr Glu Lys Gly Lys Met Asn Asn  
 85 90 95  
 Phe Leu Asp Asn Lys Asn Asp Ile Lys Thr Asn Tyr Lys Glu Ile Thr  
 100 105 110  
 Phe Ser Ile Ala Gly Ser Phe Glu Asp Glu Ile Lys Asp Leu Lys Glu  
 115 120 125  
 Ile Asp Lys Met Phe Asp Lys Thr Asn Leu Ser Asn Ser Ile Ile Thr  
 130 135 140  
 Tyr Lys Asn Val Glu Pro Thr Thr Ile Gly Phe Asn Lys Ser Leu Thr  
 145 150 155 160  
 Glu Gly Asn Thr Ile Asn Ser Asp Ala Met Ala Gln Phe Lys Glu Gln

-55-

Lys Arg Glu Ile Asp Glu Asp Thr Asp Thr Asp Gly Asp Ser Ile Pro  
 675 680 685  
 Asp Leu Trp Glu Glu Asn Gly Tyr Thr Ile Gln Asn Arg Ile Ala Val  
 690 695 700  
 Lys Trp Asp Asp Ser Leu Ala Ser Lys Gly Tyr Thr Lys Phe Val Ser  
 705 710 715 720  
 Asn Pro Leu Glu Ser His Thr Val Gly Asp Pro Tyr Thr Asp Tyr Glu  
 725 730 735  
 Lys Ala Ala Arg Asp Leu Asp Leu Ser Asn Ala Lys Glu Thr Phe Asn  
 740 745 750  
 Pro Leu Val Ala Ala Phe Pro Ser Val Asn Val Ser Met Glu Lys Val  
 755 760 765  
 Ile Leu Ser Pro Asn Glu Asn Leu Ser Asn Ser Val Glu Ser His Ser  
 770 775 780  
 Ser Thr Asn Trp Ser Tyr Thr Asn Thr Glu Gly Ala Ser Val Glu Ala  
 785 790 795 800  
 Gly Ile Gly Pro Lys Gly Ile Ser Phe Gly Val Ser Val Asn Tyr Gln  
 805 810 815  
 His Ser Glu Thr Val Ala Gln Glu Trp Gly Thr Ser Thr Gly Asn Thr  
 820 825 830  
 Ser Gln Phe Asn Thr Ala Ser Ala Gly Tyr Leu Asn Ala Asn Val Arg  
 835 840 845  
 Tyr Asn Asn Val Gly Thr Gly Ala Ile Tyr Asp Val Lys Pro Thr Thr  
 850 855 860  
 Ser Phe Val Leu Asn Asn Asp Thr Ile Ala Thr Ile Thr Ala Lys Ser  
 865 870 875 880  
 Asn Ser Thr Ala Leu Asn Ile Ser Pro Gly Glu Ser Tyr Pro Lys Lys  
 885 890 895  
 Gly Gln Asn Gly Ile Ala Ile Thr Ser Met Asp Asp Phe Asn Ser His  
 900 905 910  
 Pro Ile Thr Leu Asn Lys Lys Gln Val Asp Asn Leu Leu Asn Asn Lys  
 915 920 925  
 Pro Met Met Leu Glu Thr Asn Gln Thr Asp Gly Val Tyr Lys Ile Lys  
 930 935 940  
 Asp Thr His Gly Asn Ile Val Thr Gly Gly Glu Trp Asn Gly Val Ile  
 945 950 955 960  
 Gln Gln Ile Lys Ala Lys Thr Ala Ser Ile Ile Val Asp Asp Gly Glu  
 965 970 975  
 Arg Val Ala Glu Lys Arg Val Ala Ala Lys Asp Tyr Glu Asn Pro Glu  
 980 985 990  
 Asp Lys Thr Pro Ser Leu Thr Leu Lys Asp Ala Leu Lys Leu Ser Tyr  
 995 1000 1005  
 Pro Asp Glu Ile Lys Glu Ile Glu Gly Leu Leu Tyr Tyr Lys Asn Lys  
 1010 1015 1020  
 Pro Ile Tyr Glu Ser Ser Val Met Thr Tyr Leu Asp Glu Asn Thr Ala  
 1025 1030 1035 1040  
 Lys Glu Val Thr Lys Gln Leu Asn Asp Thr Thr Gly Lys Phe Lys Asp  
 1045 1050 1055  
 Val Ser His Leu Tyr Asp Val Lys Leu Thr Pro Lys Met Asn Val Thr  
 1060 1065 1070  
 Ile Lys Leu Ser Ile Leu Tyr Asp Asn Ala Glu Ser Asn Asp Asn Ser  
 1075 1080 1085  
 Ile Gly Lys Trp Thr Asn Thr Asn Ile Val Ser Gly Gly Asn Asn Gly  
 1090 1095 1100  
 Lys Lys Gln Tyr Ser Ser Asn Asn Pro Asp Ala Asn Leu Thr Leu Asn  
 1105 1110 1115 1120  
 Thr Asp Ala Gln Glu Lys Leu Asn Lys Asn Arg Asp Tyr Tyr Ile Ser  
 1125 1130 1135  
 Leu Tyr Met Lys Ser Glu Lys Asn Thr Gln Cys Glu Ile Thr Ile Asp  
 1140 1145 1150  
 Gly Glu Ile Tyr Pro Ile Thr Thr Lys Thr Val Asn Val Asn Lys Asp  
 1155 1160 1165  
 Asn Tyr Lys Arg Leu Asp Ile Ile Ala His Asn Ile Lys Ser Asn Pro

```

      1170      1175      1180
Ile Ser Ser Leu His Ile Lys Thr Asn Asp Glu Ile Thr Leu Phe Trp
1185      1190      1195      1200
Asp Asp Ile Ser Ile Thr Asp Val Ala Ser Ile Lys Pro Glu Asn Leu
      1205      1210      1215
Thr Asp Ser Glu Ile Lys Gln Ile Tyr Ser Arg Tyr Gly Ile Lys Leu
      1220      1225      1230
Glu Asp Gly Ile Leu Ile Asp Lys Lys Gly Gly Ile His Tyr Gly Glu
      1235      1240      1245
Phe Ile Asn Glu Ala Ser Phe Asn Ile Glu Pro Leu Gln Asn Tyr Val
      1250      1255      1260
Thr Lys Tyr Glu Val Thr Tyr Ser Ser Glu Leu Gly Pro Asn Val Ser
1265      1270      1275      1280
Asp Thr Leu Glu Ser Asp Lys Ile Tyr Lys Asp Gly Thr Ile Lys Phe
      1285      1290      1295
Asp Phe Thr Lys Tyr Ser Lys Asn Glu Gln Gly Leu Phe Tyr Asp Ser
      1300      1305      1310
Gly Leu Asn Trp Asp Phe Lys Ile Asn Ala Ile Thr Tyr Asp Gly Lys
      1315      1320      1325
Glu Met Asn Val Phe His Arg Tyr Asn Lys
1330      1335

```

<210> 36  
 <211> 735  
 <212> PRT  
 <213> Bacillus anthracis

```

<400> 36
Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser
 1      5      10      15
Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
      20      25      30
Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
      35      40      45
Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
      50      55      60
Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala
      65      70      75      80
Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
      85      90      95
Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
      100      105      110
Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
      115      120      125
Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
      130      135      140
Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser
      145      150      155      160
Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
      165      170      175
Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr
      180      185      190
Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser
      195      200      205
Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu
      210      215      220
Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr
      225      230      235      240
Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val
      245      250      255
Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser
      260      265      270

```



```

Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr
      275      280      285
Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His
      290      295      300
Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val
305      310      315
Ser Ala Gly Phe Ser Asn Ser Asn Ser Thr Val Ala Ile Asp His
      325      330      335
Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu
      340      345      350
Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn
      355      360      365
Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Cys Leu Val
      370      375      380
Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln
385      390      395
Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu
      405      410      415
Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile
      420      425      430
Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu
      435      440      445
Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe
      450      455      460
Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val
465      470      475
Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys
      485      490      495
Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Val Asn Pro Ser Asp
      500      505      510
Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys
      515      520      525
Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly
      530      535      540
Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln
545      550      555
Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr
      565      570      575
Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg
      580      585      590
Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp
      595      600      605
Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr
      610      615      620
Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser
625      630      635
Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile
      645      650      655
Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly
      660      665      670
Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr
      675      680      685
Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu
      690      695      700
Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly
705      710      715
Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly
      725      730      735

```

<210> 37  
 <211> 735  
 <212> PRT

&lt;213&gt; Bacillus anthracis

&lt;400&gt; 37

Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser  
 1 5 10 15  
 Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro  
 20 25 30  
 Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser  
 35 40 45  
 Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile  
 50 55 60  
 Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala  
 65 70 75 80  
 Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val  
 85 90 95  
 Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg  
 100 105 110  
 Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys  
 115 120 125  
 Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu  
 130 135 140  
 Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser  
 145 150 155 160  
 Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro  
 165 170 175  
 Asp Arg Asp Asn Asp Gly Ile Pro Asp Ser Leu Glu Val Glu Gly Tyr  
 180 185 190  
 Thr Val Asp Val Lys Asn Lys Arg Thr Phe Leu Ser Pro Trp Ile Ser  
 195 200 205  
 Asn Ile His Glu Lys Lys Gly Leu Thr Lys Tyr Lys Ser Ser Pro Glu  
 210 215 220  
 Lys Trp Ser Thr Ala Ser Asp Pro Tyr Ser Asp Phe Glu Lys Val Thr  
 225 230 235 240  
 Gly Arg Ile Asp Lys Asn Val Ser Pro Glu Ala Arg His Pro Leu Val  
 245 250 255  
 Ala Ala Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser  
 260 265 270  
 Lys Asn Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Glu Thr Arg Thr  
 275 280 285  
 Ile Ser Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His  
 290 295 300  
 Gly Asn Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val  
 305 310 315 320  
 Ser Ala Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His  
 325 330 335  
 Ser Leu Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu  
 340 345 350  
 Asn Thr Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn  
 355 360 365  
 Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val  
 370 375 380  
 Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Cys Gln  
 385 390 395 400  
 Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu  
 405 410 415  
 Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile  
 420 425 430  
 Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu  
 435 440 445  
 Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe  
 450 455 460  
 Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val  
 465 470 475 480

```
<210> 38
<211> 735
<212> PRT
<213> Bacillus anthracis
```

<400>	38														
Glu	Val	Lys	Gln	Glu	Asn	Arg	Leu	Leu	Asn	Glu	Ser	Glu	Ser	Ser	Ser
1				5					10					15	
Gln	Gly	Leu	Leu	Gly	Tyr	Tyr	Phe	Ser	Asp	Leu	Asn	Phe	Gln	Ala	Pro
			20					25					30		
Met	Val	Val	Thr	Ser	Ser	Thr	Thr	Gly	Asp	Leu	Ser	Ile	Pro	Ser	Ser
		35					40					45			
Glu	Leu	Glu	Asn	Ile	Pro	Ser	Glu	Asn	Gln	Tyr	Phe	Gln	Ser	Ala	Ile
	50					55					60				
Trp	Ser	Gly	Phe	Ile	Lys	Val	Lys	Lys	Ser	Asp	Glu	Tyr	Thr	Phe	Ala
65					70					75					80
Thr	Ser	Ala	Asp	Asn	His	Val	Thr	Met	Trp	Val	Asp	Asp	Gln	Glu	Val
				85					90					95	
Ile	Asn	Lys	Ala	Ser	Asn	Ser	Asn	Lys	Ile	Arg	Leu	Glu	Lys	Gly	Arg
			100					105					110		
Leu	Tyr	Gln	Ile	Lys	Ile	Gln	Tyr	Gln	Arg	Glu	Asn	Pro	Thr	Glu	Lys
		115					120					125			
Gly	Leu	Asp	Phe	Lys	Leu	Tyr	Trp	Thr	Asp	Ser	Gln	Asn	Lys	Lys	Glu
	130					135					140				
Val	Ile	Ser	Ser	Asp	Asn	Leu	Gln	Leu	Pro	Glu	Leu	Lys	Gln	Lys	Ser
145				150						155					160
Ser	Asn	Ser	Arg	Lys	Lys	Arg	Ser	Thr	Ser	Ala	Gly	Pro	Thr	Val	Pro
				165					170					175	
Asp	Arg	Asp	Asn	Asp	Gly	Ile	Pro	Asp	Ser	Leu	Glu	Val	Glu	Gly	Tyr

-61-

Ile	Ser	Asn	Pro	Asn	Tyr	Lys	Val	Asn	Val	Tyr	Ala	Val	Thr	Lys	Glu
	690					695					700				
Asn	Thr	Ile	Ile	Asn	Pro	Ser	Glu	Asn	Gly	Asp	Thr	Ser	Thr	Asn	Gly
705					710					715					720
Ile	Lys	Lys	Ile	Leu	Ile	Phe	Ser	Lys	Lys	Gly	Tyr	Glu	Ile	Gly	
				725					730					735	